

CITATION REPORT

List of articles citing

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

DOI: 10.1056/nejmoa0807646

New England Journal of Medicine, 2008, 359, 2195-207.

Source: <https://exaly.com/paper-pdf/43941965/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2237	Chick-embryo deaths traced to tincture of iodine. 1973 , 127, 581		
2236	Selective release of newly synthesised and newly captured GABA from synaptosomes by potassium depolarisation. 1975 , 258, 254-6		37
2235	Calendar of Events. 1992 , 12, 167-170		
2234	Neuronal thread protein regulation and interaction with microtubule-associated proteins in SH-Sy5y neuronal cells. 2003 , 60, 2679-91		40
2233	Biosynthesis of isoprenoids via the non-mevalonate pathway. 2004 , 61, 1401-26		463
2232	The evolution of domain arrangements in proteins and interaction networks. 2005 , 62, 435-45		100
2231	Introduction: the best of Clinical Cornerstone. 2008 , 9, 4-5		
2230	Primary Prevention and Statins: Is It Just About Going to Class?. 2008 , 83, 1313-1315		1
2229	Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism. 2008 , 8, 373-418		456
2228	Expanding the orbit of primary prevention--moving beyond JUPITER. <i>New England Journal of Medicine</i> , 2008 , 359, 2280-2	59.2	55
2227	Do Statins Cause Back and Other Forms of Musculoskeletal Pain?. 2008 , 23, 135		
2226	Injury and attention deficit hyperactivity disorder. 2008 , 337, a2244		4
2225	Pleiotropic vasoprotective effects of statins: the chicken or the egg?. 2009 , 3, 191-204		8
2224	Low drug doses may improve outcomes in chronic disease. 2009 , 191, 511-3		15
2223	OBSERVATIONAL TRAILS IN LIPIDOLOGY. 2009 , 5, 75-78		
2222	New paradigm of treatment with statins in cardiovascular prevention. 2009 , 72,		
2221	PRIMARY PREVENTION OF CARDIOVASCULAR COMPLICATIONS: VALUE OF STATINS. 2009 , 5, 80-84		3

2220	Efficacy and safety of rosuvastatin in the management of dyslipidemia. 2009 , 5, 343-52	17
2219	The inflammatory response as a target to reduce myocardial ischaemia and reperfusion injury. 2009 , 102, 240-7	107
2218	A novel clinical entity: triglyceride deposit cardiomyovasculopathy. 2009 , 16, 702-5	25
2217	Long-term use of rosuvastatin: a critical risk benefit appraisal and comparison with other antihyperlipidemics. 2009 , 1, 25-33	9
2216	Efficacy, effectiveness and real life goal attainment of statins in managing cardiovascular risk. 2009 , 5, 369-76	16
2215	A Randomized Controlled Study to Compare the Effects of Rosuvastatin 5mg and Atorvastatin 10mg on the Plasma Lipid Profile in Japanese Patients with Hypercholesterolemia (ASTRO-2). 2009 , 2, 159-173	9
2214	The JUPITER study: statins for the primary prevention of cardiovascular events in patients with inflammatory rheumatic diseases?. 2009 , 1, 35	1
2213	A systems biology consideration of the vasculopathy of sickle cell anemia: the need for multi-modality chemo-prophylaxis. 2009 , 9, 271-92	70
2212	Fractal mathematics in managed care? How a simple and revealing analysis could improve the forecasting and management of medical costs and events. 2009 , 15, 351-8	2
2211	Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals. 2009 , 5, 921-36	40
2210	[Comment from the lipidologic viewpoint]. 2009 , 98, 125-7	0
2209	Advances in lipid testing and management in patients with diabetes mellitus. 2009 , 15, 641-52	3
2208	Markers of Inflammation and Risk of Coronary Heart Disease. 2009 , 26, 217-225	37
2207	Prognostic Biomarkers in Individuals with Prevalent Coronary Heart Disease. 2009 , 26, 265-271	5
2206	Multimarker Approach in Cardiovascular Risk Prediction. 2009 , 26, 273-285	17
2205	Use of Obesity Biomarkers in Cardiovascular Epidemiology. 2009 , 26, 247-263	20
2204	Lipid Measures and Cardiovascular Disease Prediction. 2009 , 26, 209-216	7
2203	[Macrovascular diabetic complications: clinical characteristics, diagnosis and management]. 2009 , 53, 698-708	7

2202	Diabète de type 2: prise en charge efficace du risque vasculaire. 2009 , 21, 409-415	
2201	C-reactive protein and its role in coronary artery disease. 2009 , 4, 108-113	
2200	Facts and ideas from anywhere. 2009 , 22, 178-87	2
2199	Levels of C-reactive protein associated with high and very high cardiovascular risk are prevalent in patients with rheumatoid arthritis. 2009 , 4, e6242	58
2198	Paying for outcomes: innovative coverage and reimbursement schemes for pharmaceuticals. 2009 , 15, 683-7	39
2197	The JUPITER and AURORA clinical trials for rosuvastatin in special primary prevention populations: perspectives, outcomes, and consequences. 2009 , 5, 1033-42	10
2196	Anti-inflammatory effects of simvastatin on adipokines in type 2 diabetic patients with carotid atherosclerosis. 2009 , 6, 262-8	39
2195	Jupiter to Earth: CRP promotes atherothrombosis. 2009 , 7, 1-3	4
2194	JUPITER: major implications for vascular risk assessment. 2009 , 25, 133-7	5
2193	Living longer as an anaesthetist: The magic lifestyle or the lifestyle polypill? 2009 , 15, 5-10	
2192	Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). 2009 , 2, 616-23	104
2191	Obstructive sleep apnea, inflammation, and the metabolic syndrome. 2009 , 7, 271-8	86
2190	Effectiveness of rosuvastatin in reducing LDL-C and target LDL-C goal attainment in real-world clinical practice. 2009 , 25, 2817-28	8
2189	New approaches for managing antiphospholipid syndrome. 2009 , 5, 160-70	45
2188	Disappointing recent cholesterol-lowering drug trials: is it not time for a full reappraisal of the cholesterol theory?. 2009 , 100, 80-89	1
2187	Statin therapy for the metabolic syndrome: the evidence base. 2009 , 7, 393-6	5
2186	Inhibition of endothelial nitric oxide synthase by C-reactive protein: clinical relevance. 2009 , 55, 206-8	32
2185	A randomized trial of rosuvastatin in the prevention of venous thromboembolism. <i>New England Journal of Medicine</i> , 2009 , 360, 1851-61	59.2 547

2184	Oxidized LDL receptor LOX-1 binds to C-reactive protein and mediates its vascular effects. 2009 , 55, 285-94	69
2183	False profits and silent partners in health care. 2009 , 20, 79-89	4
2182	Relationship between baseline inflammatory markers, antiplatelet therapy, and adverse cardiac events after percutaneous coronary intervention: an analysis from the clopidogrel for the reduction of events during observation trial. 2009 , 2, 503-12	21
2181	Rosuvastatin 20 mg restores normal HDL-apoA-I kinetics in type 2 diabetes. 2009 , 50, 1209-15	25
2180	"Risky business": ten years is not a lifetime. 2009 , 119, 362-4	13
2179	European Perspectives. 2009 , 119,	
2178	The clinical utility of high-sensitivity C-reactive protein in cardiovascular disease and the potential implication of JUPITER on current practice guidelines. 2009 , 55, 219-28	73
2177	Tracking of high-sensitivity C-reactive protein after an initially elevated concentration: the JUPITER Study. 2009 , 55, 305-12	70
2176	Metabolic syndrome, cardiovascular risk and screening for subclinical atherosclerosis. 2009 , 7, 273-80	24
2175	C-reactive protein, genetically elevated levels and risk of ischemic heart and cerebrovascular disease. 2009 , 69, 442-6	11
2174	Despite antiatherogenic metabolic characteristics, SCD1-deficient mice have increased inflammation and atherosclerosis. 2009 , 29, 341-7	78
2173	Abdominal adiposity is associated with elevated C-reactive protein independent of BMI in healthy nonobese people. 2009 , 32, 1734-6	66
2172	Induction of the cytoprotective enzyme heme oxygenase-1 by statins is enhanced in vascular endothelium exposed to laminar shear stress and impaired by disturbed flow. 2009 , 284, 18882-92	82
2171	C-reactive protein: eighty years from discovery to emergence as a major risk marker for cardiovascular disease. 2009 , 55, 209-15	128
2170	Concentrations of C-reactive protein and B-type natriuretic peptide 30 days after acute coronary syndromes independently predict hospitalization for heart failure and cardiovascular death: just another brick in the wall?. 2009 , 55, 203-5	2
2169	Statins inhibit protein lipidation and induce the unfolded protein response in the non-sterol producing nematode <i>Caenorhabditis elegans</i> . 2009 , 106, 18285-90	74
2168	Long-term use of statins and risk of colorectal cancer: a population-based study. 2009 , 104, 3015-23	50
2167	Persistent inflammation as a catalyst for other risk factors in chronic kidney disease: a hypothesis proposal. 2009 , 4 Suppl 1, S49-55	137

2166	Risk factor management: antiatherogenic therapies. 2009 , 16 Suppl 2, S29-36	9
2165	A randomized, controlled trial of simvastatin versus rosuvastatin in patients with acute myocardial infarction: the Secondary Prevention of Acute Coronary Events--Reduction of Cholesterol to Key European Targets Trial. 2009 , 16, 712-21	15
2164	Prevention of atrial fibrillation: another good reason to recommend statins to women?. 2009 , 95, 693-4	4
2163	Abstracts of EUROMEDLAB. Innsbruck, Austria. June 7-11, 2009. 2009 , 47 Suppl 1, S5-379	
2162	C-reactive protein and the risk of stent thrombosis and cardiovascular events after drug-eluting stent implantation. 2009 , 120, 1987-95	79
2161	C-reactive protein and coronary disease: is there a causal link?. 2009 , 120, 2036-9	43
2160	Commentary: C-reactive protein and risk prediction--moving beyond associations to assessing predictive utility and clinical usefulness. 2009 , 38, 231-4	5
2159	Atherosclerosis imaging: prognostically useful or merely more of what we know?. 2009 , 2, 150-60	8
2158	Discarding logic: 2008 Ancel Keys Memorial Lecture. 2009 , 119, 1533-7	9
2157	Human C-reactive protein does not promote atherosclerosis in transgenic rabbits. 2009 , 120, 2088-94	86
2156	Potential benefits of statins on morbidity and mortality in chronic obstructive pulmonary disease: a review of the evidence. 2009 , 85, 414-21	39
2155	The GALA trial: will it influence clinical practice?. 2009 , 43, 429-32	11
2154	The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease. 2009 , 3, 309-15	20
2153	Does simvastatin cause more myotoxicity compared with other statins?. 2009 , 43, 2012-20	37
2152	Implications of increased C-reactive protein for cardiovascular risk stratification in black and white men and women in the US. 2009 , 55, 1627-36	72
2151	Inflammation in renal transplantation. 2009 , 4, 1246-54	81
2150	Association between plasma monocyte chemoattractant protein-1 concentration and cardiovascular disease mortality in middle-aged diabetic and nondiabetic individuals. 2009 , 32, 2105-10	67
2149	Is higher sodium intake associated with elevated systemic inflammation? A population-based study. 2009 , 89, 1901-4	24

2148	Association of ApoE and HDL-C with cardiovascular and cerebrovascular disease: potential benefits of LDL-apheresis therapy. 2009 , 4, 311-329	4
2147	Towards a more inclusive vision of the medical sciences. 2009 , 102, 579-82	
2146	Inhibitors of HMG-CoA Reductase: Current and Future Prospects. 2009 , 9, 1272-83	42
2145	From here to JUPITER: identifying new patients for statin therapy using data from the 1999-2004 National Health and Nutrition Examination Survey. 2009 , 2, 41-8	40
2144	Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients. 2009 , 57, 495-9	80
2143	Intensive lowering of low-density lipoprotein cholesterol levels for primary prevention of coronary artery disease. 2009 , 84, 345-52	32
2142	Current World Literature. 2009 , 20, 135-42	
2141	The acute (cerebro)vascular effects of statins. 2009 , 109, 572-84	19
2140	C-reactive protein and dialysis access. 2009 , 76, 1025-6	
2139	Low-density lipoprotein cholesterol reduction and prevention of cardiovascular disease. 2009 , 84, 307-9	8
2138	Impact of ezetimibe on atherosclerosis: is the jury still out?. 2009 , 84, 353-61	16
2137	Ponziceuticals within the medical industrial complex. 2009 , 181, 112	1
2136	Current and emerging strategies for treating dyslipidemia and macrovascular disease. 2009 , 57, 237-51	2
2135	Imaging outcomes in cardiovascular clinical trials. 2009 , 6, 524-31	4
2134	Management of type 2 diabetes and lipids: a critique of the NICE guidelines 2008. 2009 , 9, 69-74	1
2133	Does statin use affect the risk of developing prostate cancer?. 2009 , 6, 70-1	4
2132	The statins in preventive cardiology. <i>New England Journal of Medicine</i> , 2009 , 360, 541; author reply 541-2	1
2131	Rosuvastatin in patients with elevated C-reactive protein. <i>New England Journal of Medicine</i> , 2009 , 360, 1038; author reply 1041-2	59.2 4

2130	Rosuvastatin in patients undergoing hemodialysis. <i>New England Journal of Medicine</i> , 2009 , 361, 93; author reply 94-5	59.2	4
2129	JUPITER clinical directions--polling results. <i>New England Journal of Medicine</i> , 2009 , 360, e14	59.2	6
2128	The HALTS trial--halting atherosclerosis or halted too early?. <i>New England Journal of Medicine</i> , 2009 , 361, 2178-80	59.2	27
2127	Vascular dysfunction in chronic obstructive pulmonary disease. 2009 , 180, 513-20		134
2126	Statins in heart failure: retrospective cohort study using routine primary care data. 2009 , 41, 490-6		5
2125	Knowing chronic obstructive pulmonary disease by heart: cumulating evidence of systemic vascular dysfunction. 2009 , 180, 487-8		2
2124	Using statins to treat 'healthy' patients: are we there yet?. 2009 , 9, 103-5		
2123	An emerging paradigm in atherosclerosis: focus on subclinical disease. 2009 , 121, 49-59		7
2122	The gravity of JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin). 2009 , 121, 113-8		10
2121	Will molecular MR imaging play a role in identification and treatment of patients with vulnerable atherosclerotic plaques?. 2009 , 251, 309-10		4
2120	Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies. 2009 , 30, 2838-44		128
2119	Troponin and heart failure: an early warning system worth listening to?. 2009 , 5, 321-4		
2118	Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk. 2009 , 5, 231-6		7
2117	Low- and high-density lipoproteins modulate function, apoptosis, and proliferation of primary human and murine pancreatic beta-cells. 2009 , 150, 4521-30		160
2116	Impact of simvastatin on adipose tissue: pleiotropic effects in vivo. 2009 , 150, 5262-72		47
2115	Adverse effects of statins - mechanisms and consequences. 2009 , 4, 209-28		141
2114	[Cardiology 2009]. 2009 , 134, 1309-11		
2113	Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. 2009 , 302, 37-48		459

2112	Implications of recent clinical trials on pay-for-performance. 2009 , 66, 864-7	7
2111	Inflammatory markers and outcomes in cardiovascular disease. 2009 , 6, e1000147	6
2110	Doctoring the evidence: the case against lying to patients about placebos. 2009 , 9, 34-6	15
2109	Common polymorphisms in CYP2C9, subclinical atherosclerosis and risk of ischemic vascular disease in 52,000 individuals. 2009 , 9, 327-32	19
2108	HIV positivity, protease inhibitor exposure and subclinical atherosclerosis: a systematic review and meta-analysis of observational studies. 2009 , 95, 1826-35	79
2107	Effect of simvastatin vs. rosuvastatin on adiponectin and haemoglobin A1c levels in patients with non-ischaemic chronic heart failure. 2009 , 11, 1195-201	23
2106	Atorvastatin restores endothelial function in offspring of protein-restricted rats in a cholesterol-independent manner. 2009 , 53, 661-7	35
2105	A consultation-based method is equal to SCORE and an extensive laboratory-based method in predicting risk of future cardiovascular disease. 2009 , 16, 536-40	5
2104	Worsening of hyperglycemia due to atorvastatin in a renal transplant patient. 2009 , 2, 392-4	2
2103	Myocardial infarction in a 72-year-old woman with low LDL-C and increased hsCRP: implications for statin therapy. 2009 , 55, 369-74; discussion 374-5	3
2102	Is C-reactive protein a prognostic marker after angioplasty?. 2009 , 95, 957-9	7
2101	Is hsCRP Back on Board? Implications from the JUPITER Trial. 2009 , 55, 216-8	10
2100	High-sensitivity C-reactive protein predicts mortality but not stroke: the Northern Manhattan Study. 2009 , 73, 1300-7	63
2099	Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. 2009 , 302, 49-57	411
2098	The value of C-reactive protein in screening for future coronary heart disease events. 2009 , 16, 212-4	6
2097	Fallacies in clinical cardiovascular trials. 2009 , 95, 1464-8	2
2096	Dissociation of pentameric to monomeric C-reactive protein on activated platelets localizes inflammation to atherosclerotic plaques. 2009 , 105, 128-37	184
2095	Statins for all: the new premed?. 2009 , 103, 99-107	21

2094	Molecular and cellular mechanisms of the thrombotic complications of atherosclerosis. 2009 , 50 Suppl, S352-7	86
2093	Biomarkers and cardiovascular disease: determining causality and quantifying contribution to risk assessment. 2009 , 302, 92-3	17
2092	Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial. 2009 , 302, 1186-94	85
2091	Major recent trials in cardiovascular diseases. 2009 , 121, 15-24	2
2090	C-reactive protein and prognosis in diabetes: getting to the heart of the matter. 2009 , 58, 798-9	10
2089	Smoking and atherosclerotic cardiovascular disease: Part I: atherosclerotic disease process. 2009 , 3, 411-28	15
2088	Improving lipid goal attainment: is it enough?. 2009 , 120, 3-5	15
2087	Inhibition of PCSK9: a powerful weapon for achieving ideal LDL cholesterol levels. 2009 , 106, 9546-7	72
2086	Efficacy and safety of ezetimibe plus orlistat or rimonabant in statin-intolerant nondiabetic overweight/obese patients with dyslipidemia. 2009 , 14, 274-82	6
2085	Apolipoprotein e genotype, plasma cholesterol, and cancer: a Mendelian randomization study. 2009 , 170, 1415-21	40
2084	American Diabetes Association indications for statins in diabetes: is there evidence?. 2009 , 32 Suppl 2, S384-91	40
2083	Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. 2009 , 27, 2121-58	1004
2082	Infections as a stimulus for coronary occlusion, obstruction, or acute coronary syndromes. 2009 , 3, 447-54	23
2081	The metabolic syndrome: common origins of a multifactorial disorder. 2009 , 85, 614-21	102
2080	Statin-induced diabetes: will it change clinical practice?. 2009 , 32, 1941-3	8
2079	Is high-sensitivity C-reactive protein associated with subclinical peripheral atherosclerosis?. 2009 , 60, 8-11	4
2078	Thirty-year multivariate risk assessment is a stronger predictor of cardiovascular disease than the 10-year model. 2009 , 55, 2085-7	1
2077	The JUPITER trial: results, controversies, and implications for prevention. 2009 , 2, 279-85	95

2076	Is calcitriol life-protective for patients with chronic kidney disease?. 2009 , 20, 2285-90	12
2075	Sex-specific effect of body weight gain on systemic inflammation in subjects with COPD: results from the SAPALDIA cohort study 2. 2009 , 34, 332-9	16
2074	Major lipids, apolipoproteins, and risk of vascular disease. 2009 , 302, 1993-2000	1733
2073	JUPITER: a few words of caution. 2009 , 2, 286-8	8
2072	Antiatherosclerotic and anti-insulin resistance effects of adiponectin: basic and clinical studies. 2009 , 52, 126-40	85
2071	Antiphospholipid syndrome. 2009 , 52, 115-25	50
2070	Discovery and validation of new molecular targets in treating dyslipidemia: the role of human genetics. 2009 , 19, 195-201	16
2069	Monomeric C-reactive protein generation on activated platelets: the missing link between inflammation and atherothrombotic risk. 2009 , 19, 232-7	46
2068	Highlights from the 2008 American Heart Association scientific session. 2009 , 137, 791-4	
2067	Highlights from the 58th Annual Scientific Sessions of the American College of Cardiology, March 28 to 31, 2009, Orlando, Florida. 2009 , 138, 795-7	1
2066	Inflammatory biomarkers in coronary artery disease. 2009 , 53, 317-33	229
2065	Clinical impact of dyslipidemia for coronary plaque vulnerability in acute coronary syndrome without metabolic syndrome. 2009 , 54, 394-401	5
2064	Admission C-reactive protein after acute ischemic stroke is associated with stroke severity and mortality: the 'Bergen stroke study'. 2009 , 9, 18	77
2063	Statins and advanced heart failure--alive but barely breathing after CORONA and GISSI-HF. 2009 , 15, 157-8	5
2062	Current approaches to the challenge of coronary heart disease risk assessment: C-reactive protein mania and imaging-itis?. 2009 , 12, 1-2	
2061	Jupiter and accomplish. 2009 , 12, 114-9	
2060	Age-neutral guidelines for the primary prevention of cardiovascular disease. 2009 , 11, 644-5	3
2059	Patients with hypertension and the cardiometabolic syndrome: the potential impact of inflammatory biomarkers. 2009 , 11, 690-3	

2058	Synergistic effects of telmisartan and simvastatin on endothelial progenitor cells. 2010 , 14, 1645-56	24
2057	Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). 2009 , 7 Suppl 1, 332-9	219
2056	The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated meta-analysis. 2009 , 31, 236-44	124
2055	How to identify the asymptomatic high-risk patient?. 2009 , 34, 539-77	3
2054	Clinical and research applications of carotid intima-media thickness. 2009 , 103, 1316-20	41
2053	Evaluating lipid-lowering trials in the twenty-first century. 2009 , 103, 1325-8	2
2052	Eligibility of individuals with subclinical coronary artery calcium and intermediate coronary heart disease risk for reclassification (from the Framingham Heart Study). 2009 , 103, 1710-5	21
2051	The editor's roundtable: the JUPITER trial--initial results and clinical implications. 2009 , 103, 1417-25	18
2050	Serum C-reactive protein and risk of cardiovascular events in middle-aged and older chinese population. 2009 , 103, 1727-31	20
2049	Safety and efficacy of achieving very low low-density lipoprotein cholesterol levels with rosuvastatin 40 mg daily (from the ASTEROID Study). 2009 , 104, 29-35	20
2048	Is measuring C-reactive protein useful for guiding treatment in women > or = 60 years and men > or = 50 years of age?. 2009 , 104, 354-8	8
2047	The American Journal of Cardiology and Journal of Periodontology Editors' Consensus: periodontitis and atherosclerotic cardiovascular disease. 2009 , 104, 59-68	162
2046	Another look at the results of the JUPITER trial. 2009 , 104, 1603-5	17
2045	Meta-analysis of randomized controlled trials of statins versus placebo in patients with heart failure. 2009 , 104, 1708-16	85
2044	RA treatment study group: improvement in RA management. 2009 , 76, 435-7	2
2043	JUPITER and the world of stroke medicine. 2009 , 8, 129-31	6
2042	Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. 2009 , 8, 453-63	405
2041	Does inflammation fuel the fire in CKD?. 2009 , 53, 572-5	9

2040	C-reactive protein, statins, and cardiovascular risk: what can JUPITER teach us?. 2009 , 53, 737-40	1
2039	Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). 2009 , 54, 810-9	189
2038	Risk factors for lower-extremity vein graft failure. 2009 , 22, 216-26	26
2037	El control del colesterol en prevenci3n primaria. ¿Cuanto m3s bajo, mejor?. 2009 , 16, 449-451	
2036	The systems biology-based argument for taking a bold step in chemoprophylaxis of sickle vasculopathy. 2009 , 84, 543-5	6
2035	Different inflammatory responses induced by three LDL-lowering apheresis columns. 2009 , 24, 247-53	32
2034	Should patients with rheumatoid arthritis receive statin therapy?. 2009 , 60, 1205-9	17
2033	Knee osteoarthritis in obese women with cardiometabolic clustering. 2009 , 61, 1328-36	119
2032	Atherothrombotic comorbidity in the rheumatic diseases. The evidence becomes clearer. What should clinicians do?. 2009 , 61, 1284-6	3
2031	Highlights of the hotline sessions presented at the scientific sessions 2008 of the American Heart Association. 2009 , 98, 1-7	4
2030	Hotlines and clinical trial updates presented at the European Society of Cardiology Meeting 2009: data from RE-LY, PLATO, MADIT-CRT, PROTECT, SYNTAX, TRITON and more. 2009 , 98, 691-9	6
2029	Myocardial inflammation and non-ischaeamic heart failure: is there a role for C-reactive protein?. 2009 , 104, 591-9	33
2028	C-reactive protein in the very early phase of acute ischemic stroke: association with poor outcome and death. 2009 , 256, 2003-8	84
2027	Het JUPITER-onderzoek: voorkomt rosuvastatine vasculaire complicaties bij gezonde mensen met een verhoogd CRP?. 2009 , 47, 18-19	
2026	Primaire preventie na Jupiter. 2009 , 52, 60-60	4
2025	Effect of clopidogrel discontinuation at 1 year after drug eluting stent placement on soluble CD40L, P-selectin and C-reactive protein levels: DECADES (Discontinuation Effect of Clopidogrel After Drug Eluting Stent): a multicenter, open-label study. 2009 , 28, 410-7	13
2024	Usefulness of aggressive lipid-lowering therapy with rosuvastatin in hypercholesterolemic patients with concomitant type 2 diabetes. 2009 , 36, 412-8	8
2023	A novel indicator of widespread endothelial damage and ischemia in diabetic patients: ischemia-modified albumin. 2009 , 36, 425-32	38

2022	Achieving optimum lipid-lowering goals in patients with vascular disease. 2009 , 3, 323-330	
2021	Die JUPITER-Studie: Primärprävention bei erhöhtem C-reaktivem Protein. 2009 , 3, 35-36	
2020	Moving toward new statin guidelines in a post-JUPITER world: principles to consider. 2009 , 11, 249-56	17
2019	Planning primary prevention of coronary disease. 2009 , 11, 272-80	13
2018	Lipid-lowering drugs and risk for cancer. 2009 , 11, 350-7	6
2017	ApoB versus non-HDL-C: what to do when they disagree. 2009 , 11, 358-63	31
2016	The Jupiter trial: key findings, controversies, and implications. 2009 , 11, 81-2	6
2015	Emerging inflammatory markers for assessing coronary heart disease risk. 2009 , 11, 452-9	18
2014	Treatment of hypertension in metabolic syndrome: implications of recent clinical trials. 2009 , 9, 229-37	5
2013	Epidemiology of atherosclerosis in systemic lupus erythematosus. 2009 , 11, 248-54	32
2012	Diabetes und Fettleber. 2009 , 5, 653-665	0
2011	New evidence in general practice, internal medicine and cardiovascular medicine. 2009 , 4, 157-9	
2010	Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?. 2009 , 26, 469-87	13
2009	[Are the guidelines correct? Should all patients with coronary heart disease or diabetes be treated with a statin?]. 2009 , 104, 74-8	2
2008	Mylip makes an Idol turn into regulation of LDL receptor. 2009 , 66, 3399-402	11
2007	Cardiovascular prevention in clinical practice (ESC and German guidelines 2007). 2009 , 34, 4-14	6
2006	CRP in cardiovascular disease. 2009 , 34, 607-13	31
2005	Selective prescribing of simvastatin and atorvastatin by patient characteristics at treatment initiation over a 7-year period in Finland. 2009 , 65, 927-33	7

2004	Atherosclerosis is an inflammatory disease. 2009 , 31, 1-3	25
2003	CRP and the risk of atherosclerotic events. 2009 , 31, 79-94	80
2002	Update on statin-mediated anti-inflammatory activities in atherosclerosis. 2009 , 31, 127-42	64
2001	Commentary on 'Measurement in clinical trials: a neglected issue for statisticians?'. 2009 , 28, 3215-7; discussion 3223-5	
2000	The JUPITER trial and its implications for patients with diabetes. 2009 , 26, 50-51	
1999	Associations between statins and COPD: a systematic review. 2009 , 9, 32	59
1998	Translational mini-review series on immunology of vascular disease: inflammation, infections and Toll-like receptors in cardiovascular disease. 2009 , 156, 386-94	33
1997	Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence. 2009 , 70, 815-28	57
1996	Authors' reply to: Statin therapy as the fundamental therapy for cardiovascular prevention: be careful. 2009 , 71, 456-457	0
1995	Intensive lipid lowering may reduce progression of carotid atherosclerosis within 12 months of treatment: the METEOR study. 2009 , 265, 698-707	33
1994	Greater absolute reductions in LDL cholesterol should yield greater proportional reductions in risk of cardiovascular disease. 2009 , 266, 499-501	
1993	Vaccinate your child and save its grandparents from a heart attack? Current perspectives in antipneumococcal vaccination. 2009 , 266, 432-44	17
1992	Exercise protects the cardiovascular system: effects beyond traditional risk factors. 2009 , 587, 5551-8	281
1991	Chemoprevention of lung carcinogenesis in addicted smokers and ex-smokers. 2009 , 9, 476-88	76
1990	Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes. 2009 , 8, 308-20	185
1989	Is there a prognostic role for C-reactive protein in ischemic stroke?. 2010 , 122, 209-16	6
1988	Quantitative and qualitative effects of rosuvastatin on LDL-cholesterol: what is the clinical significance?. 2009 , 63, 478-85	12
1987	JUPITER: wake up and smell the coffee--the absolute and relative merits of statin use. 2009 , 63, 347-8	7

1986	SEARCHING for JUPITER: starry-eyed optimism is not warranted. 2009 , 63, 685-8	3
1985	Rosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidaemic patients with impaired fasting glucose. 2009 , 63, 1308-13	44
1984	Vascular risk screening: possible or too much, too soon?. 2009 , 63, 989-96	5
1983	Storms, tea cups and the adverse effects of statins. 2009 , 63, 1268-70	3
1982	The good and the bad: what researchers have learned about dietary cholesterol, lipid management and cardiovascular disease risk since the Harvard Egg Study. 2009 , 63, 9-14, 27-43	6
1981	Le bon et le mauvais: nouvelles connaissances sur le cholest�ol alimentaire, la ma�trise des lipides et le risque de maladies cardiovasculaires depuis la Harvard Egg Study. 2009 , 63, 37-43	
1980	Hot and bothered: C-reactive protein, inflammation and atherosclerosis. 2009 , 63, 1550-3	4
1979	Does intensive cholesterol lowering increase the risk of diabetes?. 2009 , 63, 1808; author reply 1809	5
1978	Does intensive cholesterol lowering increase the risk of diabetes?. 2009 , 63, 1809-1809	
1977	Mechanisms of obesity and related pathologies: androgen deficiency and endothelial dysfunction may be the link between obesity and erectile dysfunction. 2009 , 276, 5755-67	71
1976	Are we all hypo-statinaemics?. 2009 , 4, 185-6	
1975	Rediscovering bile acid sequestrants. 2009 , 11, 1114-21	14
1974	Effects of grape seed extract in Type 2 diabetic subjects at high cardiovascular risk: a double blind randomized placebo controlled trial examining metabolic markers, vascular tone, inflammation, oxidative stress and insulin sensitivity. 2009 , 26, 526-31	166
1973	A new indication for statins to prevent venous thromboembolism? Not yet. 2009 , 7, 511-3	8
1972	Aspirin reduces the prothrombotic activity of C-reactive protein. 2009 , 7, 1393-400	18
1971	Statins reduce cardiovascular events in primary and secondary prevention trials without causing an increase in carcinoma. 2009 , 57, 1942-3; author reply 1943-4	2
1970	Biomarkers in cardiovascular disease: beyond natriuretic peptides. 2009 , 11 Suppl 1, S23-32	32
1969	Electrochemical investigations of the interaction of C-reactive protein (CRP) with a CRP antibody chemically immobilized on a gold surface. 2009 , 643, 45-53	57

1968	Rosuvastatin along the cardiovascular continuum: from JUPITER to AURORA. 2009 , 7, 1317-27	10
1967	Primary prevention of vascular events in patients with high levels of C-reactive protein: the JUPITER study. 2009 , 7, 1041-56	10
1966	Statins: not just for the young or the faint of heart. 2009 , 72, 684-5	0
1965	Management of the antiphospholipid syndrome: new approaches. 2009 , 4, 533-549	1
1964	What is the future for drug development in atherosclerosis and dyslipidaemia?. 2009 , 4, 1-3	4
1963	Treatment strategies for peripheral artery disease. 2009 , 10, 1571-86	8
1962	Pharmacological actions of statins: potential utility in COPD. 2009 , 18, 222-32	97
1961	Integrative medicine and patient-centered care. 2009 , 5, 277-89	169
1960	High circulating autoantibodies against human oxidized low-density lipoprotein are related to stable and lower titers to unstable clinical situation. 2009 , 406, 113-8	24
1959	A prospective evaluation of the directionality of the depression-inflammation relationship. 2009 , 23, 936-44	280
1958	Lipids, atherosclerosis and CVD risk: is CRP an innocent bystander?. 2009 , 19, 521-4	64
1957	C-reactive protein impairs coronary arteriolar dilation to prostacyclin synthase activation: role of peroxynitrite. 2009 , 47, 196-202	22
1956	C-reactive protein: a multipronged assailant on endothelium-dependent vasodilation. 2009 , 47, 177-9	
1955	Low cholesterol, impulsivity and the economy. 2009 , 33, 745; author reply 746	2
1954	Immune therapy for age-related diseases. 2009 , 30, 344-50	26
1953	The importance of considering alternative or combination strategies for lowering LDL-C. 2009 , 136, 115-9	8
1952	Preventive cardiology and cardiac rehabilitation programmes in women. 2009 , 63, 28-33	12
1951	[Appropriate strategies for the cardiovascular "disease". High-risk patients]. 2009 , 133, 261-71	

1950	[C-reactive protein and carotid intima-media thickness in atherothrombotic ischemic stroke]. 2009 , 133, 496-500	3
1949	Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome. 2009 , 51, 918-24	181
1948	A combination of PPAR-gamma agonists and HMG CoA reductase inhibitors (statins) as a new therapy for the conservative treatment of AAS (aortic aneurysm syndromes). 2009 , 73, 614-8	10
1947	Clinically important interaction between statin drugs and Clostridium difficile toxin?. 2009 , 73, 1045-7	20
1946	Biomarkers of premature atherosclerosis. 2009 , 15, 323-32	69
1945	Risk assessment in the genomic era: are we missing the low-hanging fruit?. 2009 , 157, 799-801	
1944	Coronary heart disease in moderately hypercholesterolemic, hypertensive black and non-black patients randomized to pravastatin versus usual care: the antihypertensive and lipid lowering to prevent heart attack trial (ALLHAT-LLT). 2009 , 158, 948-55	13
1943	Prevention and treatment of atherosclerosis: a practitioner's guide for 2008. 2009 , 122, S38-50	32
1942	Should physicians measure high-sensitivity C-reactive protein levels to assess coronary heart disease risk?. 2009 , 122, 405-6	
1941	Autophagy: regulation and role in disease. 2009 , 46, 210-40	152
1940	Trends in plasma lipids, lipoproteins and dyslipidaemias in French adults, 1996-2007. 2009 , 102, 293-301	53
1939	Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) study. 2009 , 53, 931-5	43
1938	The year in atherothrombosis. 2009 , 53, 1326-37	5
1937	Arginine and old MACE: small molecules in atherogenesis support the concept of coronary artery disease as a complex trait. 2009 , 53, 2068-9	2
1936	Iron oxide magnetic resonance imaging for atherosclerosis therapeutic evaluation: still "rusty?". 2009 , 53, 2051-2	26
1935	Metabolic syndrome: intima-media thickness and beyond. 2009 , 53, 2280-2	2
1934	Reply. 2009 , 53, 2312-2313	2
1933	Coronary calcium scoring: calcium location needs to be integrated!. 2009 , 54, 745; author reply 745-6	

1932 Reply. **2009**, 54, 744-745

1931 Reply. **2009**, 54, 745-746

1930 The role of biomarkers and genetics in peripheral arterial disease. **2009**, 54, 1228-37 50

1929 Significance of a multiple biomarkers strategy including endothelial dysfunction to improve risk stratification for cardiovascular events in patients at high risk for coronary heart disease. **2009**, 54, 601-8 206

1928 Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. **2009**, 54, 558-65 240

1927 The coronary artery calcium score and stress myocardial perfusion imaging provide independent and complementary prediction of cardiac risk. **2009**, 54, 1872-82 164

1926 Induced cardiovascular procedural costs and resource consumption patterns after coronary artery calcium screening: results from the EISNER (Early Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research) study. **2009**, 54, 1258-67 44

1925 Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial. **2009**, 54, 2278-89 127

1924 Clinical implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. population insights from the ARIC (Atherosclerosis Risk in Communities) study. **2009**, 54, 2388-95 40

1923 The year in epidemiology, health services research, and outcomes research. **2009**, 54, 2343-51

1922 The role of lipoprotein-associated phospholipase A2 on cardiovascular disease risk assessment and plaque rupture: a clinical review. **2009**, 3, 85-93 14

1921 Is HDL function as important as HDL quantity in the coronary artery disease risk assessment?. **2009**, 3, 70-7 19

1920 Atherosclerosis in a managed care plan: hypercholesterolemia treatment patterns and low-density lipoprotein cholesterol monitoring. **2009**, 3, 385-92 2

1919 Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. **2009**, 66, 1013-22 81

1918 Physical fitness is associated with lower inflammation, even in individuals with high cholesterol □ An alternative to statin therapy?. **2009**, 4, 149-156 1

1917 Modern cardiovascular risk management in clinical practice. **2009**, 26, 275-279

1916 [LDL-cholesterol goals and changes in C reactive protein in high coronary risk patients]. **2009**, 209, 415-23 0

1915 Atherosclerosis: a complex interplay of inflammatory processes. **2009**, 4, 167-187 1

1914	Blood Lipid Disorders. 2009 , 1-5	
1913	Summary of the Clinical Studies Reported in the Annual Scientific Sessions of the American Heart Association (New Orleans, United States, November 8-12, 2008). 2009 , 62, 178-187	
1912	Biomarkers in cardiovascular medicine. 2009 , 62, 677-88	16
1911	Relationship between carotid artery stiffness index, BNP and high-sensitivity CRP. 2009 , 23, 783-7	15
1910	Obesity, inflammation, and atherosclerosis. 2009 , 6, 399-409	615
1909	Valsartan: more than a decade of experience. 2009 , 69, 2393-414	47
1908	Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. 2009 , 18, 308-47	186
1907	Circulating endothelial progenitor cells: a new approach to anti-aging medicine?. 2009 , 7, 106	30
1906	The American Journal of Cardiology and Journal of Periodontology editors' consensus: periodontitis and atherosclerotic cardiovascular disease. 2009 , 80, 1021-32	188
1905	Statins and stroke prevention. 2009 , 7, 1231-43	17
1904	Markers of inflammation and cardiovascular disease: clinical applications of C-reactive protein determination. 2009 , 9 Suppl 1, 3-7	9
1903	Comparison of incidences of cardiovascular events among new users of different statins: a retrospective observational cohort study. 2009 , 25, 2621-9	6
1902	Oleic acid and peanut oil high in oleic acid reverse the inhibitory effect of insulin production of the inflammatory cytokine TNF-alpha both in vitro and in vivo systems. 2009 , 8, 25	158
1901	Musings on genome medicine: cholesterol and coronary artery disease. 2009 , 1, 60	
1900	Lipid-lowering therapy for the primary prevention of cardiovascular disease in the elderly: opportunities and challenges. 2009 , 26, 917-31	12
1899	Chronic coronary artery disease: diagnosis and management. 2009 , 84, 1130-46	150
1898	Progressive Staging of Pilot Studies to Improve Phase III Trials for Motor Interventions. 2009 , 23, 197-206	148
1897	Statine e regressione del danno d'organo. 2009 , 3, 227-233	

1896	Cardiovascular and economic outcomes after initiation of lipid-lowering therapy with atorvastatin vs simvastatin in an employed population. 2009 , 84, 1065-72	17
1895	Diagnosis of subclinical coronary atherosclerosis: challenges and insight. 2009 , 3, 37-52	1
1894	Visceral obesity: the link among inflammation, hypertension, and cardiovascular disease. 2009 , 53, 577-84	323
1893	Statins and venous thromboembolism: a novel effect of statins?. 2009 , 25, 1807-9	6
1892	Treatment strategies to prevent stroke: focus on optimal lipid and blood pressure control. 2009 , 10, 955-66	3
1891	Clinical review: impact of statin substitution policies on patient outcomes. 2009 , 41, 242-56	21
1890	JUPITER strikes earth. 2009 , 6, 159	1
1889	Concomitant reduction in low-density lipoprotein cholesterol and glycated hemoglobin with colesvelam hydrochloride in patients with type 2 diabetes: a pooled analysis. 2009 , 7, 255-8	30
1888	Statins inhibit Rho kinase activity in patients with atherosclerosis. 2009 , 205, 517-21	97
1887	Association of inflammatory markers with angiographic severity and extent of coronary artery disease. 2009 , 206, 335-9	63
1886	Associations of very high C-reactive protein concentration with psychosocial and cardiovascular risk factors in an ageing population. 2009 , 206, 599-603	29
1885	The negative effects of hydrogenated trans fats and what to do about them. 2009 , 205, 458-65	58
1884	Inflammatory markers and growth in South Asian and European origin infants in Britain: the Manchester Children's Growth and Vascular Health Study. 2009 , 207, 227-31	11
1883	The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process. 2009 , 207, 318-27	115
1882	C-reactive protein levels and risk of mortality from cardiovascular disease in Japanese: the JACC Study. 2009 , 207, 291-7	53
1881	[Prognostic value and clinical effectiveness of high sensitivity C-reactive protein as a marker in primary prevention of major cardiac events]. 2009 , 103, 319-29	2
1880	DAHTA veröffentlicht 15 HTA-Berichte in 2008. 2009 , 103, 329-330	
1879	Novel uses for statins in surgical patients. 2009 , 7, 285-90	10

1878	Current strategies and recent advances in the therapy of hypercholesterolemia. 2009 , 10, 1-4	2
1877	Pravastatin administration does not induce detrimental effects on hemodynamics and collaterals of portal hypertensive rats. 2010 , 25, 1394-400	5
1876	Phospholipase A2 inhibitors in the treatment of atherosclerosis: a new approach moves forward in the clinic. 2009 , 18, 1425-30	13
1875	How-to guide on biomarkers: biomarker definitions, validation and applications with examples from cardiovascular disease. 2009 , 85, 538-45	92
1874	Statin therapy and risk of developing type 2 diabetes: a meta-analysis. 2009 , 32, 1924-9	308
1873	Recent advances in the management of coronary artery disease: highlights from the literature. 2009 , 23, 259-65	6
1872	2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. 2009 , 25, 567-79	567
1871	Risk prediction in cardiovascular disease: the prognostic significance of endothelial dysfunction. 2009 , 25 Suppl A, 15A-20A	49
1870	Lipid lowering for primary prevention. 2009 , 373, 1152-5	39
1869	Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. 2009 , 373, 1175-82	734
1868	Bringing JUPITER down to earth. 2009 , 373, 1147-8	13
1867	Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. 2009 , 373, 1849-60	2427
1866	Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial. 2009 , 374, 25; author reply 26-7	1
1865	Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial. 2009 , 374, 26; author reply 26-7	3
1864	[Cardiovascular issues]. 2009 , 39, 10-4	
1863	Resumen de los ensayos clínicos presentados en las Sesiones Científicas Anuales de la American Heart Association (New Orleans, Estados Unidos, 8-12 de noviembre de 2008). 2009 , 62, 178-187	14
1862	Biomarcadores en la medicina cardiovascular. 2009 , 62, 677-688	35
1861	Non-adherence to statin therapy: a major challenge for preventive cardiology. 2009 , 10, 2973-85	93

1860	Inflammation in atherosclerosis: from pathophysiology to practice. 2009 , 54, 2129-38	1415
1859	Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. <i>New England Journal of Medicine</i> , 2009 , 360, 1395-407	59.2 1414
1858	Age-associated decrease of high-density lipoprotein-mediated reverse cholesterol transport activity. 2009 , 12, 117-26	38
1857	Primary and Secondary Prevention of Cardiovascular Diseases: A Practical Evidence-Based Approach. 2009 , 84, 741-757	88
1856	Low-Density Lipoprotein Cholesterol Reduction and Prevention of Cardiovascular Disease. 2009 , 84, 307-309	4
1855	Abstract: 22 EFFICACY OF STATINS. 2009 , 10, e1646-e1648	
1854	Reactive oxidative metabolites are associated with atrial conduction disturbance in patients with atrial fibrillation. 2009 , 6, 935-40	61
1853	Erectile Dysfunction and the Window of Curability—A Harbinger of Cardiovascular Events. 2009 , 84, 102-104	24
1852	Impact of Ezetimibe on Atherosclerosis: Is the Jury Still Out?. 2009 , 84, 353-361	15
1851	Intensive Lowering of Low-Density Lipoprotein Cholesterol Levels for Primary Prevention of Coronary Artery Disease. 2009 , 84, 345-352	27
1850	Primary and secondary prevention of cardiovascular disease in older adults: a status report. 2009 , 25, 745-55, x	9
1849	Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. 2009 , 120, 2188-96	138
1848	The role of statins in chronic heart failure. 2009 , 24, 167-71	5
1847	Preventing future acute coronary events: is the target the so-called vulnerable plaque or the high-risk or vulnerable patient?. 2009 , 24, 483-9	1
1846	Obstructive sleep apnea and cardiovascular disease. 2009 , 24, 516-20	9
1845	Current Opinion in Endocrinology, Diabetes & Obesity. Current world literature. 2009 , 16, 189-202	
1844	Mechanisms for increased cardiovascular disease in chronic kidney dysfunction. 2009 , 18, 181-8	40
1843	Human C-reactive protein and the metabolic syndrome. 2009 , 20, 182-9	156

1842	Targets for LDL-lowering therapy. 2009 , 20, 282-7	18
1841	Marriage protects men from clinically meaningful elevations in C-reactive protein: results from the National Social Life, Health, and Aging Project (NSHAP). 2009 , 71, 828-35	58
1840	Pregnancy as a window to future health. 2009 , 114, 958-960	25
1839	Current world literature. 2009 , 24, 496-508	
1838	Approach to the diagnosis and management of lipoprotein disorders. 2009 , 16, 132-40	17
1837	Combination therapy of statins and fibrates in the management of cardiovascular risk. 2009 , 20, 505-11	37
1836	Myalgia in Patients on High-Dose and Low-to-Moderate Dose Statin Therapy. 2009 , 39, 202-206	1
1835	Are the pleiotropic effects of drugs used for the prevention of cardiovascular disease clinically relevant?. 2009 , 15, 463-6	1
1834	Evidence-based guidelines for cardiovascular risk reduction: the safety and efficacy of high-dose statin therapy. 2009 , 24, 429-38	3
1833	Therapy and clinical trials. 2009 , 20, 262-3	
1832	Does elevated C-reactive protein cause human atherothrombosis? Novel insights from genetics, intervention trials, and elsewhere. 2009 , 20, 393-401	34
1831	Assessment of risk for developing coronary heart disease in asymptomatic individuals. 2009 , 29, 207-19	5
1830	Current world literature. 2009 , 20, 512-9	
1829	Hyperlipidaemia and cardiovascular disease: inflammation and oxidative stress in diabetic patients. 2009 , 20, 258-9	8
1828	Cardiovascular prevention by dietary nitrate and nitrite. 2009 , 296, H1221-3	18
1827	1. Pathophysiology and Treatment of Acute Coronary Syndrome. 2009 , 98, 595-600	
1826	Inflammatory markers. 2009 , 70, M68-70	1
1825	Dyslipidemia in ESRD: Too Late to Treat?. 2009 , 2, 2	

1824	High-Dose Statin Reduces Cardiac Events in Patients With High C-Reactive Protein (JUPITER). 2009 , 101, 292-293	
1823	Genetically Elevated C-Reactive Protein and Ischemic Vascular Disease. 2009 , 2009, 3-4	
1822	HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. 2009 , 23, 929-39	112
1821	Hepatic nuclear factor 1-alpha: inflammation, genetics, and atherosclerosis. 2009 , 20, 106-11	51
1820	The role of statins for the primary and secondary prevention of coronary heart disease in women. 2009 , 15, 1054-62	17
1819	How I treat the antiphospholipid syndrome. 2009 , 114, 2020-30	65
1818	Prevalence and prognosis of asymptomatic coronary artery disease in patients with abdominal aortic aneurysm and minor or no perioperative risks. 2009 , 73, 1203-9	7
1817	Rheumatoid arthritis: model of systemic inflammation driving atherosclerosis. 2009 , 73, 977-85	119
1816	Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). 2009 , 73, 2110-7	158
1815	Statin treatment in patients with metabolic syndrome and coronary artery disease. 2009 , 73, 2013-4	
1814	Cosmic effect of rosuvastatin in COSMOS. 2009 , 73, 2015-6	
1813	Hyperlipidemia in racial/ethnic minorities: differences in lipid profiles and the impact of statin therapy. 2009 , 4, 741-754	13
1812	C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force. 2009 , 151, 483-95	376
1811	Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive Services Task Force. 2009 , 151, 496-507	242
1810	C-reactive protein and cardiovascular diseases--is it ready for primetime?. 2009 , 338, 486-92	65
1809	Journal Club. 2009 , 75, 251-252	
1808	Interaction between cigarette smoking and high-sensitivity C-reactive protein in the development of coronary vasospasm in patients without hemodynamically significant coronary artery disease. 2009 , 338, 440-6	17
1807	Cytokine biomarkers, endothelial inflammation, and atherosclerosis in the metabolic syndrome: emerging concepts. 2009 , 338, 310-8	87

1806	When statin therapy stops: implications for the patient. 2009 , 24, 454-60	18
1805	Rosuvastation to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. 2009 , 2009, 282-284	
1804	Drug combinations for dyslipidemia and obesity treatment in metabolic syndrome. 2009 , 15, 3446-62	5
1803	Current world literature. 2009 , 20, 242-9	1
1802	Statin and ezetimibe combination therapy in cardiovascular disease. 2009 , 16, 183-8	17
1801	Are the pleiotropic effects of telmisartan clinically relevant?. 2009 , 15, 2815-32	22
1800	Genetically Elevated C-Reactive Protein and Ischemic Vascular Disease. 2009 , 2009, 328-330	
1799	Editorial [Hot Topic:Modifying Cardiovascular Risk Factors: Newer Insights and Preventive Measures (Executive Editor: Aurelio Leone)]. 2009 , 15, 1034-1037	4
1798	Statins and cardiovascular events in patients with end-stage renal disease on hemodialysis. The AURORA results suggest the need for earlier intervention. 2009 , 7, 264-6	8
1797	Biomarkers of immune dysfunction in HIV. 2010 , 5, 498-503	136
1796	The connection between C-reactive protein (CRP) and diabetic vasculopathy. Focus on preclinical findings. 2010 , 6, 27-34	62
1795	Switching from atorvastatin to simvastatin in patients at high cardiovascular risk: effects on low-density lipoprotein cholesterol. 2010 , 17, 167-75	25
1794	Combination regimens with statin, niacin, and intestinally active LDL-lowering drugs: alternatives to high-dose statin therapy?. 2010 , 21, 372-7	6
1793	Current world literature. 2010 , 25, 411-21	
1792	Should adipokines be considered in the choice of the treatment of obesity-related health problems?. 2010 , 11, 122-35	86
1791	Hyperhomocysteinemia and sudden cardiac death: potential arrhythmogenic mechanisms. 2010 , 8, 64-74	18
1790	Enhancing endothelial progenitor cell function through selective estrogen receptor modulation: a potential approach to cardiovascular risk reduction. 2010 , 8, 147-55	4
1789	Psoriasis, inflammation, and vascular risk: a problem more than skin deep?. 2010 , 31, 902-4	19

1788	Pharmacotherapy of mixed dyslipidemia in the metabolic syndrome. 2010 , 5, 133-9	8
1787	Method of LDL Cholesterol Measurement Influences Classification of LDL Cholesterol Treatment Goals. 2010 , 58, 945-949	18
1786	C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. 2010 , 2010, 295-297	
1785	Current topics on hypolipidaemic therapy and cardiovascular risk assessment. 2010 , 8, 587-8	1
1784	Session 4: CVD, diabetes and cancer: A dietary portfolio for management and prevention of heart disease. 2010 , 69, 39-44	3
1783	An assessment of the effect of statin use on the incidence of acute respiratory infections in England during winters 1998-1999 to 2005-2006. 2010 , 138, 1281-8	30
1782	Clinical implications of inflammation for cardiovascular primary prevention. 2010 , 31, 777-83	66
1781	Dyslipidémies et risque cardiovasculaire : donnèes des études de prévention cardiovasculaire. 2010 , 7, 1-13	
1780	Combination therapy of calcium channel blocker and angiotensin II receptor blocker reduces augmentation index in hypertensive patients. 2010 , 339, 433-9	22
1779	Traitement par les radiations ionisantes en hématologie : indications actuelles, nouveaux concepts, nouvelles modalités. 2010 , 5, 1-15	
1778	Adiposity and hypertension: the inflammatory link. 2010 , 28, 1377-9	2
1777	Overall mortality, incremental life expectancy, and cause of death at 25 years in the program on the surgical control of the hyperlipidemias. 2010 , 251, 1034-40	58
1776	Intensive statin therapy: a goal worth targeting. 2010 , 2, 103-105	
1775	Exercise without weight loss does not reduce C-reactive protein: the INFLAME study. 2010 , 42, 708-16	90
1774	Matching pathophysiology and evidence-based medicine for optimal management of ischemic heart disease. 2010 , 11, 469-79	4
1773	Management of hypercholesterolemia in older persons for the prevention of cardiovascular disease. 2010 , 18, 132-40	16
1772	Markers of cholesterol absorption and synthesis predict the low-density lipoprotein cholesterol response to atorvastatin. 2010 , 56, 396-401	7
1771	A practical approach to the metabolic syndrome: review of current concepts and management. 2010 , 25, 502-12	25

1770	Statin prescription in men and women at cardiovascular risk: to whom and when?. 2010 , 25, 484-9	14
1769	Non-HDL C equals apolipoprotein B: except when it does not!. 2010 , 21, 518-24	25
1768	Pitavastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia. 2010 , 18, 264-7	13
1767	Statins and inflammation: an update. 2010 , 25, 399-405	76
1766	Prognostic value of myeloperoxidase in coronary artery disease: comparison of unstable and stable angina patients. 2010 , 21, 129-36	37
1765	Association of statins and diabetes mellitus. 2010 , 17, e52-5	2
1764	Do structural differences in statins correlate with clinical efficacy?. 2010 , 21, 298-304	24
1763	Depressive symptoms, race, and circulating C-reactive protein: the Coronary Artery Risk Development in Young Adults (CARDIA) study. 2010 , 72, 734-41	74
1762	The Acute (Cerebro) Vascular Effects of Statins. 2010 , 54, 100-101	
1761	Chronic coronary disease in the post-COURAGE Era: a new paradigm. 2010 , 18, 292-7	1
1760	The effect of simvastatin on lymphocyte secretory function in patients with impaired fasting glucose. 2010 , 56, 491-7	7
1759	Effects of ezetimibe add-on to statin therapy on adipokine production in patients with metabolic syndrome and stable vascular disease. 2010 , 56, 241-5	8
1758	Women and elderly: subgroups under-represented in clinical trials. 2010 , 25, 335-9	10
1757	Evaluating health outcomes in the presence of competing risks: a review of statistical methods and clinical applications. 2010 , 48, S96-105	142
1756	Cardiovascular disease in rheumatoid arthritis: a step forward. 2010 , 22, 342-7	25
1755	Statin myopathy: a review of recent progress. 2010 , 22, 644-50	55
1754	Biochemical markers for cardiovascular disease in recently postmenopausal women with or without hot flashes. 2010 , 17, 145-51	28
1753	2) Hypertension. 2010 , 99, 2096-2103	

1752 3) Dyslipidemia.. **2010**, 99, 454-460

1751 Soluble lectin-like oxidized low-density lipoprotein receptor-1 predicts prognosis after acute coronary syndrome--a pilot study. **2010**, 74, 1399-404 47

1750 Pleiotropic effects of statins. - Basic research and clinical perspectives -. **2010**, 74, 818-26 404

1749 2) Treatment of Ischemic Heart Disease.. **2010**, 99, 473-479

1748 Atherosclerosis I: LDL Cholesterol Lowering. **2010**, 303-330

1747 Optimizing statin treatment for primary prevention of coronary artery disease. **2010**, 152, 69-77 90

1746 Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. **2010**, 152, 488-96, W174 155

1745 Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk. **2010**, 153, 800-8 80

1744 Imperfect pharmacovigilance. **2010**, 103, 602-3

1743 Nonoptimal lipids commonly present in young adults and coronary calcium later in life: the CARDIA (Coronary Artery Risk Development in Young Adults) study. **2010**, 153, 137-46 66

1742 Targeting residual risk: the rationale for the use of non-HDL cholesterol. **2010**, 103, 434-7; quiz 438-9 6

1741 [Role of rosuvastatin in current lipid-lowering therapy]. **2010**, 151, 1424-8 1

1740 HIV-induced immune activation: pathogenesis and clinical relevance - summary of a workshop organized by the German AIDS Society (DAIG e.v.) and the ICH Hamburg, Hamburg, Germany, November 22, 2008. **2010**, 15, 1-12 2

1739 Rosuvastatin reduces neointima formation in a rat model of balloon injury. **2010**, 15, 461-7 13

1738 Socioeconomic and psychosocial predictors of interleukin-6 in the MIDUS national sample. **2010**, 29, 626-35 126

1737 Role of cholesterol crystals in myocardial infarction and stroke. **2010**, 5, 57-69 5

1736 Long-term clinical outcome after endovascular treatment in patients with intermittent claudication due to iliofemoral artery disease. **2010**, 74, 1689-95 19

1735 Clinical significance of mild lipid-lowering by statins for prevention of cardiovascular disease in Japanese high-risk patients. **2010**, 74, 630-1 1

1734	"Just make it lower" is an alternative strategy of lipid-lowering therapy with statins in Japanese patients: LDL-cholesterol: the lower, the better; is it true for Asians? (Con). 2010 , 74, 1731-41	24
1733	Clinical significance of intensive lipid-lowering therapy using statins in patients with coronary artery disease: LDL-cholesterol: the lower, the better; is it true for Asians? (Pro). 2010 , 74, 1718-30	22
1732	Long-term statin therapy affects the severity of chronic gastritis. 2010 , 15, 510-5	19
1731	[Therapy of dyslipidemia in rheumatic diseases]. 2010 , 69, 689-92, 694-5	3
1730	Gender differences in coronary heart disease. 2010 , 18, 598-602	410
1729	Therapeutic options for the prevention of type 2 diabetes mellitus in the metabolic syndrome. 2010 , 77, 524-32	4
1728	Should we measure C-reactive protein on earth or just on JUPITER?. 2010 , 33, 190-8	17
1727	Dyslipidemia in the elderly: should it be treated?. 2010 , 33, 4-9	29
1726	Peripheral arterial tonometry for risk stratification in men with coronary artery disease. 2010 , 33, 94-8	23
1725	Is calcium scoring of the coronary arteries necessary for proper management of asymptomatic subjects with classic risk factors?. 2010 , 33, 658-9	1
1724	Parkinson's disease: mitochondrial molecular pathology, inflammation, statins, and therapeutic neuroprotective nutrition. 2010 , 25, 371-89	38
1723	Biomarkers of inflammation and oxidative stress in atherosclerosis. 2010 , 4, 361-73	41
1722	Incidence and risk factors of peripheral arterial occlusive disease in a prospective cohort of 700 adult men followed for 5 years. 2010 , 34, 1980-1	
1721	[High-dose statin therapy for high-risk patients]. 2010 , 35, 497-502	1
1720	[New aspects of perioperative statin therapy]. 2010 , 59, 539-48	3
1719	[Rosuvastatin for primary prevention of vascular events : JUPITER trial (Justification for the Use of statins in Prevention: an Intervention Trial Evaluation Rosuvastatin)]. 2010 , 51, 103-106	1
1718	[Cardiac workup after cerebral ischemia. Consensus paper of the Working Group on Heart and Brain of the German Cardiac Society and German Stroke Society]. 2010 , 81, 444-62	12
1717	Association between mannose-binding lectin, high-sensitivity C-reactive protein and the progression of diabetic nephropathy in type 1 diabetes. 2010 , 53, 1517-24	71

1716	The effect of lipid and inflammatory profiles on the morphological changes of lipid-rich plaques in patients with non-ST-segment elevated acute coronary syndrome: follow-up study by optical coherence tomography and intravascular ultrasound. 2010 , 3, 766-72	46
1715	Comparative study of clinical characteristics between Chinese Han and German Caucasian patients with coronary heart disease. 2010 , 99, 45-50	12
1714	Cardiological evaluation after cerebral ischaemia : Consensus statement of the Working Group Heart and Brain of the German Cardiac Society-Cardiovascular Research (DGK) and the German Stroke Society (DSG). 2010 , 99, 609-25	12
1713	A systematic review of the effect of TNF-alpha antagonists on lipid profiles in patients with rheumatoid arthritis. 2010 , 29, 947-55	47
1712	[Lipid therapy in patients with diabetes]. 2010 , 160, 25-9	
1711	Targeting inflammation to slow or delay functional decline: where are we?. 2010 , 11, 603-14	26
1710	Systematic review on evidence of the effectiveness of cholesterol-lowering drugs. 2010 , 27, 348-64	18
1709	Early insights of cardiac risk and treatment response with quantitative PET monitoring of coronary-specific endothelial dysfunction and myocardial perfusion reserve. 2010 , 17, 985-9	1
1708	Lipoprotein-Associated Phospholipase A2 and C-Reactive Protein for Measurement of Inflammatory Risk: Independent or Complementary?. 2010 , 4, 57-67	1
1707	Inflammation: The Link Between Obesity and Cardiovascular Risk. 2010 , 4, 101-111	1
1706	Does the Framingham Risk Score Predict Risk in Women as Well as It Does in Men?. 2010 , 4, 229-236	1
1705	Genetic Loci Associated with C-Reactive Protein Levels and Risk Of Coronary Heart Disease. 2010 , 4, 178-180	0
1704	How Low to Go for Primary Prevention?. 2010 , 4, 245-247	
1703	Assessment of the JUPITER Trial. 2010 , 4, 399-401	
1702	Die Bedeutung von körperlicher Aktivität und körperlichem Training in der Prävention der koronaren Herzkrankheit. 2010 , 5, 165-179	
1701	Cardiovascular health and particulate vehicular emissions: a critical evaluation of the evidence. 2010 , 3, 3-27	96
1700	Therapeutic options to further lower C-reactive protein for patients on statin treatment. 2010 , 12, 34-42	13
1699	Management of the patient with statin intolerance. 2010 , 12, 48-57	32

1698	Statin effects on both low-density lipoproteins and high-density lipoproteins: is there a dual benefit?. 2010 , 12, 14-9	3
1697	Role of C-reactive protein in contributing to increased cardiovascular risk in metabolic syndrome. 2010 , 12, 110-8	50
1696	Cholesterol in beta-cell dysfunction: the emerging connection between HDL cholesterol and type 2 diabetes. 2010 , 10, 55-60	46
1695	Inflammatory biomarkers and coronary heart disease: from bench to bedside and back. 2010 , 5, 225-33	44
1694	Further opportunities for cost reduction of medical care. 2010 , 35, 561-71	7
1693	Atherosclerotic plaque regression: fact or fiction?. 2010 , 24, 311-7	15
1692	Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study. 2010 , 24, 421-8	17
1691	Lipid and C-reactive protein levels, cardiovascular disease risk factors and simvastatin treatment in Brazilian individuals. 2010 , 33, 244-50	7
1690	Secondary prevention strategies for coronary heart disease. 2010 , 29, 8-24	20
1689	Jupiter or Aurora? Micro-inflammation and dyslipidaemia: twin targets for statin therapy in CKD. 2010 , 42, 133-6	3
1688	Lipidomic analysis of variation in response to simvastatin in the Cholesterol and Pharmacogenetics Study. 2010 , 6, 191-201	86
1687	AURORA: is there a role for statin therapy in dialysis patients?. 2010 , 55, 237-40	3
1686	Serum, plasma, and dried blood spot high-sensitivity C-reactive protein enzyme immunoassay for population research. 2010 , 362, 112-20	111
1685	Exploring new indications for statins beyond atherosclerosis: Successes and setbacks. 2010 , 55, 155-62	18
1684	Cost-Effective Prevention of Coronary Heart Disease. 2010 , 6, 754-764	1
1683	Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. 2010 , 126, 314-45	161
1682	Perspectives of the non-statin hypolipidemic agents. 2010 , 127, 19-40	68
1681	Rationale and methods of the European Study on Cardiovascular Risk Prevention and Management in Daily Practice (EURIKA). 2010 , 10, 382	21

1680	Diverse effects of statins on angiogenesis: new therapeutic avenues. 2010 , 30, 169-76	45
1679	Childhood Morbidity and Health in Early Adulthood: Life course linkages in a high morbidity context. 2010 , 15, 132-146	16
1678	Eligibility for statin therapy by the JUPITER trial criteria and subsequent mortality. 2010 , 105, 77-81	9
1677	Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease. 2010 , 105, 288-92	124
1676	Relation between C-reactive protein, homocysteine levels, fibrinogen, and lipoprotein levels and leukocyte and platelet counts, and 10-year risk for cardiovascular disease among healthy adults in the USA. 2010 , 105, 1284-8	51
1675	Relation of different measures of low-density lipoprotein cholesterol to risk of coronary artery disease and death in a meta-regression analysis of large-scale trials of statin therapy. 2010 , 105, 1289-96	39
1674	Comparison of effects of statin use on mortality in patients with peripheral arterial disease with versus without elevated C-reactive protein and d-dimer levels. 2010 , 105, 1348-52	19
1673	Effect of homocysteine-lowering B vitamin treatment on angiographic progression of coronary artery disease: a Western Norway B Vitamin Intervention Trial (WENBIT) substudy. 2010 , 105, 1577-84	37
1672	Relation of microchannel structure identified by optical coherence tomography to plaque vulnerability in patients with coronary artery disease. 2010 , 105, 1673-8	119
1671	Impact of lipid-lowering therapy on outcomes in atrial fibrillation. 2010 , 105, 1768-72	10
1670	Relation of C-reactive protein to abdominal adiposity. 2010 , 106, 56-61	141
1669	Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). 2010 , 106, 204-9	112
1668	Can a statin neutralize the cardiovascular risk of unhealthy dietary choices?. 2010 , 106, 587-92	14
1667	AJC editor's consensus: rheumatoid arthritis and atherosclerotic cardiovascular disease. 2010 , 106, 442-7	17
1666	Should statin therapy be allocated on the basis of global risk or on the basis of randomized trial evidence?. 2010 , 106, 905-9	5
1665	Statin therapy in primary prevention: new insights regarding women and the elderly. 2010 , 106, 1357-9	3
1664	The JUPITER Trial: responding to the critics. 2010 , 106, 1351-6	23
1663	Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study. 2010 , 32, 492-505	41

1662	Impact of 6 weeks of treatment with low-dose metformin and atorvastatin on glucose-induced changes of endothelial function in adults with newly diagnosed type 2 diabetes mellitus: A single-blind study. 2010 , 32, 1720-8	18
1661	Effects of treatment strategy on endothelial function. 2010 , 9, 840-4	14
1660	Innate immune signals in atherosclerosis. 2010 , 134, 5-24	137
1659	Impact of triglycerides on lipid and lipoprotein biology in women. 2010 , 7, 189-205	11
1658	A randomized clinical trial to assess the effect of statins on skeletal muscle function and performance: rationale and study design. 2010 , 13, 104-11	27
1657	Subclinical atherosclerosis: evolving role of carotid intima-media thickness. 2010 , 13, 186-97	23
1656	Should we focus on novel risk markers and screening tests to better predict and prevent cardiovascular disease? Or are we putting the cart before the horse?. 2010 , 13, 149-51	
1655	The association between C-reactive protein levels and insulin therapy in obese vs nonobese veterans with type 2 diabetes mellitus. 2010 , 12, 462-8	3
1654	Effects of pioglitazone and metformin fixed-dose combination therapy on cardiovascular risk markers of inflammation and lipid profile compared with pioglitazone and metformin monotherapy in patients with type 2 diabetes. 2010 , 12, 973-82	10
1653	Short-term treatment with high-dose atorvastatin reduces LDL cholesterol but shows no anti-inflammatory effects in normolipidemic subjects with normal CRP levels. 2010 , 3, 140-6	13
1652	Effect of the rs2259816 polymorphism in the HNF1A gene on circulating levels of c-reactive protein and coronary artery disease (the ludwigshafen risk and cardiovascular health study). 2010 , 11, 157	5
1651	Lipid control and use of lipid-regulating drugs for prevention of cardiovascular events in Chinese type 2 diabetic patients: a prospective cohort study. 2010 , 9, 77	28
1650	Waist circumference as the predominant contributor to the micro-inflammatory response in the metabolic syndrome: a cross sectional study. 2010 , 7, 35	13
1649	Higher level of systemic C-reactive protein is independently predictive of coronary heart disease in older community-dwelling adults: the three-city study. 2010 , 58, 129-35	15
1648	Can statins prevent dementia in older adults?. 2010 , 58, 1393-4	2
1647	Acute activation of eNOS by statins involves scavenger receptor-B1, G protein subunit Gi, phospholipase C and calcium influx. 2010 , 160, 1765-72	25
1646	Gender-specific aspects of treatment of cardiovascular risk factors in primary and secondary prevention. 2010 , 24, 699-705	11
1645	Management of acute coronary syndromes from a gender perspective. 2010 , 24, 719-28	2

1644	Role of drugs and devices in patients at risk of sudden cardiac death. 2010 , 24, 575-94	11
1643	The Levels of Inflammatory Markers in the Treatment of Stroke study (LIMITS): inflammatory biomarkers as risk predictors after lacunar stroke. 2010 , 5, 117-25	39
1642	Fiber's impact on high-sensitivity C-reactive protein levels in cardiovascular disease. 2010 , 22, 566-72	16
1641	The effect of statin therapy on the progression of carotid artery stenosis in relation to stenosis severity. 2010 , 121, 11-5	20
1640	Association of salivary lysozyme and C-reactive protein with metabolic syndrome. 2010 , 37, 805-11	15
1639	A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors. 2010 , 64, 1220-7	91
1638	Counterfeit dapoxetine sold on the Internet contains undisclosed sildenafil. 2010 , 64, 1319-22	7
1637	Statin use and the prevention of venous thromboembolism: a meta-analysis. 2010 , 64, 1375-83	50
1636	Practice makes perfect: reflections on a primary care treatment-to-target study. 2010 , 64, 1006-8	2
1635	Relationship of serum homocysteine and high sensitivity C-reactive protein in elderly people with essential hypertension. 2010 , 64, 1318-9	3
1634	Erectile dysfunction and testosterone screening with prostate specific antigen screening at age 40: are these three gender specific determinants additive for overall men's health and do they improve traditional non-gender specific determinants to lessen cardiovascular risk and all-cause mortality?. 2010 , 64, 1754-62	5
1633	C-reactive protein lowering with rosuvastatin in the METEOR study. 2010 , 268, 155-61	26
1632	Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. 2010 , 268, 296-308	270
1631	Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease. 2010 , 268, 456-67	229
1630	Iron stores, liver transaminase levels and metabolic risk in healthy teenagers. 2010 , 40, 155-63	17
1629	Assessing the clinical utility of diagnostics used in drug therapy. 2010 , 88, 765-73	69
1628	Enrichment of clinical study populations. 2010 , 88, 774-8	71
1627	Therapeutic targeting of chemokine interactions in atherosclerosis. 2010 , 9, 141-53	105

1626	Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome. 2010 , 12, 983-93	13
1625	Is statin use associated with prostate cancer aggressiveness?. 2010 , 105, 1222-5	35
1624	Statin Use and Psoriasis Severity. 2010 , 16a, 20-22	
1623	Variants of ADAMTS1 modify the effectiveness of statins in reducing the risk of myocardial infarction. 2010 , 20, 766-74	9
1622	Omega-3 Index and sudden cardiac death. 2010 , 2, 375-88	17
1621	[Cholesterol metabolism and beta-cell function]. 2010 , 26, 385-90	11
1620	Paradoxical association of C-reactive protein with endothelial function in rheumatoid arthritis. 2010 , 5, e10242	15
1619	Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients. 2010 , 5, e13188	74
1618	Endothelium, venous thromboembolism and ischaemic cardiovascular events. 2010 , 103, 56-61	60
1617	Effects of statins on serum inflammatory markers: the U.S. National Health and Nutrition Examination Survey 1999-2004. 2010 , 17, 1176-82	23
1616	Highly sensitive C-reactive protein and male gender are independently related to the severity of coronary disease in patients with metabolic syndrome and an acute coronary event. 2010 , 43, 297-302	11
1615	[Evaluation of analytical measurement ranges of three full range C-reactive protein tests using immunoturbidimetric assay]. 2010 , 30, 9-16	1
1614	Antibodies against oxLDL and acute coronary syndrome. 2010 , 95, 47-54	13
1613	Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia. 2010 , 6, 1023-37	26
1612	Chronic CRP-exposure inhibits VEGF-induced endothelial cell migration. 2010 , 17, 203-12	29
1611	Tough questions about the value of statin therapy for primary prevention: did JUPITER miss the moon?. 2010 , 16, 417-23	5
1610	Benefits of statin therapy and compliance in high risk cardiovascular patients. 2010 , 6, 843-53	42
1609	Clinical utility of rosuvastatin and other statins for cardiovascular risk reduction among the elderly. 2011 , 6, 27-35	12

1608	Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective. 2010 , 4, 383-413	76
1607	COMPARATIVE EFFICACY OF THE STATINS IN PREVENTING AND TREATING OF THE CORONARY HEART DISEASE. 2010 , 6, 865-869	2
1606	Role of bile acid sequestrants in the treatment of type 2 diabetes. 2010 , 1, 146-52	8
1605	Statin therapy reduces inflammatory markers in hypercholesterolemic patients with high baseline levels. 2010 , 17, 722-9	33
1604	Can intensive lipid-lowering therapy with statins ameliorate atherosclerosis in Japanese patients? Rationale and design of the JART study. 2010 , 17, 416-22	5
1603	Dyslipidemia Management in Women and Men. 2010 , 175-185	
1602	Recent cholesterol-lowering drug trials: New data, new questions. 2010 , 19, 65-92	1
1601	Pitavastatin approved for treatment of primary hypercholesterolemia and combined dyslipidemia. 2010 , 6, 997-1005	6
1600	Antipsychotics and metabolics in the post-CATIE era. 2010 , 4, 23-42	26
1599	Earth to JUPITER: how a potent statin may actually be detrimental for lifestyle-associated diseases. 2010 , 61, 119	
1598	Gender differences in cardiovascular disease: hormonal and biochemical influences. 2010 , 17, 511-31	114
1597	Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. 2010 , 170, 1024-31	277
1596	Slightly elevated high-sensitivity C-reactive protein (hsCRP) concentrations are associated with carotid atherosclerosis in women with varying degrees of glucose tolerance. 2010 , 61, 793-801	7
1595	Residual risk for secondary ischemic events in patients with atherothrombotic disease: opportunity for future improvements in patient care. 2010 , 42, 19-35	20
1594	New evidence on pitavastatin: efficacy and safety in clinical studies. 2010 , 11, 817-28	39
1593	Plasma interleukin-8 is not an effective risk stratification tool for adults with vasopressor-dependent septic shock. 2010 , 38, 1436-41	35
1592	Can lipid abnormalities predict renal disease in patients with diabetes?. 2010 , 5, 151-155	1
1591	Statin therapy for low-LDL, high-hsCRP patients: from JUPITER to CORONA. 2010 , 56, 505-7	7

1590	Pleiotropic effects of statins in atherosclerotic disease. 2010 , 8, 1235-7	24
1589	Rosuvastatin is similarly effective for primary prevention of cardiovascular disease in women as in men. 2010 , 15, 74-5	
1588	Mortality reductions produced by sustained prostate cancer screening have been underestimated. 2010 , 17, 147-51	20
1587	Ancestry as a determinant of mean population C-reactive protein values: implications for cardiovascular risk prediction. 2010 , 3, 436-44	56
1586	Computed tomography coronary plaque imaging as a secondary end point for randomized pharmaceutical trials: more bang for the buck?. 2010 , 3, 225-7	
1585	The role of colesvelam hydrochloride in hypercholesterolemia and type 2 diabetes mellitus. 2010 , 44, 1196-206	13
1584	European Atherosclerosis Society screening recommendations for lipoprotein(a) and high-sensitivity C-reactive protein: double standard or failure of evidence-based medicine?. 2010 , 56, 1544-6	6
1583	Serum C-reactive protein is linked to cerebral microstructural integrity and cognitive function. 2010 , 74, 1022-9	165
1582	Encouraging appropriate treatment for familial hypercholesterolemia. 2010 , 5, 339-354	9
1581	Inflammation in atherosclerosis: transition from theory to practice. 2010 , 74, 213-20	537
1580	Testicular cancer survivorship: research strategies and recommendations. 2010 , 102, 1114-30	215
1579	A 1-year lifestyle intervention for weight loss in individuals with type 2 diabetes reduces high C-reactive protein levels and identifies metabolic predictors of change: from the Look AHEAD (Action for Health in Diabetes) study. 2010 , 33, 2297-303	72
1578	Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for "intermediate risk". 2010 , 3, 447-52	47
1577	The numbers are in: statins for the primary prevention of cardiovascular disease in women. 2010 , 121, 1063-5	5
1576	Dysfunctional HDL as a diagnostic and therapeutic target. 2010 , 30, 151-5	109
1575	Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database. 2010 , 51, 1546-53	160
1574	Combination therapy with rosuvastatin and fenofibric acid for mixed dyslipidemia: overview of efficacy and safety. 2010 , 5, 627-649	2
1573	C-reactive protein-mediated vascular injury requires complement. 2010 , 30, 1189-95	34

1572	Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study. 2010 , 3, 276-85	81
1571	The role of usual source of care in cholesterol treatment. 2010 , 23, 179-85	13
1570	In hypertensive people treated with an antihypertensive, concomitant statin administration has no additional effect on blood pressure. 2010 , 15, 143-4	1
1569	Association between statins and prostate tumor inflammatory infiltrate in men undergoing radical prostatectomy. 2010 , 19, 722-8	41
1568	Statin use and the risk of prostate-specific antigen recurrence after radiation therapy with or without hormone therapy for prostate cancer. 2010 , 28, 2651-2	8
1567	Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. 2010 , 28, 2653-9	129
1566	The ENHANCE trial: analysis and clinical significance. 2010 , 5, 161-166	3
1565	Centralized Pan-European survey on the undertreatment of hypercholesterolemia in patients using lipid lowering drugs--the CEPHEUS-Greece survey. 2010 , 61, 465-74	16
1564	A link between impaired lung function and increased cardiac stress. 2010 , 79, 355-62	8
1563	Association of inflammatory markers and carotid intima-media thickness with the risk of cardiovascular events in high-risk patients. 2010 , 30, 180-7	18
1562	Pioglitazone suppresses inflammation in vivo in murine carotid atherosclerosis: novel detection by dual-target fluorescence molecular imaging. 2010 , 30, 1933-9	45
1561	2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2010 , 122, 2748-64	279
1560	Letter by Nakajima and Saito regarding article, "Human C-reactive protein does not promote atherosclerosis in transgenic rabbits". 2010 , 122, e406; author reply e407	
1559	Targeting patients for statin therapy for the primary prevention of vascular events: what is the best approach?. 2010 , 122, 1446-8	2
1558	Effect of statin therapy on colorectal cancer. 2010 , 59, 1572-85	110
1557	C-reactive protein for risk assessment in coronary artery disease. 2010 , 96, 325-7	1
1556	Promises and limitations of mendelian randomization for evaluation of biomarkers. 2010 , 56, 388-90	7
1555	Reproducibility in serial C-reactive protein and interleukin-6 measurements in post-myocardial infarction patients: results from the AIRGENE study. 2010 , 56, 861-4	19

1554	Age-related change in endothelial and microvessel function and therapeutic consequences. 2010 , 20, 161-170	2
1553	Contemporary predictors of coronary artery disease in patients referred for angiography. 2010 , 17, 280-8	9
1552	Use of statin therapy to reduce cardiovascular risk in older patients. 2010 , 915296	6
1551	C-reactive protein and risk of venous thromboembolism in the general population. 2010 , 30, 1672-8	54
1550	eNOS G894T Polymorphism and Abdominal Aortic Aneurysms. 2010 , 61, 227-228	1
1549	C-reactive protein in arrhythmogenic right ventricular dysplasia/cardiomyopathy and relationship with ventricular tachycardia. 2010 , 2010,	18
1548	Niacin or ezetimibe for patients with, or at risk of coronary heart disease. 2010 , 4, 99-110	3
1547	Reducing residual vascular risk in patients with atherogenic dyslipidemia: where do we go from here?. 2010 , 5, 811-826	20
1546	Impact of C-reactive protein and pulse pressure evaluated at the start of peritoneal dialysis on cardiovascular events in the course of treatment with peritoneal dialysis. 2010 , 30, 300-10	7
1545	Statins in sepsis. 2010 , 23, 38-49	6
1544	Dalcetrapib: a review of Phase II data. 2010 , 19, 795-805	31
1543	Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal. 2010 , 170, 1032-6	84
1542	Cardiovascular Disease in Patients with Chronic Kidney Disease. 2010 , 128-144	1
1541	Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). 2010 , 121, 143-50	135
1540	Prediabetes: the importance of early identification and intervention. 2010 , 122, 129-43	35
1539	Serum bilirubin predicts long-term clinical outcomes in patients with cardiac syndrome X. 2010 , 96, 1227-32	31
1538	Non-LDL-related dyslipidaemia and coronary risk: a case-control study. 2010 , 7, 204-12	15
1537	After cardiac surgery, how does nutrition fit in with risk factors?. 2010 , 34, 163-8	3

1536	Pharmacotherapy of dyslipidemias in the adult population. 2010 , 11, 3041-52	7
1535	Multiple cytokine biomarkers in heart failure. 2010 , 10, 147-57	16
1534	The role of bile acid sequestrants in the management of type 2 diabetes mellitus. 2010 , 8 Suppl 1, S15-21	4
1533	Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. 2010 , 31, 149-64	225
1532	Inflammatory markers, cholesterol and statins: pathophysiological role and clinical importance. 2010 , 48, 1685-91	54
1531	Design, operation, and interpretation of clinical trials. 2010 , 89, 759-72	34
1530	Varespladib methyl in cardiovascular disease. 2010 , 19, 1245-55	12
1529	Prognostic value of endothelial microparticles in patients with heart failure. 2010 , 12, 1223-8	80
1528	Lipid lowering goals: back to nature?. 2010 , 4, 185-91	12
1527	ABC de la nefropatà diabètica: UNA guà pràctica para el mèdico general. 2010 , 21, 579-583	
1526	Diabetic dyslipidemia: extending the target beyond LDL cholesterol. 2010 , 17 Suppl 1, S20-4	11
1525	Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension. 2010 , 24, 263-73	47
1524	Differences in the prevalence of metabolic syndrome and levels of C-reactive protein after puerperium in women with hypertensive disorders during pregnancy. 2010 , 33, 1012-7	5
1523	Pitavastatin for the treatment of primary hyperlipidemia and mixed dyslipidemia. 2010 , 8, 1079-90	10
1522	Effects of atorvastatin 20 mg, rosuvastatin 10 mg, and atorvastatin/ezetimibe 5 mg/5 mg on lipoproteins and glucose metabolism. 2010 , 15, 167-74	27
1521	Cardiovascular risk in uremic patients: darkness after AURORA. 2010 , 32, 269-72	0
1520	Cost effectiveness of rosuvastatin in patients at risk of cardiovascular disease based on findings from the JUPITER trial. 2010 , 13, 428-37	19
1519	Risk factors for near-term myocardial infarction in apparently healthy men and women. 2010 , 56, 559-67	24

1518	Cost-effectiveness of using high-sensitivity C-reactive protein to identify intermediate- and low-cardiovascular-risk individuals for statin therapy. 2010 , 122, 1478-87	48
1517	Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. 2010 , 121, 1069-77	222
1516	C-reactive protein uptake by macrophage cell line via class-A scavenger receptor. 2010 , 56, 478-81	16
1515	Statins in the treatment of heart failure. 2010 , 3, 462-4	5
1514	Prediction of cardiovascular event risk reduction from lipid changes associated with high potency dyslipidemia therapy. 2010 , 26, 365-75	11
1513	Endothelial function as a functional expression of cardiovascular risk factors. 2010 , 4, 351-60	87
1512	Lipid-lowering agents and new onset diabetes mellitus. 2010 , 11, 1965-70	12
1511	Establishing a clinical basis for hsCRP in the prevention and treatment of cardiovascular disease. 2010 , 56, 1186-7	6
1510	A review of perioperative statin therapy for noncardiac surgery. 2010 , 14, 283-90	11
1509	Pioglitazone and mechanisms of CV protection. 2010 , 103, 213-28	18
1508	Modeling the 4D Study: statins and cardiovascular outcomes in long-term hemodialysis patients with diabetes. 2010 , 5, 856-66	13
1507	High-density lipoprotein cholesterol increase and non-cardiovascular mortality: a meta-analysis. 2010 , 96, 1345-51	13
1506	Pitavastatin further decreases serum high-sensitive C-reactive protein levels in hypertensive patients with hypercholesterolemia treated with angiotensin II, type-1 receptor antagonists. 2010 , 32, 341-6	3
1505	Persistence with statins and onset of rheumatoid arthritis: a population-based cohort study. 2010 , 7, e1000336	68
1504	Prehypertension subtype with elevated C-reactive protein: risk of ischemic stroke in a general Japanese population. 2010 , 23, 1108-13	23
1503	Lovastatin induces VSMC differentiation through inhibition of Rheb and mTOR. 2010 , 299, C119-27	28
1502	Cardiovascular disease is preventable among women. 2010 , 8, 175-87	7
1501	Arzneiverordnungs-Report 2010. 2010 ,	28

1500	Lovastatin decreases acute mucosal inflammation via 15-epi-lipoxin A4. 2010 , 3, 270-9	80
1499	Stents and statins: history, clinical outcomes and mechanisms. 2010 , 8, 1283-95	7
1498	Measuring hsCRP--an important part of a comprehensive risk profile or a clinically redundant practice?. 2010 , 7, e1000196	12
1497	Headache and biomarkers predictive of vascular disease in a representative sample of US children. 2010 , 164, 358-62	24
1496	2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2010 , 122, e584-636	45 ¹
1495	Perspective: beyond storytelling in medicine: an encounter-based curriculum. 2010 , 85, 794-8	8
1494	By Jove! What is a clinician to make of JUPITER?. 2010 , 170, 1073-7	40
1493	Total and individual coronary artery calcium scores as independent predictors of mortality in hemodialysis patients. 2010 , 31, 419-25	93
1492	Sevelamer decreases systemic inflammation in parallel to a reduction in endotoxemia. 2010 , 29, 352-6	41
1491	Venous thromboembolism risk factor assessment and prophylaxis. 2010 , 25, 219-23	17
1490	C-reactive protein and all-cause mortality--the Copenhagen City Heart Study. 2010 , 31, 1624-32	79
1489	Has atorvastatin more than a DUAAL face?. 2010 , 31, 2567-8	
1488	C-reactive protein is a bystander of cardiovascular disease. 2010 , 31, 2092-6	45
1487	Advances in emerging therapies 2009. 2010 , 41, e67-70	2
1486	Contemporary results of carotid endarterectomy for asymptomatic carotid stenosis. 2010 , 41, 975-9	45
1485	Atorvastatin reduces macrophage accumulation in atherosclerotic plaques: a comparison of a nonstatin-based regimen in patients undergoing carotid endarterectomy. 2010 , 41, 1163-8	54
1484	Women and research on cardiovascular diseases in Europe: a report from the European Heart Health Strategy (EuroHeart) project. 2010 , 31, 1677-1681	46
1483	Treating antiretroviral-induced dyslipidemia in HIV-infected adults. 2010 , 35, 32-7; quiz 37-8	9

1482	C-reactive protein levels and post-ICU mortality in nonsurgical intensive care patients. 2010 , 138, 856-62	28
1481	Cost-effectiveness of statin therapy for vascular event prevention in adults with elevated C-reactive protein: implications of JUPITER. 2010 , 26, 2485-97	14
1480	Optimizing lipid-lowering therapy in the prevention of coronary heart disease. 2010 , 3, 649-61	
1479	Rolle der Inflammation in der Atherosklerose [Ein Update]. 2010 , 39, 140-146	2
1478	Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome. 2010 , 95, 829-36	121
1477	Recent advances in cardiology. 2010 , 6, 11-7	5
1476	Rheumatoid arthritis: RA--lowering cardiovascular risk with statins. 2010 , 6, 123-4	
1475	Obesity without established comorbidities of the metabolic syndrome is associated with a proinflammatory and prothrombotic state, even before the onset of puberty in children. 2010 , 95, 1060-8	94
1474	Atorvastatin attenuates murine anti-glomerular basement membrane glomerulonephritis. 2010 , 77, 428-35	27
1473	Inflammatory biomarkers predicting events in atherosclerosis. 2010 , 17, 1690-707	27
1472	Biomarkers of vulnerable atheromatous plaques: translational medicine perspectives. 2010 , 50, 1-22	15
1471	Retrospective, observation study: Quantitative and qualitative effect of ezetimibe and HMG-CoA reductase inhibitors on LDL-cholesterol: are there disappearance thresholds for small, dense LDL and IDL?. 2010 , 5, 143-52	2
1470	Does the blood pressure-lowering effect of statins contribute to their beneficial cardiovascular effects?. 2010 , 8, 775-9	9
1469	Use of rosuvastatin in preventing vascular events in patients with elevated C-reactive protein. Commentary. 2010 , 122, 169-71	1
1468	METEOR Trial Reports on the Effect of Rosuvastatin on Progression of Carotid Intima-Media Thickness in Low-Risk Individuals with Subclinical Atherosclerosis. 2010 , 38, 180-2	2
1467	The JUPITER lipid lowering trial and vitamin D: Is there a connection?. 2010 , 2, 50-4	10
1466	Presence of coronary plaques in patients with nonalcoholic fatty liver disease. 2010 , 254, 393-400	145
1465	Treating arteries instead of risk factors: a paradigm change in management of atherosclerosis. 2010 , 41, 1193-9	106

1464	Lipoprotein-associated phospholipase A2: role in atherosclerosis and utility as a cardiovascular biomarker. 2010 , 8, 425-38	23
1463	Ischaemic nephropathy secondary to atherosclerotic renal artery stenosis: clinical and histopathological correlates. 2010 , 25, 3615-22	58
1462	Therapy modifications and low-density lipoprotein cholesterol goal attainment rates associated with the initiation of generic simvastatin. 2010 , 26, 121-8	16
1461	Perioperative statin use: an update. 2010 , 28, 739-51	8
1460	[What is the impact of the new clinical trial data? What are the lessons for patient management?]. 2010 , 137, 11-5	
1459	To B or not to B: is non-high-density lipoprotein cholesterol an adequate surrogate for apolipoprotein B?. 2010 , 85, 446-50	14
1458	La diète méditerranéenne traditionnelle pour la prévention de l'infarctus et des cancers. 2010 , 2, 40-45	
1457	Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma. 2010 , 85, 349-56	105
1456	Peripheral artery disease: current insight into the disease and its diagnosis and management. 2010 , 85, 678-92	190
1455	Hemostatic effects of simvastatin in subjects with impaired fasting glucose. 2010 , 62, 1090-8	7
1454	Hemostatic effects of fenofibrate in patients with mixed dyslipidemia and impaired fasting glucose. 2010 , 62, 1099-107	7
1453	Clinical update on nursing home medicine: 2010. 2010 , 11, 543-66	3
1452	Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering. 2010 , 10 Suppl 1, 10-7	35
1451	Pleiotropic effects of statins: evidence for benefits beyond LDL-cholesterol lowering. 2010 , 10 Suppl 1, 3-9	42
1450	Cardiorenal versus Renocardiac Syndrome. 2010 , 15-34	
1449	Study Population. 2010 , 55-66	
1448	Carotid ultrasound identifies high risk subclinical atherosclerosis in adults with low framingham risk scores. 2010 , 23, 802-8	37
1447	Cardiovascular disease, SCI and exercise: unique risks and focused countermeasures. 2010 , 32, 2228-36	39

1446	[Advances in cholesterol-lowering interventions]. 2010 , 57, 210-9	8
1445	Acute coronary syndrome: emerging tools for diagnosis and risk assessment. 2010 , 55, 1403-15	83
1444	Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. 2010 , 55, 1209-1216	165
1443	Redefining normal low-density lipoprotein cholesterol: a strategy to unseat coronary disease as the nation's leading killer. 2010 , 56, 630-6	23
1442	Rosuvastatin and cardiovascular continuum when time is important. 2010 , 55, 1645-6; author reply 1646	9
1441	ST-segment resolution and outcome in myocardial infarction. 2010 , 55, 1646-7; author reply 1647	2
1440	Baseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid-altering therapy. 2010 , 55, 2846-54	112
1439	Reply. 2010 , 55, 1646	2
1438	Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. 2010 , 55, 1266-1273	157
1437	More progression toward regression? Beyond low-density lipoprotein cholesterol lowering. 2010 , 55, 2743-4	1
1436	Screening asymptomatic subjects for subclinical atherosclerosis: not so obvious. 2010 , 56, 106-8	25
1435	Association of combinations of lipid parameters with carotid intima-media thickness and coronary artery calcium in the MESA (Multi-Ethnic Study of Atherosclerosis). 2010 , 56, 1034-41	55
1434	Multiple biomarkers for predicting cardiovascular events: lessons learned. 2010 , 55, 2092-5	32
1433	High-dose statin, not so IDEAL?. 2010 , 55, 2516-7	
1432	Carotid ultrasound, coronary calcium, and dyslipidemia patterns in the MESA (Multi-Ethnic Study of Atherosclerosis) cohort. 2010 , 56, 1042-4	1
1431	Evidence of pre-procedural statin therapy a meta-analysis of randomized trials. 2010 , 56, 1099-109	134
1430	Coronary artery calcium progression: an important clinical measurement? A review of published reports. 2010 , 56, 1613-22	180
1429	2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2010 , 56, e50-103	976

1428	2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Ca. 2010 , 4, 83-8	102
1427	When is equal not equal? 2010 , 4, 83-8	22
1426	No evidence of impaired endothelial function or altered inflammatory state in patients with familial hypercholesterolemia treated with statins. 2010 , 4, 288-92	14
1425	Cholesterol crystals piercing the arterial plaque and intima trigger local and systemic inflammation. 2010 , 4, 156-64	110
1424	High-density lipoproteins: marker of cardiovascular risk and therapeutic target. 2010 , 4, 359-64	26
1423	The absence of coronary calcium: clinical and therapeutic implications for the clinical lipidologist. 2010 , 4, 472-7	1
1422	Statin use and lipid levels in older adults: National Health and Nutrition Examination Survey, 2001 to 2006. 2010 , 4, 483-90	32
1421	Serial coronary CT angiography-verified changes in plaque characteristics as an end point: evaluation of effect of statin intervention. 2010 , 3, 691-8	126
1420	Statins in the elderly: what evidence of their benefit in prevention?. 2010 , 103, 61-5	1
1419	C-reactive protein and vascular risk: from March to Jupiter. 2010 , 103, 139-41	
1418	Drug treatment of hyperlipidaemia: a guide to the rational use of lipid-lowering drugs. 2010 , 70, 1363-79	38
1417	Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. 2010 , 33, 171-87	132
1416	Does upsizing statins have a downside?. 2010 , 33, 435-6; author reply 436-7	4
1415	El uso de rosuvastatina reduce la aparición de tromboembolismo venoso en personas sanas y frente a placebo. 2010 , 8, 24-25	
1414	Rosuvastatin stimulates clonogenic potential and anti-inflammatory properties of endothelial progenitor cells. 2010 , 34, 709-15	21
1413	Multiple markers of inflammation and weight status: cross-sectional analyses throughout childhood. 2010 , 125, e801-9	162
1412	Na ⁺ H ⁺ exchanger-1: a link with atherogenesis?. 2010 , 19, 1545-56	6
1411	Does baseline carotid intima-media thickness modify the effect of rosuvastatin when compared with placebo on carotid intima-media thickness progression? The METEOR study. 2010 , 17, 223-9	9

1410	Targeting cardiovascular risk in rheumatoid arthritis: a dual role for statins. 2010 , 6, 157-64	18
1409	Comparison of sequential rosuvastatin doses in hypercholesterolaemia: a meta-analysis of randomised controlled trials. 2010 , 26, 537-47	5
1408	Hypertension 2010: what was new for the cardiologist?. 2010 , 11, 2579-97	6
1407	Rosuvastatin: a review of its use in the prevention of cardiovascular disease in apparently healthy women or men with normal LDL-C levels and elevated hsCRP levels. 2010 , 10, 383-400	11
1406	Chronic Disease Prevention Research Methods and Their Reliability, With Illustrations From the Women's Health Initiative. 2010 , 105, 1431-1443	3
1405	Emerging drugs for hyperlipidemia. 2010 , 15, 433-51	13
1404	The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. 2010 , 49, 295-307	265
1403	To JUPITER and beyond: statins, inflammation, and primary prevention. 2010 , 14, 310	9
1402	Statins in patients with chronic kidney disease: why, who and when?. 2010 , 11, 2665-74	16
1401	Prolonged inflammation following critical illness may impair long-term survival: a hypothesis with potential therapeutic implications. 2010 , 75, 32-4	5
1400	Tempol, a superoxide dismutase mimetic, prevents cerebral vessel remodeling in hypertensive rats. 2010 , 80, 445-52	34
1399	On reducing cardiovascular disease to a rarity: clinical strategies and their cost-effectiveness. 2010 , 19, 225-7	
1398	Is diabetes the cost to pay for a greater cardiovascular prevention?. 2010 , 144, 309-10	4
1397	DDDR pacing results in left ventricular asynchrony with preservation of ejection fraction and NT-proBNP: a prospective study in sick sinus syndrome and normal ventricular function. 2010 , 144, 310-2	
1396	Serum levels of C-reactive protein in patients with stable coronary artery disease: JUPITER in perspective. 2010 , 144, 448-9	2
1395	Rosuvastatin and vitamin D: might there be hypovitaminosis D on JUPITER?. 2010 , 145, 556-7	8
1394	[Are prevention and compassion antagonistic values?]. 2010 , 135, 650-2	1
1393	[Tables for cholesterol lowering therapy planning. An update]. 2010 , 135, 120-3	7

1392	Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. 2010 , 87, 98-107	137
1391	Update of cerebral vascular disease: issues for the primary care physician. 2010 , 56, 40-71	10
1390	C-reactive protein; a potential marker of second cancer and cardiovascular disease in testicular cancer survivors?. 2010 , 46, 3425-33	16
1389	Reversible and non-reversible cardiovascular risk in patients treated with lipid-lowering therapy: analysis of SEAS and JUPITER trials. 2010 , 21, 372-3	7
1388	Inflammation and brain injury: acute cerebral ischaemia, peripheral and central inflammation. 2010 , 24, 708-23	230
1387	Self-reported experiences of everyday discrimination are associated with elevated C-reactive protein levels in older African-American adults. 2010 , 24, 438-43	218
1386	Cardiac glycosides potently inhibit C-reactive protein synthesis in human hepatocytes. 2010 , 394, 233-9	9
1385	Dietary restriction suppresses inflammation and delays the onset of stroke in stroke-prone spontaneously hypertensive rats. 2010 , 399, 98-103	25
1384	Association of urinary polycyclic aromatic hydrocarbons and serum C-reactive protein. 2010 , 110, 79-82	51
1383	Weak associations between prognostic biomarkers and disease in preliminary studies illustrates the breach between statistical significance and diagnostic discrimination. 2010 , 411, 467-73	5
1382	Anti-inflammatory Agents: Present and Future. 2010 , 140, 935-50	641
1381	Managing cardiovascular risk factors: trial evidence in women. 2010 , 20, 445-50	8
1380	Cytokine production by islets in health and diabetes: cellular origin, regulation and function. 2010 , 21, 261-7	166
1379	Aspirin resistance following pediatric cardiac surgery. 2010 , 126, 200-6	20
1378	Atorvastatin has antithrombotic effects in patients with type 1 diabetes and dyslipidemia. 2010 , 126, e225-31	47
1377	Association of statin prescription with small abdominal aortic aneurysm progression. 2010 , 159, 307-13	124
1376	Maximizing scientific knowledge from randomized clinical trials. 2010 , 159, 937-43	10
1375	Novel biomarkers in cardiovascular disease: update 2010. 2010 , 160, 583-94	115

1374	Statins decrease the occurrence of venous thromboembolism in patients with cancer. 2010 , 123, 60-5	46
1373	Vulnerable plaques and patients: improving prediction of future coronary events. 2010 , 123, 10-6	30
1372	Treating mixed hyperlipidemia and the atherogenic lipid phenotype for prevention of cardiovascular events. 2010 , 123, 892-8	30
1371	Statins withdrawal, vascular complications, rebound effect and similitude. 2010 , 99, 255-62	16
1370	Statins--is there potential for uncovering new benefits (or detriments)? 2010 , 28, 67-9	1
1369	The diabetic CKD patient--a major cardiovascular challenge. 2010 , 36 Suppl 1, 34-46	12
1368	Post-transcriptional regulons coordinate the initiation and resolution of inflammation. 2010 , 10, 24-35	208
1367	Lovastatin inhibits oxidized L-A-phosphatidylcholine B-arachidonoyl-gamma-palmitoyl (ox-PAPC)-stimulated interleukin-8 mRNA and protein synthesis in human aortic endothelial cells by depleting stores of geranylgeranyl pyrophosphate. 2010 , 208, 50-5	1
1366	Angiotensin II receptor blocker and statins lower elevated levels of osteopontin in essential hypertension--results from the EUTOPIA trial. 2010 , 209, 184-8	41
1365	Mycophenolate mofetil attenuates plaque inflammation in patients with symptomatic carotid artery stenosis. 2010 , 211, 231-6	50
1364	Association of C-reactive protein and homocysteine with subclinical coronary plaque subtype and stenosis using low-dose MDCT coronary angiography. 2010 , 212, 501-6	11
1363	Association of monocyte subset counts with coronary fibrous cap thickness in patients with unstable angina pectoris. 2010 , 212, 628-35	65
1362	Novel insights into anti-inflammatory actions of HDL. 2010 , 212, 388-9	1
1361	Impact of inflammatory markers on platelet inhibition and cardiovascular outcome including stent thrombosis in patients with symptomatic coronary artery disease. 2010 , 213, 256-62	48
1360	Perioperative statin therapy reduces mortality in normolipidemic patients undergoing cardiac surgery. 2010 , 140, 1018-27	22
1359	[Should we modify our therapeutic behavior as a consequence of the 2009 revision of the ESH/ESC guidelines for the management of arterial hypertension?]. 2010 , 210, 511-6	1
1358	[Ischemic heart disease: 2009 update]. 2010 , 63 Suppl 1, 49-60	5
1357	C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. 2010 , 375, 132-40	1584

1356	Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. 2010 , 375, 735-42	1644
1355	C-reactive protein and cardiovascular risk: more fuel to the fire. 2010 , 375, 95-6	17
1354	Balancing the benefits of statins versus a new risk-diabetes. 2010 , 375, 700-1	18
1353	C-reactive protein measurement and cardiovascular disease [Authors' reply. 2010 , 375, 1077-1078	1
1352	HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. 2010 , 376, 333-9	178
1351	JUPITER, rosuvastatin, and the European Medicines Agency. 2010 , 375, 2071	4
1350	Statins and risk of incident diabetes. 2010 , 375, 2139; author reply 2141-2	
1349	Statins and risk of incident diabetes. 2010 , 375, 2140-1; author reply 2141-2	5
1348	Dissociating HDL cholesterol from cardiovascular risk. 2010 , 376, 305-6	5
1347	Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. 2010 , 376, 1670-81	3845
1346	L'Infection VIH : une maladie chronique inflammatoire. 2010 , 40, H1-H4	0
1345	2010 guidelines of the Taiwan Society of Cardiology for the management of hypertension. 2010 , 109, 740-73	72
1344	C-reactive protein: risk factor, biomarker and/or therapeutic target?. 2010 , 26 Suppl A, 41A-44A	72
1343	C-reactive protein is a mediator of cardiovascular disease. 2010 , 31, 2087-91	135
1342	Statin prescription is essential in peripheral vascular disease. 2010 , 21, 175-7, quiz 178	1
1341	Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. 2010 , 130, 1785-96	447
1340	Fundamentals of Clinical Trials. 2010 ,	244
1339	Clinical Pharmacology: Current Topics and Case Studies. 2010 ,	

1338	Recent advances in rheumatoid arthritis. 2010 , 86, 243-50	10
1337	Screening for heart disease: C-reactive protein versus coronary artery calcium. 2010 , 8, 125-31	9
1336	Nuclear Hormone Receptor Medicinal Chemistry. 2010 , 77-188	
1335	Electrochemical immunosensor for simultaneous detection of dual cardiac markers based on a poly(dimethylsiloxane)-gold nanoparticles composite microfluidic chip: a proof of principle. 2010 , 56, 1701-7	105
1334	Statins and the reduction of sudden cardiac death: antiarrhythmic or anti-ischemic effect?. 2010 , 10, 155-64	14
1333	Physiopathologie de la maladie athfo-thrombotique : quelques donnès fondamentales pour comprendre le risque r̄siduel. 2010 , 4, 361-368	
1332	Cholesterol-lowering therapy for primary prevention: still much we don't know. 2010 , 170, 1007-8	14
1331	Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia. 2010 , 10, 11-28	65
1330	Statines et diab̄te : mauvaise science ou mauvaise m̄decine ? : Statins in diabetics: Poor science, bad medicine!. 2010 , 4, 79-81	
1329	Inflammatory markers and treatment of elevated LDL-C. Foreword. 2010 , 4, 237	
1328	The anesthesia patient with acute coronary syndrome. 2010 , 28, 55-66	
1327	Lipid lowering for secondary prevention of cardiovascular disease in older adults. 2010 , 27, 959-72	10
1326	Metabolic syndrome as a risk factor for diabetes. 2010 , 8, 407-12	47
1325	Interpretation of Mendelian randomization studies and the search for causal pathways in atherothrombosis: the need for caution. 2010 , 8, 465-9	4
1324	Statistical methods for assessment of added usefulness of new biomarkers. 2010 , 48, 1703-11	238
1323	Improving risk stratification for cardiovascular disease. 2010 , 8, 1091-3	2
1322	Acute renal failure with the combined use of rosuvastatin and fenofibrate. 2010 , 32, 633-5	4
1321	Statin treatment for patients with heart failure. 2010 , 7, 249-55	17

1320	Treating rheumatoid arthritis to target: recommendations of an international task force. 2010 , 69, 631-7	1300
1319	Ischemic stroke in the elderly: an overview of evidence. 2010 , 6, 256-65	161
1318	Peripheral vascular endothelial dysfunction in glaucomatocyclitic crisis: a preliminary study. 2010 , 51, 272-6	18
1317	Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. 2010 , 107, 1170-84	298
1316	Prognostic value, clinical effectiveness, and cost-effectiveness of high-sensitivity C-reactive protein as a marker for major cardiac events in asymptomatic individuals: a health technology assessment report. 2010 , 26, 30-9	16
1315	Toward optimal health: advances in the cardiovascular care of women. [An interview with Jodi R. Godfrey and Wenger K. Nanette]. 2010 , 19, 659-64	
1314	Interaction between inflammation and blood viscosity predicts cardiovascular mortality. 2010 , 44, 107-112	16
1313	Chronic inflammation and cardiovascular risk. 2010 , 52, 18-18	
1312	Proceedings from the scientific symposium: Sex differences in cardiovascular disease and implications for therapies. 2010 , 19, 1059-72	37
1311	Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials. 2010 , 10, 73-84	29
1310	Non-malignant drivers of elevated C-reactive protein levels differ in patients with and without a history of cancer. 2010 , 14, 295-303	3
1309	A comparative study of anti-inflammatory and antidyslipidemic effects of fenofibrate and statins on rheumatoid arthritis. 2010 , 20, 238-243	21
1308	The cardiovascular continuum refined: A hypothesis. 2010 , 19, 273-7	7
1307	Primary prevention using statins: to be or not to be?. 2010 , 26, 2701-6	2
1306	Current role of statins in the treatment of essential hypertension. 2010 , 11, 2635-50	13
1305	Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. 2010 , 69, 1920-5	213
1304	Cardiovascular co-morbidity in patients with rheumatic diseases. 2011 , 13, 225	9
1303	Evaluating optimal lipid levels in patients with mixed dyslipidemia following short- and long-term treatment with fenofibric acid and statin combination therapy: a post hoc analysis. 2011 , 27, 1067-78	5

1302	Promises and partnership: FDA's Critical Path Initiative and its intersection with pharmacology: an ASPET 2011 annual meeting symposium. 2011 , 10, 827-837	2
1301	Epidemiological link between low cholesterol and suicidality: a puzzle never finished. 2011 , 14, 268-87	20
1300	Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone?. 2011 , 43, 167-71	30
1299	Do statins improve outcomes and delay the progression of non-rheumatic calcific aortic stenosis?. 2011 , 97, 523-9	30
1298	Effects of rosuvastatin on subclinical atherosclerosis and arterial stiffness in rheumatoid arthritis: a randomized controlled pilot trial. 2011 , 40, 411-21	30
1297	Pathophysiology of thrombosis in myeloproliferative neoplasms. 2011 , 96, 183-6	29
1296	Is prevention a fantasy, or the future of medicine? A panoramic view of recent data, status, and direction in cardiovascular prevention. 2011 , 5, 61-81	32
1295	Controversies in the cardiovascular management of type 2 diabetes. 2011 , 97, 6-14	19
1294	Cardiovascular risk assessment. 2011 , 53, 121-128	1
1293	Papel de la proteína C reactiva en las enfermedades cardiovasculares. 2011 , 18, 273-278	5
1292	Asymmetric responsiveness of physician prescription behavior to drug promotion of competitive brands within an established therapeutic drug class. 2011 , 28, 133-54	8
1291	Review of the relationship between C-reactive protein and exercise. 2011 , 15, 265-75	47
1290	Recent advances in preventive cardiology and lifestyle medicine: a themed series. 2011 , 123, 2274-83	51
1289	Que choisir en association aux statines chez les patients à haut risque cardiovasculaire : la niacine ou l'ezetimibe ?. 2011 , 5, 7-8	
1288	Extreme all-cause mortality in JUPITER requires reexamination of vital records. 2011 , 120, 84-8	1
1287	Interventions for cardiovascular disease prevention. 2011 , 29, 15-34	12
1286	Lipid-lowering therapy with statins for the primary and secondary prevention of cardiovascular disease. 2011 , 29, 87-103	31
1285	Opening a new lipid "apo-theary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk. 2011 , 86, 762-80	25

1284	Prevención primaria cardiovascular con estatinas: beneficio clínico real aún por confirmar. 2011 , 9, 24-25	
1283	Los beneficios cardiovasculares del tratamiento con estatinas contrarrestan el ligero incremento del riesgo de desarrollar diabetes. 2011 , 9, 27-28	
1282	Los beneficios cardiovasculares del tratamiento con estatinas contrarrestan el ligero incremento del riesgo de desarrollar diabetes. 2011 , 9, 68-69	
1281	Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers. 2011 , 57, 63-9	30
1280	The cost-effectiveness of C-reactive protein testing and rosuvastatin treatment for patients with normal cholesterol levels. 2011 , 57, 784-91	29
1279	The cost-effectiveness of rosuvastatin therapy JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). 2011 , 57, 792-3	4
1278	Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol. 2011 , 57, 1666-75	163
1277	Quantification of coronary atherosclerosis and inflammation to predict coronary events and all-cause mortality. 2011 , 57, 1455-64	115
1276	Calcium and C-reactive protein hot enough to predict the future?. 2011 , 57, 1465-7	5
1275	Is reclassification of intermediate-risk subjects by coronary artery calcium scoring clinically useful?. 2011 , 58, 1081; author reply 1081-3	1
1274	ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. 2011 , 57, 2037-114	325
1273	Adiposopathy is "sick fat" a cardiovascular disease?. 2011 , 57, 2461-73	270
1272	Statins and risk of cancer: a retrospective cohort analysis of 45,857 matched pairs from an electronic medical records database of 11 million adult Americans. 2011 , 58, 530-7	54
1271	Benefit of early statin therapy in patients with acute myocardial infarction who have extremely low low-density lipoprotein cholesterol. 2011 , 58, 1664-71	84
1270	How much statin intervention is enough?. 2011 , 58, 1672-3	4
1269	High-sensitivity C-reactive protein is within normal levels at the very onset of first ST-segment elevation acute myocardial infarction in 41% of cases: a multiethnic case-control study. 2011 , 58, 2654-61	51
1268	A point-of-care platelet function assay and C-reactive protein for prediction of major cardiovascular events after drug-eluting stent implantation. 2011 , 58, 2630-9	54
1267	Continuation of mortality reduction after the end of randomized therapy in clinical trials of lipid-lowering therapy. 2011 , 5, 97-104	18

1266	Clinical perspective: have the results of recent clinical trials of lipid-lowering therapies influenced the way we should practice? A Latin American perspective of current issues in clinical lipidology. 2011 , 5, 124-132	3
1265	Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (≥ 10 mg/L). <i>cmb@bcm.tmc.edu</i> . 2011 , 5, 401-7	3
1264	Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. 2011 , 5, 338-67	201
1263	Prevalence and risk factors of carotid vessel wall inflammation in coronary artery disease patients: FDG-PET and CT imaging study. 2011 , 4, 1195-205	49
1262	Ethical considerations in geriatric cardiology. 2011 , 2, 363-370	1
1261	Statins and myocardial remodelling: cell and molecular pathways. 2011 , 13, e22	40
1260	Pharmacogenomics and adverse drug reactions: the case of statins. 2011 , 12, 1499-509	18
1259	The kallikrein-kinin system as a regulator of cardiovascular and renal function. 2011 , 1, 971-93	76
1258	Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. 2011 , 48, 155-70	313
1257	Co-stimulatory molecules in and beyond co-stimulation - tipping the balance in atherosclerosis?. 2011 , 106, 804-13	43
1256	Representative Chiral Drugs. 2011 , 401-448	1
1255	Statins for primary prevention of venous thromboembolism. 2011 , CD008203	6
1254	Complications Associated with Diabetes. 2011 , 201-249	
1253	Pharmacological strategies for lowering LDL cholesterol: statins and beyond. 2011 , 8, 253-65	75
1252	Matrix metalloproteinase inhibition with tetracyclines for the treatment of coronary artery disease. 2011 , 64, 561-6	26
1251	[Pharmaco-economic optimization of cholesterol-lowering treatment with statins]. 2011 , 137, 119-25	1
1250	Effect of two intensive statin regimens on progression of coronary disease. <i>New England Journal of Medicine</i> , 2011 , 365, 2078-87	59.2 574
1249	Clinical experience with rosuvastatin in the management of hyperlipidemia and the reduction of cardiovascular risk. 2011 , 9, 1383-90	4

1248	Erectile dysfunction: a harbinger or consequence: does its detection lead to a window of curability?. 2011 , 32, 125-34	22
1247	Biomarkers of therapeutic response in patients with chronic obstructive pulmonary disease: a critical review of the literature. 2011 , 71, 1821-37	12
1246	Novel 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: a patent review. 2011 , 21, 187-203	9
1245	Comprehensive Cardiovascular Medicine in the Primary Care Setting. 2011 ,	
1244	Inflammatory biomarkers, physical activity, waist circumference, and risk of future coronary heart disease in healthy men and women. 2011 , 32, 336-44	80
1243	Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. 2011 , 42, 517-84	1148
1242	La proteña C reactiva como blanco terapùtico en la prevenci3n cardiovascular: ¿ficción o realidad?. 2011 , 11, 30-35	1
1241	Statins, inflammation and kidney disease. 2011 , 7, 385-97	52
1240	Integrated safety in tocilizumab clinical trials. 2011 , 13, R141	224
1239	Biomarkers in the critically ill patient: C-reactive protein. 2011 , 27, 241-51	63
1238	Women and heart disease. 2011 , 29, 35-45	13
1237	Biologic response modifiers: relevance & repercussions. 2011 , 25, 719-22	
1236	Lymphocyte-suppressing effect of simvastatin in mixed dyslipidemic patients but not impaired glucose tolerance patients. 2011 , 63, 95-101	8
1235	Ezetimibe inhibe la adhesi3n y la migraci3n de monocitos a trav3s de la ruta de las proteincinasas activadas extracelularmente (p44/p42ERK1/2. 2011 , 23, 160-167	
1234	Effects of rosuvastatin on the coordinated proteomic response of human coronary smooth muscle cells to low density lipoproteins. 2011 , 23, 191-200	
1233	High-dose atorvastatin and risk of atrial fibrillation in patients with prior stroke or transient ischemic attack: analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. 2011 , 161, 993-9	26
1232	Effect of rosuvastatin on C-reactive protein and progression of aortic stenosis. 2011 , 161, 1133-9	18
1231	Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. 2011 , 162, 106-14.e2	33

1230	Interleukin-1 β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). 2011 , 162, 597-605	598
1229	Frequency and correlates of treatment intensification for elevated cholesterol levels in patients with cardiovascular disease. 2011 , 162, 725-732.e1	41
1228	Atherosclerotic cardiovascular disease screening in adults: American College Of Preventive Medicine position statement on preventive practice. 2011 , 40, 381.e1-10	36
1227	Immunosuppressive therapy with oral prednisone to prevent restenosis after PCI. A multicenter randomized trial. 2011 , 124, 434-43	23
1226	Dose-related effect of statins in venous thrombosis risk reduction. 2011 , 124, 852-9	34
1225	Effect of obesity on the association between ATF3 gene haplotypes and C-reactive protein level in Taiwanese. 2011 , 412, 1026-31	9
1224	Biochemical markers in acute coronary syndrome. 2011 , 412, 1279-96	34
1223	Rationale and design of STOP DVT study: rosuvastatin for the prevention of deep vein thrombosis in patients undergoing total knee replacement arthroplasty--a prospective randomized open-label controlled trial. 2011 , 32, 779-82	1
1222	Chronic inflammatory diseases and cardiovascular risk: a systematic review. 2011 , 27, 174-82	180
1221	Framing cardiovascular disease event risk prediction. 2011 , 27, 171-3	7
1220	Cardiometabolic risk in Canada: a detailed analysis and position paper by the cardiometabolic risk working group. 2011 , 27, e1-e33	116
1219	Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference. 2011 , 27, 635-62	135
1218	Elevated leukocyte count in asymptomatic subjects is associated with a higher risk for cerebral white matter lesions. 2011 , 113, 177-80	10
1217	Apheresis-inducible cytokine pattern change in severe, genetic dyslipidemias. 2011 , 56, 835-41	12
1216	Effect of atorvastatin on lipoprotein (a) and interleukin-10: a randomized placebo-controlled trial. 2011 , 37, 124-30	25
1215	Immune suppression and immune activation in depression. 2011 , 25, 221-9	204
1214	Brain inflammation is induced by co-morbidities and risk factors for stroke. 2011 , 25, 1113-22	150
1213	Post-pericardial injury syndrome after continuous-flow ventricular assistance. 2011 , 30, 726-9	5

1212	Effects of statin therapy on non-calcified coronary plaque assessed by 64-slice computed tomography. 2011 , 150, 146-50	20
1211	Statintherapy in the primary and the secondary prevention of ischaemic cerebrovascular diseases. 2011 , 148, 131-8	7
1210	Reverse epidemiology reflects C-reactive protein as a bystander of atherosclerosis in established systemic inflammation models. 2011 , 146, 422-3	10
1209	The influence of inflammation outweighing the metabolic syndrome on cardiovascular risk and mortality. 2011 , 146, 431	5
1208	What else does the JUPITER trial add regarding C-reactive protein and cardiovascular disease?. 2011 , 149, 387	2
1207	The large clinical statin trials. 2011 , 150, 108-11	2
1206	Burden of acute myocardial infarction. 2011 , 150, 111-2	15
1205	C-reactive protein and endothelial dysfunction: gazing at the coronaries. 2011 , 152, 1-3	11
1204	Statins, cholesterol depletion and risk of incident diabetes. 2011 , 152, 275-6	3
1203	Optimal statin type and dosage for vascular patients. 2011 , 53, 837-44	22
1202	High-sensitivity C-reactive protein predicts cardiovascular events and myocardial damage after vascular surgery. 2011 , 54, 474-9	8
1201	Public health impact of statin prescribing strategies based on JUPITER. 2011 , 52, 159-63	5
1200	Effect of a plant stanol ester-containing spread, placebo spread, or Mediterranean diet on estimated cardiovascular risk and lipid, inflammatory and haemostatic factors. 2011 , 21, 213-21	55
1199	The effect of increased dietary fruit and vegetable consumption on endothelial activation, inflammation and oxidative stress in hypertensive volunteers. 2011 , 21, 658-64	26
1198	High sensitivity C-reactive protein predicts the development of new carotid artery plaques in older persons. 2011 , 21, 776-82	15
1197	Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition. 2011 , 21, 835-43	79
1196	Cardiovascular disease in the elderly. 2011 , 64, 697-712	45
1195	[Rationale and methods of the study on nutrition and cardiovascular risk in Spain (ENRICA)]. 2011 , 64, 876-82	163

1194	[Benefits of statin therapy based on plasma carbohydrate antigen 125 values following an admission for acute heart failure]. 2011 , 64, 1100-8	9
1193	[ESC/EAS Guidelines for the management of dyslipidaemias]. 2011 , 64, 1168.e1-1168.e60	37
1192	Effects of obstructive sleep apnea and its treatment on cardiovascular risk in CAD patients. 2011 , 105, 1557-64	10
1191	Prevençã de la diabetes mellitus 2. 2011 , 37, 496-503	0
1190	Inflammation associated with obesity: relationship with blood and bone marrow endothelial cells. 2011 , 19, 2130-6	22
1189	Metabolic syndrome: nature, therapeutic solutions and options. 2011 , 12, 1887-1900	62
1188	ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). 2011 , 32, 1769-818	2020
1187	Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. 2011 , 104, 109-24	222
1186	Statins for the primary prevention of cardiovascular disease. 2011 , CD004816	178
1185	Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in hypercholesterolemia. 2011 , 214, 122-8	64
1184	Anacetrapib: hope for CETP inhibitors?. 2011 , 29, 327-39	10
1183	Targeting inflammation as a therapeutic strategy in accelerated atherosclerosis in rheumatoid arthritis. 2011 , 29, 231-42	19
1182	Statin pre-treatment is associated with lower platelet activity and favorable outcome in patients with acute non-cardio-embolic ischemic stroke. 2011 , 15, R163	15
1181	Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: effect of Rosuvastatin versus AtorvastatiN). 2011 , 27, 1119-29	37
1180	Cardiovascular drug therapy in the elderly: benefits and challenges. 2011 , 8, 13-28	109
1179	Drug safety evaluation of rosuvastatin. 2011 , 10, 969-86	21
1178	Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the American Heart Association. 2011 , 57, 1404-23	552
1177	Cardiovascular Disease in the Elderly. 2011 , 64, 697-712	3

1176	Rationale and Methods of the Study on Nutrition and Cardiovascular Risk in Spain (ENRICA). 2011 , 64, 876-882	9
1175	Benefits of Statin Therapy Based on Plasma Carbohydrate Antigen 125 Values Following an Admission for Acute Heart Failure. 2011 , 64, 1100-1108	1
1174	ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society	100
1173	Most of the patients presenting myocardial infarction would not be eligible for intensive lipid-lowering based on clinical algorithms or plasma C-reactive protein. 2011 , 214, 148-50	13
1172	Differential metabolic effects of distinct statins. 2011 , 215, 1-8	103
1171	The double-faced metabolic and inflammatory effects of standard drug therapy in patients after percutaneous treatment with drug-eluting stent. 2011 , 215, 170-5	11
1170	Apolipoprotein E genotypes, circulating C-reactive protein and angiographic coronary artery disease: the Ludwigshafen Risk and Cardiovascular Health Study. 2011 , 215, 487-93	8
1169	Anti-inflammatory, anti-proliferative and anti-atherosclerotic effects of quercetin in human in vitro and in vivo models. 2011 , 218, 44-52	245
1168	Lipopolysaccharide-binding protein (LBP) is associated with total and cardiovascular mortality in individuals with or without stable coronary artery disease--results from the Ludwigshafen Risk and Cardiovascular Health Study (LURIC). 2011 , 219, 291-7	38
1167	ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). 2011 , 217 Suppl 1, S1-44	152
1166	ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). 2011 , 217, 3-46	459
1165	Influence of pericoronary adipose tissue on local coronary atherosclerosis as assessed by a novel MDCT volumetric method. 2011 , 219, 151-7	36
1164	Association of lower total bilirubin level with statin usage: the United States National Health and Nutrition Examination Survey 1999-2008. 2011 , 219, 728-33	26
1163	Efectos hipoglucemiantes de las resinas de intercambio. Del secuestro de los ácidos biliares a la activación del metabolismo de la glucosa. 2011 , 23, 3-8	
1162	C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study. 2011 , 377, 469-76	132
1161	CRP: star trekking the galaxy of risk markers. 2011 , 377, 441-2	5
1160	Associations between C-reactive protein, coronary artery calcium, and cardiovascular events: implications for the JUPITER population from MESA, a population-based cohort study. 2011 , 378, 684-92	232
1159	Global trends in body-mass index [Authors' reply]. 2011 , 377, 1917-1918	8

1158	C-reactive protein in the Heart Protection Study. 2011 , 377, 1918; author reply 1918-9	3
1157	Predictive ability of coronary artery calcium and CRP. 2011 , 378, 641-3	6
1156	Controversies in treatment of chronic obstructive pulmonary disease. 2011 , 378, 1038-47	51
1155	Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment. 2011 , 5, 24-34	44
1154	Inflammation and the development of atherosclerosis. 2011 , 18, 351-8	116
1153	Global Identification of Protein Prenyltransferase Substrates: Defining the Prenylated Proteome. 2011 , 29, 207-234	5
1152	The importance of HDL-C and CRP in cardiovascular risk evaluation in longevous elderly individuals. 2011 , 9, 397-403	6
1151	American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. 2011 , 17 Suppl 2, 1-53	329
1150	A new algorithm for the management of stable coronary artery disease incorporating CT coronary angiography and fractional flow reserve: how we can improve outcomes and reduce costs. 2011 , 194, 666-669	
1149	Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy. 2011 , 18, 1018-28	74
1148	The Starving Cell: Metabolic Syndrome as an Adaptive Process. 2011 ,	0
1147	Do preoperative statins reduce atrial fibrillation after coronary artery bypass grafting?. 2011 , 17, 376-82	12
1146	Current Antidiabetic Therapies and Mechanisms. 2011 , 253-278	
1145	. 2011 ,	1
1144	Reply. 2011 , 120, 236-236	
1143	Drugs that affect lipid metabolism. 2011 , 33, 921-934	
1142	Prophylactic intra-aortic balloon pump reduces C-reactive protein levels and early mortality in high-risk patients undergoing percutaneous coronary intervention. 2011 , 66, 499-504	18
1141	The methyl ester of rosuvastatin elicited an endothelium-independent and 3-hydroxy-3-methylglutaryl coenzyme A reductase-independent relaxant effect in rat aorta. 2011 , 44, 438-44	4

- 1140 [Statins in the patient with chronic kidney disease and with diabetes mellitus]. **2011**, 76, 55-9
- 1139 Should we focus on "venous vulnerability" instead of "plaque vulnerability" in symptomatic atherosclerotic patients?. **2011**, 106, 995-6 9
- 1138 Venous thromboembolism in patients with symptomatic atherosclerosis. **2011**, 106, 1095-102 21
- 1137 Does medicalization of life imperil health? Expanding indications for diagnosis and treatment of chronic "disease". **2011**, 17, 469-80 2
- 1136 Inflammation in cardiovascular tissue engineering: the challenge to a promise: a minireview. **2011**, 2011, 958247 23
- 1135 Atherosclerotic Plaque Regression and Arterial Reverse Remodelling in Carotid and Femoral Arteries by Statin Use in Primary Prevention Setting: Ultrasound Findings. **2011**,
- 1134 Endothelial Dysfunction and Therapeutic Intervention in Type 2 Diabetes. **2011**,
- 1133 Association Between Fatty Liver and Cardiovascular Disease: Mechanism and Clinical Implications. **2011**,
- 1132 Residual Vascular Risk in T2DM: The Next Frontier. **2011**,
- 1131 Aortic Stenosis - New Insights in Stenosis Progression and in Prevention. **2011**,
- 1130 [Coronary computed tomography: current role and future perspectives for cardiovascular risk stratification]. **2011**, 76, 115-20
- 1129 Lipid-lowering therapy: who can benefit?. **2011**, 7, 525-34 27
- 1128 Rosuvastatin prevents proteinuria and renal inflammation in nitric oxide-deficient rats. **2011**, 66, 1457-62 12
- 1127 What do we really know about VBID? Quality of the evidence and ethical considerations for health plan sponsors. **2011**, 17, 156-74 4
- 1126 Statins: cardiovascular risk reduction in percutaneous coronary intervention-basic and clinical evidence of hyperacute use of statins. **2011**, 2011, 904742 7
- 1125 Ezetimibe and vascular inflammation. **2011**, 9, 99-108 7
- 1124 Ezetimibe and vascular endothelial function. **2011**, 9, 87-98 3
- 1123 Predictors of coronary intervention-related myocardial infarction in stable angina patients pre-treated with statins. **2011**, 7, 67-72 6

1122	USE OF ROSUVASTATIN AS A GEROPROTECTOR IN PEOPLE ENGAGED IN NATURAL GAS PRODUCING. 2011 , 7, 447-451	
1121	Mean common or mean maximum carotid intima-media thickness as primary outcome in lipid-modifying intervention studies. 2011 , 18, 946-57	13
1120	Effect of laparoscopic adjustable gastric banding on metabolic syndrome and its risk factors in morbidly obese adolescents. 2011 , 2011, 906384	13
1119	CHALLENGES IN ATHEROSCLEROSIS. 62-88	
1118	Anti-inflammatory nutrition as a pharmacological approach to treat obesity. 2011 , 2011,	36
1117	Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey. 2011 , 5, 325-80	162
1116	Effects of ezetimibe added to ongoing statin therapy on C-reactive protein levels in hypercholesterolemic patients. 2011 , 41, 253-8	2
1115	Inflammatory concepts of obesity. 2011 , 2011, 529061	74
1114	Place of pitavastatin in the statin armamentarium: promising evidence for a role in diabetes mellitus. 2011 , 5, 283-97	9
1113	High-Sensitivity C-Reactive Protein and Cardiovascular Disease. 2011 , 3, 178-186	
1112	Statins: the high risks of discontinuation and large benefits of continuation. 2011 , 7, 931-2	2
1111	Atherosclerotic plaque biomarkers: beyond the horizon of the vulnerable plaque. 2011 , 7, 22-7	27
1110	Myths and facts concerning the use of statins in very old patients. 2011 , 11, 17-23	4
1109	Elevated hemostasis markers after pneumonia increases one-year risk of all-cause and cardiovascular deaths. 2011 , 6, e22847	72
1108	Geographic variation in cardiovascular inflammation among healthy women in the Women's Health Study. 2011 , 6, e27468	6
1107	Stabilisation of atherosclerotic plaques. Position paper of the European Society of Cardiology (ESC) Working Group on atherosclerosis and vascular biology. 2011 , 106, 1-19	110
1106	Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trials. 2011 , 342, d1250	95
1105	Possible contributions of lipoproteins and cholesterol to the pathogenesis of diabetes mellitus type 2. 2011 , 22, 26-32	87

1104	Mechanisms for the anti-inflammatory effects of statins. 2011 , 22, 165-70	168
1103	The autoimmune concept of atherosclerosis. 2011 , 22, 327-34	76
1102	Statins and stroke: prevention and beyond. 2011 , 24, 75-80	23
1101	Are statins diabetogenic?. 2011 , 26, 342-7	77
1100	How to stay heart healthy in 2011: considerations for the primary prevention of cardiovascular disease in women. 2011 , 7, 433-51	9
1099	Annual drug update: 2010 in review. 2011 , 36, 10-22; quiz 23	2
1098	Uric acid in heart disease: a new C-reactive protein?. 2011 , 23, 174-7	26
1097	Hold, raise, or fold: C-reactive protein, hormone therapy, and cardiovascular risk. 2011 , 18, 8-10	1
1096	Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV/hepatitis C virus-coinfected patients with prior nonresponse or relapse. 2011 , 25, 1131-3	20
1095	The effect of ezetimibe and simvastatin on monocyte cytokine release in patients with isolated hypercholesterolemia. 2011 , 57, 505-12	22
1094	Liver X receptor gene polymorphisms and variable cardiovascular outcomes in patients treated with antihypertensive therapy: results from the INVEST-GENES study. 2011 , 21, 333-40	18
1093	Effect of soy isoflavones on circulating C-reactive protein in postmenopausal women: meta-analysis of randomized controlled trials. 2011 , 18, 1256-62	36
1092	The role of lipoprotein-associated phospholipase A2 (Lp-PLA ₂) in cardiovascular disease. 2011 , 6, 108-13	18
1091	Medical therapy of aortic aneurysms: a pathophysiology-based approach. 2011 , 9, 572-84	3
1090	Ezetimibe; more than a low density lipoprotein cholesterol lowering drug? An update after 4 years. 2011 , 9, 62-86	22
1089	Assessing the treatment effect in metabolic syndrome without perceptible diabetes (ATTEMPT): a prospective-randomized study in middle aged men and women. 2011 , 9, 647-57	29
1088	Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. 2011 , 2011, 368-370	
1087	Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. 2011 , 2011, 267-269	

1086	External Carotid Artery Stenting to Treat Patients With Symptomatic Ipsilateral Internal Carotid Artery Occlusion: A Multicenter Case Series. 2011 , 2011, 231-233	
1085	Don't worry, be happy: positive affect and reduced 10-year incident coronary heart disease: The Canadian Nova Scotia Health Survey. 2011 , 2011, 269-271	
1084	Statin-induced diabetes: perhaps, it's the tip of the iceberg. 2011 , 104, 174-8	4
1083	Anacetrapib: a new weapon against dyslipidemia. 2011 , 6, 227-35	1
1082	Recent developments in cardiovascular risk assessment: relevance to the nephrologist. 2011 , 26, 3080-3	3
1081	HIV-1 decreases the levels of neurotrophins in human lymphocytes. 2011 , 25, 1126-8	22
1080	Effects of Maximal Atorvastatin and Rosuvastatin Treatment on Markers of Glucose Homeostasis and Inflammation. 2011 , 2011, 57-60	
1079	Contemporary Results of Carotid Endarterectomy for Asymptomatic Carotid Stenosis. 2011 , 2011, 230-231	
1078	Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease. 2011 , 2011, 60-63	
1077	Inflammation, C-reactive protein and cardiometabolic risk: how compelling is the potential therapeutic role of n-3 PUFAs in cardiovascular disease?. 2011 , 6, 627-630	1
1076	Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development. 2011 , 90, 777-90	137
1075	Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial. 2011 , 75, 1493-505	88
1074	Intensive lipid-lowering therapy with rosuvastatin stabilizes lipid-rich coronary plaques. -Evaluation using dual-source computed tomography.-. 2011 , 75, 2621-7	26
1073	Efficacy analysis of the lipid-lowering and renoprotective effects of rosuvastatin in patients with chronic kidney disease. 2011 , 58, 663-74	17
1072	Prevention of atherosclerosis in overweight/obese patients. - In need of novel multi-targeted approaches-. 2011 , 75, 1019-27	40
1071	Treatments for the Metabolic Syndrome. 2011 , 327-346	0
1070	The IMPROVE-IT trial: current status and potential clinical implications of ezetimibe. 2011 , 1, 137-144	
1069	New considerations in the design of clinical trials for anti-atherosclerotic drugs. 2011 , 1, 795-803	1

1068	Controlling lipids after acute coronary syndromes: what is the best strategy?. 2011 , 6, 253-255	
1067	Treatment with EB fatty acids reduces serum C-reactive protein concentration. 2011 , 6, 723-729	4
1066	[Skeletal and extra-skeletal consequences of vitamin D deficiency]. 2011 , 152, 1312-9	8
1065	Enteric microbiome metabolites correlate with response to simvastatin treatment. 2011 , 6, e25482	127
1064	Statin-Induced Muscle Toxicity. 125-135	
1063	Cardiac biomarkers for perioperative management. 319-326	
1062	[Effects of early statin treatment on inflammatory biomarkers and clinical deterioration in patients with acute ischemic stroke]. 2011 , 51, 6-13	2
1061	Atorvastatin inhibits collar-induced intimal thickening of rat carotid artery: effect on C-type natriuretic peptide expression. 2012 , 5, 675-9	2
1060	Macrophage activation is associated with poorer long-term outcomes in renal transplant patients. 2011 , 25, 744-54	9
1059	Therapies for diabetic dyslipidaemia. 2011 , 13, 313-25	26
1058	Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin(1). 2011 , 28, 100-8	27
1057	Haemostatic effects of simvastatin in subjects with impaired glucose tolerance. 2011 , 41, 473-81	4
1056	Adipokines and thrombosis. 2011 , 38, 864-71	36
1055	Preventing the aortic complications of Marfan syndrome: a case-example of translational genomic medicine. 2011 , 72, 6-17	6
1054	A prospective case-controlled cohort study of endothelial function in patients with moderate to severe psoriasis. 2011 , 164, 26-32	25
1053	What is the role of alternative biomarkers for coronary heart disease?. 2011 , 75, 289-93	5
1052	How do prescribing doctors anticipate the effect of statins?. 2011 , 17, 420-8	6
1051	The impact of antiproteinuric therapy on the prothrombotic state in patients with overt proteinuria. 2011 , 9, 2416-23	10

1050	Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers. 2011 , 52, 1351-8	21
1049	Gender-based cardiometabolic risk evaluation in minority and non-minority men grading the evidence of non-traditional determinants of cardiovascular risk. 2011 , 65, 134-47	7
1048	Comparative effects of rosuvastatin and atorvastatin on glucose metabolism and adipokine levels in non-diabetic patients with dyslipidaemia: a prospective randomised open-label study. 2011 , 65, 679-83	28
1047	Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance. 2011 , 65, 1141-8	49
1046	Anti-inflammatory and monocyte-suppressing effects of simvastatin in patients with impaired fasting glucose. 2011 , 108, 131-7	7
1045	Meta-analysis of the cardiovascular benefits of intensive lipid lowering with statins. 2011 , 124, 188-95	18
1044	Mechanisms involved in the association between periodontal diseases and cardiovascular disease. 2011 , 17, 450-61	94
1043	Anti-inflammatory therapeutics for the treatment of atherosclerosis. 2011 , 10, 365-76	197
1042	Highlights of 10 years of immunology in Nature Reviews Immunology. 2011 , 11, 693-702	75
1041	C-reactive protein levels and body mass index: elucidating direction of causation through reciprocal Mendelian randomization. 2011 , 35, 300-8	180
1040	Progress and challenges in translating the biology of atherosclerosis. 2011 , 473, 317-25	2436
1039	Statins regulate interleukin-1 β -induced RANKL and osteoprotegerin production by human gingival fibroblasts. 2011 , 46, 483-90	12
1038	Comorbidities of diabetes and hypertension: mechanisms and approach to target organ protection. 2011 , 13, 244-51	234
1037	Hypertension and lipid management in prediabetic states. 2011 , 13, 270-4	4
1036	Circulating, imaging, and genetic biomarkers in cardiovascular risk prediction. 2011 , 21, 105-12	9
1035	Periodontal and coronary heart disease in patients undergoing coronary angiography. 2011 , 60, 127-33	6
1034	Low-grade inflammation, and dysfunction of high-density lipoprotein and its apolipoproteins as a major driver of cardiometabolic risk. 2011 , 60, 499-512	56
1033	Statins for Cardiovascular Disease Prevention. 2011 , 7, 419-420	

1032	One-step homogeneous C-reactive protein assay for saliva. 2011 , 373, 19-25	85
1031	Impact of early statin initiation on secondary prevention in Japanese patients with coronary artery disease. 2011 , 57, 172-80	11
1030	Rosuvastatin lowers coenzyme Q10 levels, but not mitochondrial adenosine triphosphate synthesis, in children with familial hypercholesterolemia. 2011 , 158, 458-62	20
1029	Influence and critique of the JUPITER Trial (Statins v no statins for primary prevention of cardiovascular events in patients with normal lipids and elevated C-reactive protein). 2011 , 24, 172-9	3
1028	Nuevas herramientas en la estratificación del riesgo cardiovascular. 2011 , 11, 21-28	
1027	Innate immunity and monocyte-macrophage activation in atherosclerosis. 2011 , 8, 9	92
1026	Contemporary management of transient ischemic attack: role of the pharmacist. 2011 , 31, 193-213	4
1025	Longitudinal assessment of estimated glomerular filtration rate in apparently healthy adults: a post hoc analysis from the JUPITER study (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). 2011 , 33, 717-25	29
1024	Pitavastatin calcium: clinical review of a new antihyperlipidemic medication. 2011 , 33, 1023-42	6
1023	The editor's roundtable: JUPITER follow-up. 2011 , 107, 1549-57	2
1022	The editor's roundtable: Closing the clinical practice gap-using evidence-based treatments for managing lipids. 2011 , 107, 230-42	0
1021	Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation. 2011 , 107, 387-92	53
1020	Effect of simvastatin and fenofibrate on cytokine release and systemic inflammation in type 2 diabetes mellitus with mixed dyslipidemia. 2011 , 107, 1010-1018.e1	56
1019	Usefulness of preprocedure high-sensitivity C-reactive protein to predict death, recurrent myocardial infarction, and stent thrombosis according to stent type in patients with ST-segment elevation myocardial infarction randomized to bare metal or drug-eluting stenting during primary percutaneous coronary intervention. 2011 , 107, 1597-603	20
1018	Effect of statins on cholesterol crystallization and atherosclerotic plaque stabilization. 2011 , 107, 1710-7	78
1017	Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose. 2011 , 108, 3B-24B	212
1016	The editor's roundtable: role of percutaneous coronary intervention and drug-eluting stents in patients with stable coronary heart disease. 2011 , 108, 1417-25	2
1015	Novel Biomarkers and Subclinical Atherosclerosis. 2011 , 461-486	

1014	Lectin-like oxidized LDL receptor 1 is involved in CRP-mediated complement activation. 2011 , 57, 1398-405	30
1013	Statin-induced myopathy: a review and update. 2011 , 10, 373-87	194
1012	Misinformation in the medical literature: what role do error and fraud play?. 2011 , 37, 498-503	20
1011	Personalized vascular medicine: individualizing drug therapy. 2011 , 16, 391-404	14
1010	Role of C-reactive protein in cerebrovascular disease: a critical review. 2011 , 9, 1565-84	53
1009	Statins and intracerebral hemorrhage: collaborative systematic review and meta-analysis. 2011 , 124, 2233-42	117
1008	Established and novel biomarkers in ST-elevation myocardial infarction. 2011 , 7, 523-46	
1007	Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease. 2011 , 56, 3439-49	69
1006	Statins in heart failure-where do we stand?. 2011 , 25, 99-104	4
1005	C-reactive protein, statins and the risk of vascular events: a better understanding. 2011 , 25, 545-9	6
1004	The discovery of LOX-1, its ligands and clinical significance. 2011 , 25, 379-91	111
1003	Stroke prevention in atrial fibrillation. 2011 , 25, 561-70	4
1002	Cytokine production from peripheral blood mononuclear cells and polymorphonuclear leukocytes in patients studied for suspected obstructive sleep apnea. 2011 , 15, 3-11	22
1001	[Chronic inflammation and biomarkers. Is ageing an expression of chronic inflammation?]. 2011 , 44, 153-7	1
1000	Late-breaking clinical trials presented at the American Heart Association Congress in Chicago 2010. 2011 , 100, 1-9	22
999	Statin effect on thrombin inhibitor effectiveness during percutaneous coronary intervention: a post-hoc analysis from the ISAR-REACT 3 trial. 2011 , 100, 579-85	3
998	Evidence-based statin prescription for cardiovascular protection in renal impairment. 2011 , 15, 456-63	12
997	Lipid lowering therapy in type 2 diabetes. 2011 , 161, 289-96	8

- 996 C-reactive protein promotes diabetic kidney disease in a mouse model of type 1 diabetes. **2011**, 54, 2713-23 54
- 995 Clinical Utility of Multiple Biomarker Panels for Cardiovascular Disease Risk Prediction. **2011**, 5, 165-173 1
- 994 Peripheral Artery Disease in the Elderly: Prevalence, Clinical Implications, and Therapy. **2011**, 5, 457-466
- 993 Comparison Between Serum hsCRP and LDL Cholesterol for Search of a Better Predictor for Ischemic Heart Disease. **2011**, 26, 210-3 11
- 992 Prevalence of coronary artery calcium scores and silent myocardial ischaemia was similar in Indian Asians and European whites in a cross-sectional study of asymptomatic subjects from a U.K. population (LOLIPOP-IPC). **2011**, 18, 435-42 5
- 991 The challenge of imaging-guided therapeutic management. **2011**, 18, 995-6
- 990 Assessing Risk and Predicting Outcomes in Coronary Artery Disease: Physiology, Anatomy, or Biology?. **2011**, 4, 180-189 1
- 989 A practical approach to lipid management in the elderly. **2011**, 15, 65-70 1
- 988 Treatment of risk factors to prevent stroke. **2011**, 8, 463-74 13
- 987 Japan Prevention Trial of Diabetes by Pitavastatin in Patients with Impaired Glucose Tolerance (the J-PREDICT study): rationale, study design, and clinical characteristics of 1269 patients. **2011**, 2, 134-140 18
- 986 Target organ damage in a population at intermediate cardiovascular risk, with adjunctive major risk factors: Cardiovascular PREvention Sacco Study (CAPRESS). **2011**, 6, 337-47 1
- 985 The epidemiological concept of residual risk. **2011**, 6 Suppl 1, 45-51 21
- 984 High doses of rosuvastatin are superior to low doses of rosuvastatin plus fenofibrate or n-3 fatty acids in mixed dyslipidemia. **2011**, 46, 521-8 20
- 983 Statins in combinations: from ARBITER-6 HALTS to ACCORD--what works?. **2011**, 13, 4-8
- 982 Statin therapy in metabolic syndrome and hypertension post-JUPITER: what is the value of CRP?. **2011**, 13, 31-42 29
- 981 Are cardiovascular benefits in statin lipid effects dependent on baseline lipid levels?. **2011**, 13, 64-72 4
- 980 The role of C-reactive protein as a risk predictor of coronary atherosclerosis: implications from the JUPITER trial. **2011**, 13, 154-61 36
- 979 Systemic inflammation and the dynamics of HDL cholesterol-associated residual cardiovascular risk. **2011**, 13, 187-9

978	The incremental value of lipids and inflammatory biomarkers in determining residual cardiovascular risk. 2011 , 13, 373-80	8
977	The role of atherosclerosis imaging in redefining normal and abnormal cholesterol values, and risk reduction in primary prevention statin trials. 2011 , 13, 422-30	4
976	The JUPITER trial: myth or reality?. 2011 , 13, 413-21	7
975	Optimal medical therapy, lifestyle intervention, and secondary prevention strategies for cardiovascular event reduction in ischemic heart disease. 2011 , 13, 287-95	7
974	Coronary artery calcium: utilization for primary prevention of CHD. 2011 , 13, 465-74	6
973	The role of triglycerides in atherosclerosis. 2011 , 13, 544-52	201
972	Predictors of statin adherence. 2011 , 13, 553-8	40
971	Inflammatory Markers Associated with Coronary Heart Disease in Persons with HIV Infection. 2011 , 13, 94-101	16
970	To what extent can preventive treatments prevent damage from systemic lupus erythematosus?. 2011 , 13, 317-23	3
969	Pulse wave velocity and carotid atherosclerosis in white and Latino patients with hypertension. 2011 , 11, 15	19
968	Pharmacological and non-pharmacological interventions to influence adipose tissue function. 2011 , 10, 13	35
967	Carotid plaque regression following 6-month statin therapy assessed by 3T cardiovascular magnetic resonance: comparison with ultrasound intima media thickness. 2011 , 13, 37	40
966	On the clinical meaningfulness of a treatment's effect on a time-to-event variable. 2011 , 30, 2341-8	6
965	Cardiovascular disease risk in rheumatoid arthritis: progress, debate, and opportunity. 2011 , 63, 484-99	42
964	Effects of rosuvastatin on vascular biomarkers and carotid atherosclerosis in lupus: a randomized, double-blind, placebo-controlled trial. 2011 , 63, 875-83	44
963	Low frequency of primary lipid screening among medicare patients with rheumatoid arthritis. 2011 , 63, 1221-30	45
962	Pathogenesis of postoperative adhesion formation. 2011 , 98, 1503-16	146
961	Emerging genomic applications in coronary artery disease. 2011 , 4, 473-82	30

960	Genetic susceptibility of the arterial wall is an important determinant of atherosclerosis in C57BL/6 and FVB/N mouse strains. 2011 , 31, 1814-20	9
959	The oral spleen tyrosine kinase inhibitor fostamatinib attenuates inflammation and atherogenesis in low-density lipoprotein receptor-deficient mice. 2011 , 31, 1991-9	49
958	Clinical review: The evolving role of HDL in the treatment of high-risk patients with cardiovascular disease. 2011 , 96, 1246-57	87
957	Cardiovascular disease in women. 2011 , 7, 613-27	2
956	Biomarkers for predicting postmenopausal coronary heart disease. 2011 , 5, 485-95	3
955	Creating a physically active society: the next great challenge. 2011 , 25, 291-3	
954	Pentraxins and atherosclerosis: the role of PTX3. 2011 , 17, 38-46	41
953	Management of dyslipidemia in HIV-infected patients. 2011 , 6, 447-462	20
952	Carotid artery atherosclerosis: effect of intensive lipid therapy on the vasa vasorum--evaluation by using dynamic contrast-enhanced MR imaging. 2011 , 260, 224-31	65
951	Imaging assessment of cardiovascular risk in asymptomatic adults. 2011 , 197, W1046-51	5
950	Event reduction: revisiting why we treat with statins and harnessing current evidence towards optimal therapy. 2011 , 12, 99-117	4
949	The assessment of vascular function during dietary intervention trials in human subjects. 2011 , 106, 981-94	12
948	The dysfunctional endothelium in CKD and in cardiovascular disease: mapping the origin(s) of cardiovascular problems in CKD and of kidney disease in cardiovascular conditions for a research agenda. 2011 , 1, 6-9	45
947	Estimating treatment effects for individual patients based on the results of randomised clinical trials. 2011 , 343, d5888	94
946	Statins and prevention of infections: systematic review and meta-analysis of data from large randomised placebo controlled trials. 2011 , 343, d7281	47
945	Central obesity and smoking are key modifiable risk factors for elevated C-reactive protein in Asian individuals who are not eligible for statin therapy. 2011 , 1, e8	4
944	Primärprävention des Schlaganfalls Was ist neu?. 2011 , 38, 414-427	0
943	Atherosclerosis: current status of prevention and treatment. 2011 , 20, 213-22	18

942	Dyslipidemia, statins, and venous thromboembolism. 2011 , 37, 897-902	16
941	Relationship between venous and arterial thrombosis: a review of the literature from a causal perspective. 2011 , 37, 885-96	67
940	Increased waist circumference is the component of metabolic syndrome the most strongly associated with elevated C-reactive protein in elderly. 2011 , 9, 281-5	8
939	Statin myopathy: a common dilemma not reflected in clinical trials. 2011 , 78, 393-403	145
938	Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus. 2011 , 12, 1429-38	15
937	Can we dramatically reduce the incidence of coronary heart disease?. 2011 , 8, 721-5	33
936	Effect of rosuvastatin on hemoglobin levels in patients with anemia and low-grade inflammation: a post hoc analysis of the JUPITER trial. 2011 , 51, 1483-7	5
935	Preliminary findings regarding proinflammatory markers and brain-derived neurotrophic factor among adolescents with bipolar spectrum disorders. 2011 , 21, 479-84	76
934	Current Controversies in Nutrition: The Blind Leading the Blind: Common Problems with the Nature of Clinical Trials. 2011 , 17, 279-283	
933	Oxidative stress and endothelial dysfunction: therapeutic implications. 2011 , 43, 259-72	82
932	Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk $\geq 5\%$ or Framingham risk $>20\%$: post hoc analyses of the JUPITER trial requested by European health authorities. 2011 , 32, 75-83	27
931	Inflammatory gene variants in the Tsimane, an indigenous Bolivian population with a high infectious load. 2011 , 57, 33-52	27
930	Beneficial effect of atorvastatin on renal function in patients with type 2 diabetes. 2011 , 39, 1504-12	7
929	Inflammatory markers in coronary heart disease. 2011 , 100, 23-38	62
928	Statins and the risk of new-onset diabetes: a review of recent evidence. 2011 , 22, 460-6	76
927	Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction. 2011 , 123, 551-65	197
926	Dyslipidemia management. 2011 , 17, 1242-54	
925	Should C-reactive protein be a target of therapy?. 2011 , 34 Suppl 2, S155-60	18

924	Introduction to the Third World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy): outcome studies versus clinical experience in the treatment of diabetes. 2011 , 34 Suppl 2, S99-100	1
923	Effects of statins on coronary and peripheral endothelial function in humans: a systematic review and meta-analysis of randomized controlled trials. 2011 , 18, 704-16	92
922	Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis. 2011 , 183, E1189-202	84
921	Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis. 2011 , 342, d1672	86
920	Kinesin-like protein 6 (KIF6) polymorphism and the efficacy of rosuvastatin in primary prevention. 2011 , 4, 312-7	42
919	Lipid-lowering drug therapy in elderly patients. 2011 , 17, 877-93	18
918	C-reactive protein and high-sensitivity C-reactive protein: an update for clinicians. 2011 , 123, 114-9	106
917	ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. 2011 , 123, 2434-506	255
916	The safety and efficacy of statin therapy in the pediatric population. 2011 , 26, 44-52	1
915	Statin therapy dose and risk of new-onset diabetes. 2011 , 306, 1325-6; author reply 1326	1
914	Association between obesity, high-sensitivity C-reactive protein \geq mg/L, and subclinical atherosclerosis: implications of JUPITER from the Multi-Ethnic Study of Atherosclerosis. 2011 , 31, 1430-8	69
913	The effect of subantimicrobial-dose-doxycycline periodontal therapy on serum biomarkers of systemic inflammation: a randomized, double-masked, placebo-controlled clinical trial. 2011 , 142, 262-73	65
912	Statin Therapy Associated with Fatal Rhabdomyolysis. 2011 , 12, 40-42	4
911	Effects of rosuvastatin versus atorvastatin on rho-associated coiled-coil containing protein kinase activity and endothelial function in patients with atherosclerosis. 2011 , 39, 2314-22	7
910	Statin Therapy Dose and Risk of New-Onset Diabetes--Reply. 2011 , 306, 1326-1326	
909	Sex/gender differences in cardiovascular disease prevention: what a difference a decade makes. 2011 , 124, 2145-54	561
908	Inflammation as a marker for the prediction of internal carotid artery restenosis following eversion endarterectomy--evidence from clinical studies. 2011 , 62, 535-42	14
907	Rosuvastatin in diabetic hemodialysis patients. 2011 , 22, 1335-41	80

906	Making it more sensitive: the new era of troponin use. 2011 , 123, 1361-3	23
905	Cost-effectiveness of the use of low- and high-potency statins in people at low cardiovascular risk. 2011 , 183, E1180-8	25
904	Drug-induced changes in risk/biomarkers and their relationship with renal and cardiovascular long-term outcome in patients with diabetes. 2011 , 57, 186-95	2
903	Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the american heart association. 2011 , 123, 1243-62	1065
902	Cross-sectional associations of albuminuria and C-reactive protein with functional disability in older adults with diabetes. 2011 , 34, 710-7	12
901	Benefit of intensive statin therapy in women: results from PROVE IT-TIMI 22. 2011 , 4, 328-36	50
900	Vascular inflammation stratified by C-reactive protein and low-density lipoprotein cholesterol levels: analysis with 18F-FDG PET. 2011 , 52, 10-7	44
899	Drug therapy for the prevention of type 2 diabetes ¶s there a medical rationale?. 2011 , 11, 168-174	1
898	Blood Pressure-Lowering Aspects of Lipid-Lowering and Anti-Diabetic Drugs. 2011 , 4, 1-6	2
897	Treatment of diabetic vasculopathy: an overview. 2011 , 21	0
896	Effective Lipid-lowering Therapy in High-risk Patients. 2011 , 1,	
895	Blood C-reactive protein concentration with ABCD¶ is a better prognostic tool than ABCD¶ alone. 2011 , 32, 97-105	9
894	Treatment Options for Hypercholesterolemia and Combined Dyslipidemia: Focus on Pitavastatin. 2011 , 3, 311-324	
893	LDL-LOWERING INDEPENDENT EFFECTS OF EARLY PRE-TREATMENT WITH HIGH-DOSE STATINS IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS. 2011 , 1,	
892	Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCMB study. 2011 , 10, 65	31
891	The ezetimibe controversy: implications for clinical practice. 2011 , 5, 199-208	12
890	Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians. 2011 , 2, 307-23	14
889	Therapeutic approaches to target inflammation in type 2 diabetes. 2011 , 57, 162-7	90

888	Left atrial enlargement: a cause of stroke?. 2011 , 183, 1129-30	4
887	Coupling of Fcγ receptor I to Fcγ receptor IIb by SRC kinase mediates C-reactive protein impairment of endothelial function. 2011 , 109, 1132-40	22
886	Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era. 2011 , 124, 146-53	112
885	High-sensitivity C-reactive protein and clopidogrel treatment in patients at high risk of cardiovascular events: a substudy from the CHARISMA trial. 2011 , 97, 626-31	11
884	Effects of statin treatment on endothelial function, oxidative stress and inflammation in patients with arterial hypertension and normal cholesterol levels. 2011 , 29, 1757-64	25
883	High-sensitivity C-reactive protein, obesity, and subclinical atherosclerosis: implications of JUPITER from the MESA study. 2011 , 31, 1251-2	7
882	Nontraditional risk factors and biomarkers for cardiovascular disease: mechanistic, research, and clinical considerations for youth: a scientific statement from the American Heart Association. 2011 , 123, 2749-69	227
881	Statins are not associated with a decrease in all cause mortality in a high-risk primary prevention setting. 2011 , 16, 8-9	
880	High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial. 2011 , 203, 756-64	112
879	Inflammatory markers and risk of cerebrovascular events in patients initiating dialysis. 2011 , 6, 1292-300	6
878	The efficacy and safety of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors in chronic kidney disease, dialysis, and transplant patients. 2011 , 6, 664-78	23
877	The cardiovascular biomarker conundrum: challenges and solutions. 2011 , 306, 2151-2	8
876	Hyperlipidemia in Primary Care. 2011 ,	1
875	Studies on Renal Disorders. 2011 ,	3
874	Inflammatory markers in hyperlipidemia: from experimental models to clinical practice. 2011 , 17, 4132-46	35
873	Systemic manifestations of COPD. 2011 , 139, 165-73	153
872	Increased mortality rates in the JUPITER trial. 2011 , 120, 235; reply pg 236	1
871	High-sensitivity C-reactive protein levels fall during statin therapy in HIV-infected patients receiving ritonavir-boosted protease inhibitors. 2011 , 25, 1128-31	31

870	Selection of nonnucleoside reverse transcriptase inhibitor-associated mutations in HIV-1 subtype C: evidence of etravirine cross-resistance. 2011 , 25, 1123-6	17
869	Intensifying statin therapy to maximize cardiovascular risk reduction: is 50 the new 70? Goals are getting old. 2011 , 6, 131-136	4
868	High-sensitivity C-reactive protein, vascular imaging, and vulnerable plaque: more evidence to support trials of antiinflammatory therapy for cardiovascular risk reduction. 2011 , 4, 195-7	9
867	Traditional risk factors for incident cardiovascular events have limited importance in later life compared with the health in men study cardiovascular risk score. 2011 , 42, 952-9	18
866	Dyslipidemias in the older subject: features, significance and treatment dilemmas. 2011 , 6, 339-350	2
865	Monomeric C-reactive protein is prothrombotic and dissociates from circulating pentameric C-reactive protein on adhered activated platelets under flow. 2011 , 92, 328-37	62
864	Cardiovascular implications from untreated human immunodeficiency virus infection. 2011 , 32, 945-51	59
863	Statins--beyond lipids in CKD. 2011 , 26, 407-10	9
862	Oral activated charcoal adsorbent (AST-120) ameliorates extent and instability of atherosclerosis accelerated by kidney disease in apolipoprotein E-deficient mice. 2011 , 26, 2491-7	56
861	Recruitment of immigrant and ethnic minorities in primary prevention trials of cardiovascular disease. 2011 , 104, 469-76	12
860	Lupus Atherosclerosis Prevention Study (LAPS). 2011 , 70, 760-5	156
859	Relationship of blood pressure and obesity with inflammatory cytokines among African Americans. 2011 , 5, 149-57	7
858	Orally administered eicosapentaenoic acid induces rapid regression of atherosclerosis via modulating the phenotype of dendritic cells in LDL receptor-deficient mice. 2011 , 31, 1963-72	65
857	HMG CoA reduction in patients with average cholesterol concentrations. 2011 , 57, 1072-3	2
856	Diabetes and cardiovascular disease: when it comes to lipids, statins are all you need. 2011 , 34 Suppl 2, S380-2	9
855	Atherosclerosis drug development in jeopardy: the need for predictive biomarkers of treatment response. 2011 , 3, 72cm6	12
854	C-reactive protein and prediction of 1-year mortality in prevalent hemodialysis patients. 2011 , 6, 2452-61	99
853	A tale of three labels: translating the JUPITER trial data into regulatory claims. 2011 , 8, 417-22	2

852	Plasma myeloperoxidase predicts incident cardiovascular risks in stable patients undergoing medical management for coronary artery disease. 2011 , 57, 33-9	73
851	Evaluating the clinical utility of a biomarker: a review of methods for estimating health impact. 2011 , 123, 1116-24	90
850	Lipid-lowering effects of ezetimibe and simvastatin in combination. 2011 , 9, 131-45	13
849	High-density lipoprotein (HDL) cholesterol: leveraging practice-based biobank cohorts to characterize clinical and genetic predictors of treatment outcome. 2011 , 11, 162-73	8
848	Rosuvastatin attenuates the elevation in blood pressure induced by overexpression of human C-reactive protein. 2011 , 34, 869-75	10
847	The Medicalization of Life: Are We First Doing Harm?. 2011 , 17, 6-8	
846	Biomarkers: Coronary artery calcium is a better risk marker than hsCRP. 2011 , 8, 616-8	3
845	Pharmacotherapy: Implications of high-dose statin link with incident diabetes. 2011 , 8, 543-4	3
844	Lipid parameters for measuring risk of cardiovascular disease. 2011 , 8, 197-206	144
843	Statins in hemorrhagic stroke. 2011 , 11, 1141-9	8
842	Monocyte chemoattractant protein-1 is related to metabolic syndrome and homocysteine in subjects without clinically significant atherosclerotic cardiovascular disease. 2011 , 71, 1-6	13
841	Treatment of lipid disorders in obesity. 2011 , 9, 1069-80	32
840	Atlas of Atherosclerosis and Metabolic Syndrome. 2011 ,	5
839	4th Annual Symposium on Self Monitoring of Blood Glucose (SMBG) Applications and Beyond, May 12-14, 2011, Budapest, Hungary. 2011 , 13, 1161-76	2
838	Emerging drugs for coronary artery disease. From past achievements and current needs to clinical promises. 2011 , 16, 203-33	1
837	Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. 2011 , 70, 482-7	320
836	Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies. 2011 , 12, 13-30	50
835	Ang II Upregulation of the T-lymphocyte renin-angiotensin system is amplified by low-grade inflammation in human hypertension. 2011 , 24, 716-23	28

834	Major contribution of the P2Y ₆ receptor in purinergic regulation of TNF α -induced vascular inflammation. 2011 , 123, 2404-13	64
833	The CRP genotype, serum levels and lung function in men: the Caerphilly Prospective Study. 2011 , 120, 347-55	23
832	Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications. 2011 , 104, 13-26	60
831	[Cardiovascular risk assessment and risk stratification- guided therapy: predict, prevent and individualize]. 2011 , 11, 551-6	1
830	Chemokines and stroke: the subcellular harbingers of apoplexy?. 2011 , 77, 1116-7	
829	Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. 2011 , 6, 1316-25	91
828	C-reactive protein levels in the brugada syndrome. 2011 , 2011, 341521	5
827	Primary prevention of stroke: blood pressure, lipids, and heart failure. 2011 , 32, 545-52	52
826	Medical angioplasty - hope and expectations: an optimistic overview. 2011 , 18, 101-10	
825	Increased plasma soluble uPAR level is a risk marker of respiratory cancer in initially cancer-free individuals. 2011 , 20, 609-18	36
824	Multimarker risk model containing troponin-T, interleukin 10, myeloperoxidase and placental growth factor predicts long-term cardiovascular risk after non-ST-segment elevation acute coronary syndrome. 2011 , 97, 1061-6	43
823	Pitavastatin: finding its place in therapy. 2011 , 2, 101-17	9
822	Measuring mortality reductions in cancer screening trials. 2011 , 33, 36-45	30
821	From circulating biomarkers to genomics and imaging in the prediction of cardiovascular events in the general population. 2012 , 44, 433-47	4
820	Preventive pharmacotherapy in type 2 diabetes mellitus. 2012 , 16, 33-43	8
819	The 719Arg variant of KIF6 and cardiovascular outcomes in statin-treated, stable coronary patients of the treating to new targets and incremental decrease in end points through aggressive lipid-lowering prospective studies. 2012 , 5, 51-7	17
818	Omega-3 fatty acids ameliorate atherosclerosis by favorably altering monocyte subsets and limiting monocyte recruitment to aortic lesions. 2012 , 32, 2122-30	55
817	Genome-wide association study evaluating lipoprotein-associated phospholipase A2 mass and activity at baseline and after rosuvastatin therapy. 2012 , 5, 676-85	30

816 Conclusion. **2012**, 19, 54-5

815 Loss of the preconditioning effect of rosuvastatin during sustained therapy: a human in vivo study. **2012**, 302, H153-8 11

814 Does inflammation determine whether obesity is metabolically healthy or unhealthy? The aging perspective. **2012**, 2012, 456456 54

813 Strategies to preserve the use of statins in patients with previous muscular adverse effects. **2012**, 69, 291-300 13

812 Clinical neuroprotective drugs for treatment and prevention of stroke. **2012**, 13, 7739-61 15

811 Does C-reactive protein contribute to atherothrombosis via oxidant-mediated release of pro-thrombotic factors and activation of platelets?. **2012**, 3, 433 15

810 Value of C-reactive protein as a risk factor for acute coronary syndrome: a comparison with apolipoprotein concentrations and lipid profile. **2012**, 2012, 419804 14

809 Interleukin-1 α accelerates the onset of stroke in stroke-prone spontaneously hypertensive rats. **2012**, 2012, 701976 19

808 Statins in postmenopausal women linked to increased diabetes risk **2012**, 18, 3 1

807 Writing for publication in a medical journal. **2012**, 16, 899-903 4

806 Iron reduction benefits: positive results from a "negative" prospective randomized controlled trial. **2012**, 46, 596-7

805 Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: a post hoc ATTEMPT analysis. **2012**, 63, 358-66 21

804 Therapeutic interventions against inflammatory and angiogenic mediators in proliferative diabetic retinopathy. **2012**, 2012, 629452 62

803 Statin use and the risk of Clostridium difficile in academic medical centres. **2012**, 61, 1538-42 42

802 High-sensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation: an exploratory analysis of the JUPITER trial. **2012**, 33, 531-7 80

801 Preclinical mouse models and methods for the discovery of the causes and treatments of atherosclerosis. **2012**, 7, 207-16 14

800 Statins and Clostridium difficile: a clinically relevant interaction?. **2012**, 61, 1523-4

799 Some aspects of preventing coronary heart disease. **2012**, 63, 17-23 4

798	Differential alterations of the CD4 and CD8 T cell subsets in HIV-infected patients on highly active antiretroviral therapy with low CD4 T cell restoration. 2012 , 67, 1228-37	28
797	A multiple biomarker risk score for guiding clinical decisions using a decision curve approach. 2012 , 19, 874-84	9
796	Novel biomarkers in cardiovascular disease: research tools or ready for personalized medicine?. 2012 , 20, 111-7	8
795	The effects of statins on prevention of stroke and dementia: a review. 2012 , 32, 240-9	6
794	Novel anti-inflammatory strategies in atherosclerosis. 2012 , 23, 532-9	35
793	Do aspirin and statins prevent severe sepsis?. 2012 , 25, 345-50	8
792	The evolution and refinement of traditional risk factors for cardiovascular disease. 2012 , 20, 118-29	39
791	Low-density lipoprotein-lowering strategies: target versus maximalist versus population percentile. 2012 , 27, 405-11	15
790	Hyperlipidaemia and cardiovascular disease: HDL, inflammation and surprising results of AIM-HIGH study. 2012 , 23, 260-262	5
789	Biomarkers in native and transplant kidneys: opportunities to improve prediction of outcomes in chronic kidney disease. 2012 , 21, 619-27	10
788	Effect of interleukin 1 α inhibition in cardiovascular disease. 2012 , 23, 548-53	56
787	Hypothyroidism as a risk factor for development of cardiovascular disease in patients with rheumatoid arthritis. 2012 , 39, 954-8	21
786	Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation: endorsed by the American Society of Transplant Surgeons, American Society of Transplantation, and National Kidney Foundation. 2012 , 126, 617-63	181
785	Hyperlipidemia as an instigator of inflammation: inaugurating new approaches to vascular prevention. 2012 , 1, 3-5	14
784	Lipid-modifying therapies and risk of pancreatitis: a meta-analysis. 2012 , 308, 804-11	99
783	Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. 2012 , 5, 257-64	200
782	Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. 2012 , 307, 1302-9	512
781	Association of C-reactive protein with cardiovascular disease mortality according to diabetes status: pooled analyses of 25,979 participants from four U.K. prospective cohort studies. 2012 , 35, 396-403	74

780	Evaluation of colesevelam hydrochloride for the treatment of type 2 diabetes. 2012 , 8, 515-25		13
779	Screening and identifying high-risk individuals in the general population by using traditional risk factors. 2012 , 11-22		
778	Resting heart rate as a tool for risk stratification in primary care: does it provide incremental prognostic information?. 2012 , 19, 275-84		11
777	Statin therapy decreases serum levels of high-sensitivity C-reactive protein and tumor necrosis factor- α in HIV-infected patients treated with ritonavir-boosted protease inhibitors. 2012 , 13, 153-61		41
776	Statins and risk of new-onset diabetes mellitus. 2012 , 126, e282-4		56
775	Inflammation in coronary artery disease and acute myocardial infarction - is the stage set for novel therapies?. 2012 , 18, 4358-69		26
774	Lipidtherapie bei Diabetes mellitus. 2012 , 7, R37-R50		0
773	Cardiovascular disease: Should statin therapy be expanded in patients with CKD?. 2012 , 8, 440-1		1
772	C-reactive protein, fibrinogen, and cardiovascular disease prediction. <i>New England Journal of Medicine</i> , 2012 , 367, 1310-20	59.2	750
771	Statins: is it really time to reassess benefits and risks?. <i>New England Journal of Medicine</i> , 2012 , 366, 1752-59.2	59.2	69
770	A randomized study of how physicians interpret research funding disclosures. <i>New England Journal of Medicine</i> , 2012 , 367, 1119-27	59.2	126
769	Impact of age and sex on primary preventive treatment for cardiovascular disease in the West Midlands, UK: cross sectional study. 2012 , 345, e4535		42
768	Novel strategies for managing dyslipidemia: treatment beyond statins. 2012 , 124, 43-54		12
767	Präventive Kardiologie. 2012 , 08, 321-334		
766	Biomarkers associated with vulnerable atheromatous plaque. 2012 , 19, 2588-96		5
765	Repeating tests: different roles in research studies and clinical medicine. 2012 , 6, 691-703		12
764	The role of platelets in athero-thrombotic events. 2012 , 18, 5197-214		49
763	Effects of atorvastatin on endothelial function and the expression of proinflammatory cytokines and adhesion molecules in young subjects with successfully repaired coarctation of aorta. 2012 , 98, 325-9		24

762	Comparing the effectiveness of rosuvastatin and atorvastatin in preventing cardiovascular outcomes: estimates using the Archimedes model. 2012 , 15, 1118-29	13
761	Coronary artery calcium scanning in asymptomatic patients with diabetes mellitus: a paradigm shift. 2012 , 4, 342-50	19
760	Statins in the management of dyslipidemia associated with chronic kidney disease. 2012 , 8, 214-23	38
759	Hypertension and C-reactive protein. 2012 , 35, 969-71	1
758	CVD screening in low-risk, asymptomatic adults: clinical trials needed. 2012 , 9, 599-604	29
757	C-reactive protein as a predictor of hypertension in the Hong Kong Cardiovascular Risk Factor Prevalence Study (CRISPS) cohort. 2012 , 26, 108-16	29
756	The rise of cardiovascular medicine. 2012 , 33, 838-45, 845a	34
755	Puesta al dâ en el manejo de las dislipidemias. 2012 , 23, 681-687	
754	Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy?. 2012 , 19, 474-83	13
753	Fibroblast growth factor-21 (FGF21) regulates low-density lipoprotein receptor (LDLR) levels in cells via the E3-ubiquitin ligase Mylip/Idol and the Canopy2 (Cnpy2)/Mylip-interacting saposin-like protein (Msap). 2012 , 287, 12602-11	46
752	Folate receptor: a macrophage "achilles' heel"?. 2012 , 1, e004036	4
751	Immunologic basis of cardiovascular disease in HIV-infected adults. 2012 , 205 Suppl 3, S375-82	186
750	Periodontal disease and atherosclerotic vascular disease: does the evidence support an independent association?: a scientific statement from the American Heart Association. 2012 , 125, 2520-44	653
749	Potencialidad de los biomarcadores de inflamaci3n en la detecci3n precoz de la enfermedad cardiovascular. 2012 , 23, 666-671	
748	Cardiovascular disease, statins and vitamin D. 2012 , 21, 214-20	2
747	Estratificaci3n de riesgo cardiovascular en la poblaci3n chilena. 2012 , 23, 657-665	
746	Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial. 2012 , 58, 183-9	110
745	High-sensitive C-reactive protein: universal prognostic and causative biomarker in heart disease?. 2012 , 6, 19-34	34

744	Lifestyle Measures to Reduce Inflammation. 2012 , 6, 4-13	9
743	Cardiology in Family Practice. 2012 ,	3
742	Another Telescope for Examining Statins: the SATURN Trial. 2012 , 30, 115-119	
741	Reducing Inflammation: Statins or Lifestyle?. 2012 , 6, 21-23	
740	The case for more intensive use of statins. 2012 , 3, 201-10	2
739	The effect of rosuvastatin on incident pneumonia: results from the JUPITER trial. 2012 , 184, E367-72	54
738	Low cholesterol, statins and outcomes in patients with first-ever acute ischemic stroke. 2012 , 34, 213-20	32
737	Statins: Cholesterol guidelines and Indian perspective. 2015 , 19, 546-53	8
736	COVID-19 and Stroke: Incidental, Triggered or Causative. 2020 , 23, 318-324	12
735	Effect of intensive lifestyle modification & metformin on cardiovascular risk in prediabetes: A pilot randomized control trial. 2018 , 148, 705-712	5
734	Analysis of glycemic status in diabetes-naïve patients on statins: A hospital-based cross-sectional study. 2018 , 50, 320-325	1
733	Suppression of Nitric Oxide Production and Cardiovascular Risk Factors in Healthy Seniors and Hypercholesterolemic Subjects by a Combination of Polyphenols and Vitamins. 2012 , S5, 8	11
732	Long-term effects of Nigella sativa L. oil on some physiological parameters in normal and streptozotocin-induced diabetic rats. 2011 , 01, 46-53	9
731	Accelerated Atherosclerosis in Takayasu Disease: Case-Control Study. 2017 , 07, 12-24	2
730	Awareness and use of cardiovascular risk scores by family physicians in southeastern Ontario. 2013 , 03, 487-490	3
729	The Application of the LDL Principle. 2016 , 06, 109-125	10
728	Targeting the Inflammation Culprit in Patients with Psoriasis/Psoriatic Arthritis and Associated Cardiovascular Comorbidities. Is the IL-17 Inhibitor the New Kid on the Block?. 2019 , 09, 267-294	1
727	Effect of hypolipidemic treatment on glycemic profile in patients with mixed dyslipidemia. 2013 , 4, 365-71	11

726	PCSK9 and carbohydrate metabolism: A double-edged sword. 2017 , 8, 311-316	15
725	Favourable effect of statin therapy on early survival benefit at the time of percutaneous coronary intervention for ST-elevation myocardial infarction and shock. 2010 , 6, 350-5	10
724	The ability of high dose rosuvastatin to improve plaque composition in non-intervened coronary arteries: rationale and design of the Integrated Biomarker and Imaging Study-3 (IBIS-3). 2012 , 8, 235-41	28
723	Statin use prior to angiography for the prevention of contrast-induced acute kidney injury: a meta-analysis of 19 randomised trials. 2016 , 12, 366-74	14
722	JUPITER and satellites: Clinical implications of the JUPITER study and its secondary analyses. 2011 , 3, 207-14	7
721	Adipose tissue and vascular inflammation in coronary artery disease. 2014 , 6, 539-54	32
720	Treat-to-target concept implementation for evaluating rheumatoid arthritis patients in daily practice. 2019 , 6, 136-141	5
719	Statins role in cancer prevention and development-recent meta-analyses. 2013 , 2, 100	2
718	Gender disparities in optimal lipid control among patients with coronary artery disease. 2014 , 21 Suppl 1, S20-8	16
717	Pitavastatin reduces elevated IL-18 levels in Japanese subjects with hypercholesterolemia: sub-analysis of Kansai investigation of statin for hyperlipidemic intervention in metabolism and endocrinology (KISHIMEN). 2011 , 18, 8-15	4
716	Mechanism of statin-induced myopathy investigated using microarray technology. 2009 , 16, 30-2	4
715	Biomarkers and heart disease. 2011 , 7, S9-11	14
714	Postprandial effect of orlistat on the peaking of lipid level after sequential high fat meals. 2012 , 10, 458-63	6
713	The role of novel atherosclerosis markers in peripheral artery disease: is there a gender difference?. 2018 , 29, 322-330	10
712	PCSK9 Inhibitors: Clinical Relevance, Molecular Mechanisms, and Safety in Clinical Practice. 2019 , 112, 453-460	3
711	Updated Cardiovascular Prevention Guideline of the Brazilian Society of Cardiology - 2019. 2019 , 113, 787-891	29
710	Changes in body weight, C-reactive protein, and total adiponectin in non-obese women after 12 months of a small-volume, home-based exercise program. 2013 , 68, 1121-7	5
709	Four Statin Benefit Groups Defined by The 2013 ACC/AHA New Cholesterol Guideline are Characterized by Increased Plasma Level of Electronegative Low-Density Lipoprotein. 2016 , 32, 667-675	6

708	Proper Management of People with Obesity during the COVID-19 Pandemic. 2020 , 29, 84-98	18
707	TLR4 Asp299Gly (rs4986790) polymorphism and coronary artery disease: a meta-analysis. 2015 , 3, e1412	7
706	Repeated In-Stent Restenosis Despite Aggressive Lipid Lowering by PCSK-9 Inhibitor Treatment: A Case Report. 2021 , 255, 123-126	1
705	Statins and lipoprotein(a); facing the residual risk.. 2021 ,	
704	Inflammatory hypothesis of atherogenesis: Will colchicine be added to the armamentarium in the prevention of coronary artery disease?. 2021 , 9, 100057	
703	Gene-Environment Interactions for Cardiovascular Disease. 2021 , 23, 75	0
702	Coronary artery calcium scoring in patients with statin associated muscle symptoms: Prescribing statins for those most likely to benefit. 2021 ,	0
701	Obesity and Cardiovascular Disease: The Emerging Role of Inflammation. 2021 , 8, 768119	5
700	Efficacy and Safety of Lipid-Lowering Drugs of Different Intensity on Clinical Outcomes: A Systematic Review and Network Meta-Analysis. 2021 , 12, 713007	1
699	Statin treatment effectiveness and the SLCO1B1*5 reduced function genotype: long-term outcomes in women and men.	
698	Association Between Baseline Diastolic Blood Pressure and the Efficacy of Intensive vs Standard Blood Pressure-Lowering Therapy. 2021 , 4, e2128980	2
697	Low-density lipoprotein cholesterol levels and adverse clinical outcomes in chronic kidney disease: Results from the KNOW-CKD. 2021 ,	1
696	The multifaceted therapeutic value of targeting ATP-citrate lyase in atherosclerosis. 2021 , 27, 1095-1105	3
695	Challenges in Optimizing Lipid Management in Women. 2021 , 1	1
694	Should healthy people take statins too?.	
693	Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. 2009 , 2009, 25-26	
692	Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. 2009 , 2009, 1-3	
691	Periodontal disease: Chronic low-grade inflammation accelerating aging. 2009 , 29, 186-189	

- 690 Control of Dyslipidemia. **2009**, 52, 299 3
- 689 3.???CRP??????????? ?????????????????????(N Engl J Med 2006)??????????. **2009**, 40, 1715-1725
- 688 Achieving lipid targets with combination therapy. **2009**, 2009,
- 687 Recent advances in management of cerebrovascular diseases. **2009**, 1,
- 686 Prevention of Cardiovascular Disease. **2009**, 403-436
- 685 Dyslipidemia: Pathogenesis and Management. **2010**, 435-456
- 684 Treatment of Lipid Abnormalities. **2010**, 619-625
- 683 Recent Cholesterol-Lowering Drug Trials: New Data, New Questions. **2010**, 185-191
- 682 Biomarkers. **2010**, 225-239
- 681 Concepto de medicina personalizada posgenética. **2010**, 1-12
- 680 Cardiovascular Risk Factors and Peripheral Arterial Disease. **2010**, 165-172
- 679 Willingness to Pay for Over-the-counter Pravastatin in Self-medication for the Primary Prevention of Myocardial Infarction. **2010**, 15, 1-9
- 678 Hyperlipidemia effects on clinical indexes of stroke in Japanese patients. **2010**, 32, 242-253 1
- 677 Bewegungstherapie bei koronarer Herzkrankheit. **2010**, 115-142 1
- 676 Traitement des complications cardiovasculaires du stress. **2010**, 203-222
- 675 Epidemiology and Primary Prevention of Stroke. **2010**, 362-368
- 674 Cardiovascular Epidemiology. **2010**, 589-595
- 673 ??????????????????????PET?????????????????. **2010**, 41, 233-243

672 Should We Treat According to the SHAPE Guidelines?. **2011**, 581-586

671 Cardiovascular risk management in patients with inflammatory arthritis: what is good for the joint is good for the heart and vice versa!. **2010**, 2,

670 Inflammatory Markers and Novel Risk Factors. **2011**, 107-123

669 Cardiovascular Epidemiology and Characterization of Atherosclerotic Disease Risk Factors. **2011**, 3-24

668 The Metabolic Syndrome: 2009. **2011**, 137-163

667 Management of Dyslipidemia. **2011**, 59-89

666 Deep Venous Thrombosis and Pulmonary Embolism. **2011**, 325-352

665 Early Disease, Early Detection, Early Treatment: Some Common Threads and Some Important Problems. **2011**, 495-507

664 Recent advances in preventing cardiovascular disorders by managing lipid levels. **2010**, 2, 66

1

663 Newer Coronary Risk Factors. **2011**, 113-139

662 Strategies for Treating Abnormal Lipid Profiles with Drugs. **2011**, 163-193

661 Obesity and the Metabolic Syndrome. **2011**, 67-92

660 Rust and Rupture: Atherosclerosis. **2011**, 89-97

659 Cardio-Renal Connection: The Role of Hypoxia and Oxidative Stress. **2011**, 499-533

658 Cardiovasculair Risicomanagement Bij Vrouwen. **2011**, 89-104

657 Drug Therapy for Dyslipidemia. **2011**, 121-139

656 Atherosclerosis in the Rheumatic Diseases: Compounding the Age Risk. **2011**, 17-25

655 Novel Biomarkers and the Assessment of Cardiovascular Risk. **2011**, 54-63

- 654 Genetics of Cardiovascular Disease and Its Role in Risk Prediction. **2011**, 46-53
- 653 Kardiovaskuläre Risikofaktoren und deren therapeutische Beeinflussung. **2011**, 1-12 1
- 652 [Interventions for life style related disease in the elderly: dyslipidemia]. **2011**, 48, 29-32
- 651 Primary Prevention of Stroke. **2011**, 242-251
- 650 Diabetes Mellitus. **2011**, 731-755
- 649 Biochemical or Electrocardiographic Evidence of Acute Myocardial Injury. **2011**, 120-122
- 648 Correlation between LDL-cholesterol and C-reactive protein among an apparently healthy population in the city of Athens. **2011**, 03, 338-342
- 647 Metabolic Syndrome and Cardiovascular Disease. **2011**, 371-387
- 646 Prevention of Ischemic Heart Disease in Women. **2011**, 398-414
- 645 Pathologie Veineuse Aiguë. **2011**, 3-116
- 644 [Dyslipidemia]. **2011**, 48, 250-2
- 643 Statins for progression of aortic valve stenosis and the best evidence for making decisions in health care. **2011**, 129, 41-5 1
- 642 Preventive Cardiology. **2011**, 1-13
- 641 Biomarkers of Stroke. **2011**, 13, 57
- 640 Molecular Mechanisms of the Acute Coronary Syndromes: The Roles of Inflammation and Immunity. **2011**, 53-60 0
- 639 Circulating levels of inflammatory biomarkers associated with ischemic stroke subtype. **2011**, 33, 564-571
- 638 Lipid management after a coronary event. **2011**, 328-337
- 637 Molecular genetics of atherosclerosis and acute coronary syndromes. **2011**, 35-43

636 C-reactive protein as an inflammatory marker of acute infections outside intensive care settings: case report and evidence-based literature review. **2011**, 1, 3-9

635 Disorders of Lipid Metabolism. **2011**, 1633-1674

634 Effects of recreational dance exercise on cardiovascular risk factors, vascular structure and function in older women.. **2011**, 20, 35-46

633 Predoperatsionnaya terapiya statinamiu patsientov s ishemicheskoy bolezn'yu serdtsa. **2011**, 2, 51-54

1

632 Screening Patients with Prediabetes and Diabetes for Cardiovascular Disease. 34-40

631 Effects of rosuvastatin on instent restenosis, plasma lipid level and inflammatory factors after coronary stenting. **2011**, 31, 227-228

630 Chemokine MCP-1 and atherosclerosis. **2011**, 53, 365-368

629 Acute Coronary Syndromes. **2012**, 19-50

628 Hyperlipidemia. **2012**, 141-151

1

627 Approach to the Patient with Chest Pain. **2012**, 349-371

626 Lipid-lowering therapy in elderly patients: Focus on statins and outcome. **2011**, 17, 415-424

625 Pentraxins and Atherosclerosis. **2012**, 219-237

624 Inflammatory Biomarkers. **2012**, 481-495

623 C-reactive protein and sociodemographic parameters in Moscow residents aged 55 years and older. **2011**, 10, 64-69

2

622 Intffts des marqueurs biologiques dans les maladies cardiovasculaires. **2012**, 196, 217-222

621 Meta-analysis on the Role of High-sensitivity C-reactive Protein Monitoring in Relation to the Presence of Glucose Intolerance in Patients Treated with HMG-CoA Reductase Inhibitors. **2012**, 38, 479-490

620 PENTRAXIN 3 : A NEW BIOMARKER OF INFLAMMATION IN ACUTE CORONARY SYNDROMES-FROM BENCH TO BEDSIDE. **2012**, 58, 293-302

619 Prevention and Management of Stroke. **2012**, 1359-1367

- 618 A case of pseudoaneurysm formed 10 years after segmental liver resection for hepatocellular carcinoma. **2012**, 53, 55-63
- 617 Lipoprotein Disorders and Cardiovascular Disease. **2012**, 975-995 2
- 616 Stable Ischemic Heart Disease. **2012**, 1210-1269
- 615 Hypertension, Obesity, and Metabolic Syndrome. **2012**, 133-146
- 614 Risk Markers for Atherothrombotic Disease. **2012**, 914-934 4
- 613 Cardiovascular Disease in Women. **2012**, 1757-1769
- 612 Cardiovascular Disease. **2012**, 478-549
- 611 Final tips in interpreting evidence-based medicine. **2012**, 105, 173-80
- 610 The Future of Drug Treatments. 296-323
- 609 Optimization of primary and secondary prevention. **2012**, 259-277
- 608 Treatment algorithm in patients with stable angina. **2012**, 312-330
- 607 Predictive Value of the Low-Density Lipoprotein Cholesterol to High-Density Lipoprotein Cholesterol Ratio for the Prevention of Stroke Recurrence in Japanese Patients Treated with Rosuvastatin. **2012**, 32, 513-521 3
- 606 Optimization of primary and secondary prevention. **2012**, 259-277
- 605 Medical Management of Carotid Artery Disease. 389-404
- 604 Prevention of Cardiovascular Disease. 345-377
- 603 Novel Biomarkers of Cardiovascular Disease. **2013**, 27-43
- 602 Attention to Prevention. **2013**, 13-26
- 601 Lipid Management. 68-89

- 600 Statins and diabetes mellitus: risks and benefits. **2012**, 11, 85-90 1
- 599 Relationship of Omega-3 Fatty Acids on C-Reactive Protein and Homocysteine in Haitian and African Americans with and without Type 2 Diabetes. **2013**, 3, 0
- 598 Preventive Cardiology. **2013**, 767-780
- 597 Fish Oil and C-Reactive Protein. **2013**, 393-404
- 596 Statins in the treatment and the prevention of the progression of atherosclerosis of patients with coronary heart disease. **2013**, 4, 28-35 1
- 595 Impact of Medical Therapy on Cardiovascular Secondary Prevention. **2013**, 1075-1100
- 594 Benefits and Risks of Exercise for the Coronary Patient. **2013**, 1037-1051
- 593 Epidemiology of Cardiovascular Disease. **2013**, 3-18
- 592 C-Reactive Protein in Cardiovascular Disease. **2013**, 3-18
- 591 PCI Considerations in Women: Gender-Specific Outcomes and Challenges. **2014**, 227-241
- 590 Dyslipidemia. **2014**, 489-502
- 589 Classification of Cardiovascular Disease Risk and Cardiovascular Disease Prevention in Women. **2014**, 13-42
- 588 Impact of Diabetes Mellitus and the Metabolic Syndrome on the Female Heart. **2014**, 265-286
- 587 Cardiovascular Disease Prevention in Women. **2014**, 1-55
- 586 Coronary Calcification: Roles in Risk Prediction and Monitoring Therapies. **2014**, 145-154
- 585 Biology of Aging and Implications for Heart Failure Therapy and Prevention. **2014**, 15-33
- 584 Drugs in the Primary and Secondary Prevention of Coronary Artery Disease. **2014**, 1-32
- 583 Native Coronary Artery and Bypass Graft Atherosclerosis. **2014**, 1-31

582 Prevention of Cardiovascular Disease in Older Adults. **2014**, 1-28

581 Dyslipidemia in Dialysis. **2014**, 179-202

580 Review of Clinical Trials Pertaining to Dyslipidemias in CKD. **2014**, 111-127

579 Phospholipases in Cardiovascular Disease. **2014**, 73-83

1

578 Sudden Cardiac Death in Adults. **2014**, 981-991

577 Dyslipidemias in the Geriatric Chronic Kidney Disease Patients. **2014**, 255-267

576 Blood Lipid Disorders?. **2014**,

575 Lipid-Lowering Drugs. **2014**, 1-19

574 Monitoring the Progression and Regression of Coronary Atherosclerosis with Intravascular Ultrasound. **2014**, 67-79

573 The ideal management of blood cholesterol: a review of the updated 2013 ACC/AHA cholesterol guideline for reducing cardiovascular risk. **2014**, 57, 857

572 Integration of Biomarkers with Plaque Imaging. **2014**, 203-214

571 Lipid-Lowering Agents and Their Effects on Osteonecrosis: Pros and Cons. **2014**, 255-259

570 Effect of pitavastatin on vascular reactivity in hypercholesterolemic rabbits. **2014**, 103, 4-12

569 Management of elevated blood cholesterol in the psychiatric patient: What's new in the guidelines?. **2014**, 4, 100-106

568 Efficacy and safety of Mertenil (rosuvastatin) 40 mg in patients with familial hypercholesterolemia. **2014**, 11, 42-47

567 The Current Status of Statins in Stroke Prevention. **2014**, 1,

566 Lipid-Lowering Agents. **2015**, 783-796

565 Coronary Heart Disease in Women: Evolution of Our Knowledge. **2015**, 13-25

1

564 Concept of Metabolic Surgery. **2014**, 47-66

563 Metabolic Syndrome. **2014**, 69-114

562 THE POSSIBLE INFLUENCE OF BISPHOSPHONATE THERAPY AND ITS COMBINATION WITH STATINS ON PARAMETERS OF AORTIC STIFFNESS IN WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS. **2014**, 17, 15-21

561 Cardiovascular Disease Prevention in Women. **2015**, 1719-1761

560 Cardiovascular Disease. **2015**, 25-53

559 Lipid and Inflammation in Atherosclerosis. **2015**, 37-63

558 New Risk Factors of Cardiovascular Disease. **2015**, 3-19

557 Raised Blood Cholesterol: Preventable Risk Factor for Cardiovascular Disease. **2015**, 69-79

556 Monitoring Committee Structure and Function. **2015**, 343-372

555 Inflammation Biomarkers and Cardiometabolic Risk. **2015**, 1-24

554 Drugs in the Primary and Secondary Prevention of Coronary Artery Disease. **2015**, 1665-1693

553 How to Estimate Cardiovascular Risk. **2015**, 29-39

552 Cardiovascular Disease in Women: An Update. **2015**, 129-141

551 C-Reactive Protein and its Pathophysiological Roles in Atherosclerosis. 247-256

550 The correlation of the efficacy and safety of statins with the aim of primary and secondary prevention: myths and reality. **2015**, 12, 96-102

1

549 Heart Healthy = Prostate Healthy and S.A.M. are the Ideal Natural Recommendations for Prostate Cancer. **2016**, 169-181

548 Statin Myopathy. **2016**, 113-122

547 Management of Risks Factors for Older Women: Osteoporosis and Cardiovascular Disease. **2016**, 1-15

- 546 Risk Analysis of New-onset Impaired Glucose Tolerance with Statins by Using a Spontaneous Reporting Database of Adverse Events. **2016**, 42, 98-106 2
- 545 S.A.M. and Breast Cancer Focus on Statins, Red Yeast Rice, Sterols, and Other Integrative Cholesterol Medicines: The Real Natural Options. **2016**, 141-171
- 544 Myths and Facts about Placebo. **2016**, 6, 43-54
- 543 CORRELATION BETWEEN SERUM hs-CRP AND LDL CHOLESTEROL AS A PREDICTOR OF CARDIOVASCULAR DISEASES. **2016**, 5, 1725-1728
- 542 Pharmacological management of cardiovascular disease in patients with rheumatoid arthritis. **2017**, 73-92
- 541 Hope for primary cardiovascular prevention with the HOPE (Heart Outcomes Prevention Evaluation)-3 trial findings. **2016**, 2016, e201613
- 540 Acute Stroke Emergency Management. **2017**, 303-314
- 539 What did the European guidelines on cardiovascular disease prevention lose in clinical practice in 2016?. **2017**, 20, 7
- 538 Management of Risks Factors for Older Women: Osteoporosis and Cardiovascular Disease. **2017**, 517-530
- 537 Effect of Atorvastatin on Glycaemic Parameters in Normoglycaemic and Prediabetic Subjects: A Prospective, Panel Study. **2017**, 11, FC04-FC09 4
- 536 Cardiovascular Disease Risk in Women: What Makes It Different from Men. **2017**, 1-31 0
- 535 Cardiovascular Risk Management Targeting Inflammation in Addition to Lipid-lowering Therapy. **2017**, 12, 88
- 534 Cholesterol crystal embolization following plaque rupture: a systemic disease with unusual features. **2017**, 31, 82-94 14
- 533 Treatment of patients with high cardiovascular risk: a modern view on combined therapy. **2017**, 14, 12-16 0
- 532 Hyperlipidemia. **2017**,
- 531 What has the GLAGOV clinical study shown?. **2017**, 63, 329-332
- 530 Dyslipidemia. **2017**,
- 529 Laboratory tests and biopsychosocial approach in the examination of patients with brachiocephalic arteries atherosclerosis. **2017**, 16, 4-16 0

- 528 The Role of Rosuvastatin in Primary and Secondary Prevention of Cardiovascular Events and Influence on Patient Compliance. **2017**, 12, 396-399 0
- 527 High-intensity therapy: rationale, indications and safety issues. Prospects of rosuvastatin in clinical practice. **2017**, 8, 15-24
- 526 Markers of early target-organ brain damage in essential arterial hypertension: the search continues. Possibilities of diffusion tensor magnetic resonance imaging. **2017**, 14, 50-54
- 525 Epidemiology of hypercholesterolemia. **2018**, 64, 30-37 1
- 524 Obstacles to Optimal Lipid-Lowering Therapy - Any Solution?. **2018**, 82, 948-950
- 523 Traitement des dyslipidémies. **2018**, 123-139.e1
- 522 Data Monitoring: Structure for Clinical Trials and Sequential Monitoring Procedures. **2018**, 235-267
- 521 Cardiovascular Disease Risk Factor Responses to a Type 2 Diabetes Care Model Including Nutritional Ketosis at One Year: An Open Label, Non-Randomized, Controlled Study.
- 520 Ailevi hiperkolesterolemi hastalarında lipid aferezinin lipid profili ve hs-CRP üzerine etkileri. 24-31
- 519 Efficacité et effets indésirables des statines: évidences et polémiques. **2018**, 202, 817-835
- 518 HIGH INTENSITY HYPOLIPIDEMIC THERAPY AND DECREASED LEVEL OF LOW DENSITY LIPOPROTEIDES CHOLESTEROL: IS THE APPROACH JUSTIFIED? POINT OF VIEW. **2018**, 191-201
- 517 New clinical and pharmacological aspects of the use of atorvastatin for primary and secondary prevention of complications of cardiovascular diseases. **2018**, 110-117
- 516 Randomized Trials. **2019**, 79-111
- 515 Diagnostic and Therapeutic Targeting of Inflammation. **2019**, 239-246
- 514 Postoperative cognitive disorders: the pathogenesis, methods of prevention and treatment. **2019**, 25 2
- 513 Evaluation of Serum Levels of Inflammation, Fibrinolysis and Oxidative Stress Markers in Coronary Artery Disease Prediction: A Cross-Sectional Study. **2019**, 113, 675-676 1
- 512 Atherosclerosis Risk Factors. **2019**, 9-45
- 511 Healthy lifestyle as a decisive factor in the prevention of cardiovascular diseases. **2019**, 22, 56 1

- 510 In Defense of the LDL Hypothesis. **2019**, 09, 245-252
- 509 Cardiometabolic Risk in Overweight and Obese Children in Bangladesh. **2019**, 09, 103-117
- 508 Prevention of cardiovascular event targeted vascular inflammation, and pathology of thrombosis. **2019**, 30, 837-844
- 507 Statins and the Kidney. **2019**, 1330-1333.e2
- 506 De vuelta a la clínica: sin justificaci3n no existe pregunta de investigaci3n que valga. **2019**, 155, 168-175 0
- 505 Improving the Quality of Life of Patients with Arterial Hypertension in Diabetes Mellitus. **2019**, 9, 110-114
- 504 Infogr3ficos para decis3o compartilhada no uso de estatinas em paciente de alto risco cardiovascular. **2019**, 14, 1809
- 503 Current Medical and Surgical Stroke Prevention Therapies for Patients with Carotid Artery Stenosis. **2019**, 16, 96-103 1
- 502 Patient-Reported Outcomes in Online Communications on Statins, Memory, and Cognition: Qualitative Analysis Using Online Communities (Preprint).
- 501 [Possibilities of Computed Tomography of the Heart in Risk Stratification and Determination of Optimal Strategy of Primary Prevention of Cardiovascular Complications of Atherosclerosis]. **2019**, 59, 70-80 0
- 500 [The problem of safety of lipid-lowering therapy]. **2019**, 59, 13-26 1
- 499 Difficult Asthma: Unmet Needs and Future Directions. **2020**, 313-324
- 498 Myocardial ischemic changes of electrocardiogram in intracerebral hemorrhage: A case report and review of literature. **2019**, 7, 3586-3597
- 497 Discontinuing statins or not in the elderly? Study protocol for a randomized controlled trial.
- 496 Asymptomatic HyperCKemia. **2020**, 25-35
- 495 LDL as a therapeutic objective. **2019**, 31 Suppl 2, 1-15 2
- 494 Acute Stroke Emergency Management. **2020**, 273-282
- 493 Reading and Interpreting the Literature on Randomized Controlled Trials. **2020**, 1-12

492	Revascularization: Femoropopliteal. 2020 , 111-124.e3	
491	Evaluation of the effectiveness of lipid-lowering agents. 2020 , 26, 78-85	
490	Approaches Based on Artificial Intelligence and the Internet of Intelligent Things to Prevent the Spread of COVID-19: Scoping Review (Preprint).	
489	Phytosterols Supplementation Reduces Endothelin-1 Plasma Concentration in Moderately Hypercholesterolemic Individuals Independently of Their Cholesterol-Lowering Properties. 2020 , 12,	5
488	Secondary prevention after acute coronary syndrome. 2020 , 66, 236-241	
487	C-reactive protein and cardiovascular disease: From animal studies to the clinic (Review). 2020 , 20, 1211-1219	3
486	Inhibition of Rho-kinase is involved in the therapeutic effects of atorvastatin in heart ischemia/reperfusion. 2020 , 20, 3147-3153	2
485	Statin Intolerance and Noncompliance: An Empiric Approach. 2021 ,	1
484	Epicardial adipocyte-derived TNF- α modulates local inflammation in patients with advanced coronary artery disease. 2021 ,	1
483	New and emerging lipid-modifying drugs to lower LDL cholesterol. 2021 , 10,	1
482	Association between Biomarkers of Oxidative Stress and Inflammation with Cardiac Necrosis and Heart Failure in Non-ST Segment Elevation Myocardial Infarction Patients and Various Degrees of Kidney Function. 2021 , 2021, 3090120	1
481	History of Lipidology. 2021 , 1-9	
480	Effect of Anagliptin versus Sitagliptin on Inflammatory Markers: Sub-Analysis from the REASON Trial. 2020 , 13, 4993-5001	2
479	Statins: unexpected help in COVID-19. 2020 , 26, 509-517	2
478	Effect of Bempedoic Acid on atherogenic lipids and inflammation: A meta-analysis. 2021 , 33, 117-126	2
477	C-Reactive Protein and Other Inflammatory Markers in Cardiovascular Disease: Inflammatory Disorders and Atherosclerosis. 2021 , 565-583	1
476	Inflammation and Atherosclerotic Cardiovascular Disease. 2021 , 289-333	
475	The Low-Density Lipoprotein Cholesterol Hypothesis: An Update. 2021 , 121-138	

- 474 Comparison of 2018 AHA-ACC Multi-Society Cholesterol Guidelines with 2013 ACC-AHA Cholesterol Guidelines. **2021**, 107-120
- 473 Pharmacology of Statins. **2021**, 191-205
- 472 Cardiovascular Risk Assessment: From Global Risk Scoring to Risk Enhancing Factors. **2021**, 35-59
- 471 The Role of Genetics in Preventive Cardiology: Utility of Clinically Available Genetic Tests. **2021**, 335-364
- 470 Cardiovascular Disease in Women: Focus on Lipid Management. **2021**, 467-487
- 469 Efficacy and Safety of Pitavastatin in a Real-World Setting: Observational Study Evaluating SaFety in Patient Treated with Pitavastatin in Korea (PROOF Study). **2020**, 35, 882-891 1
- 468 MECHANISMS OF ATHEROGENESIS AND ITS INTENSIFICATION IN PATIENTS WITH RHEUMATOID ARTHRITIS. **2020**, 8-24
- 467 C-Reactive Protein and Incident Hypertension in Black and White Americans in the REasons for Geographic And Racial Differences in Stroke (REGARDS) Cohort Study. **2021**, 34, 698-706 1
- 466 Rosuvastatin therapy in people with HIV at intermediate cardiovascular risk does not decrease biomarkers of inflammation and immune activation. **2020**, 1
- 465 Inflammatory Markers in Cardiovascular Disease; Lessons Learned and Future Perspectives. **2021**, 19, 323-342 8
- 464 Altered lipid metabolism and serum lipids in chronic kidney disease. **2022**, 43-60 1
- 463 Primary Prevention of Coronary Artery Disease. **2020**, 61-73
- 462 Statins: A distant hope and thousand dangers in near. **2020**, 11, 77
- 461 Origins of Cardiopulmonary Disease in Early Life. **2020**, 17-24
- 460 Endothelial dysfunction as early predictor of atherosclerosis. **2020**, 4, 28-33 2
- 459 Atherosclerosis, Inflammation, and Genetics - And you Thought it Was Just LDL-cholesterol. **2020**, 114, 273-274 2
- 458 Robust Biomarkers: Methodologically Tracking Causal Processes in Alzheimer's Measurement. **2020**, 289-318 1
- 457 Encyclopedia of Behavioral Medicine. **2020**, 1295-1297

456	Effects of Statin Treatment on Patients with Angina and Normal or Nearly Normal Angiograms. 2020 , 15, e15	1
455	Effects of colchicine on tissue factor in oxLDL-activated T-lymphocytes. 2021 , 1	1
454	Dyslipidemia, Diabetes and Atherosclerosis: Role of Inflammation and ROS-Redox-Sensitive Factors. 2021 , 9,	5
453	Cardiorespiratory fitness, white blood cell count, and mortality in men and women. 2021 ,	1
452	Treatment Strategies in Patients with Diabetes Mellitus and Ischemic Heart Disease. 2021 , 228-237	
451	Inflammation in Cardiovascular Disease: From Basic Concepts to Clinical Application. 2020 ,	
450	A practical approach to lipid management in the elderly.	
449	Role of Statins in the Primary Prevention of Atherosclerotic Cardiovascular Disease and Mortality in the Population with Mean Cholesterol in the Near-Optimal to Borderline High Range: A Systematic Review and Meta-Analysis.	
448	[Relevance between Methods of Obtaining Drug Information and the Utilization of the Information in Community Pharmacies -Research on Awareness of Drug Information of "Increased Risk of Developing Diabetes in Patients Treated with HMG-CoA Reductase Inhibitors" in Community Pharmacies]. 2020 , 140, 1185-1193	0
447	How Impactful Is Presentation in Email? The Effect of Avatars and Signatures. 2020 , 10, 1-26	1
446	Hypertension and Hypercholesterolemia: is it Time for Anti-«Lipitensive» Therapy?. 2020 , 16, 842-851	
445	Erectile dysfunction and the "window of curability": a harbinger of cardiovascular events. 2009 , 84, 102-4	3
444	American heart association 2008 scientific sessions United European gastroenterology week american college of rheumatology scientific meeting. 2009 , 34, 30-7	
443	From evidence to practice: consensus in cardiovascular risk assessment and diabetes. 2009 , 30, 179-86	2
442	PROCLAIM: pilot study to examine the effects of clopidogrel on inflammatory markers in patients with metabolic syndrome receiving low-dose aspirin. 2009 , 36, 530-9	9
441	Polycystic ovary syndrome: a major unrecognized cardiovascular risk factor in women. 2009 , 2, 232-9	30
440	Inflammation, high-sensitivity C-reactive protein, and vascular protection. 2010 , 37, 40-1	7
439	Is Jupiter also a god of primary prevention?. 2010 , 37, 6-7	2

- 438 Update on lipids and C-reactive protein in acute and chronic coronary heart disease. **2010**, 37, 307-8
- 437 High-sensitivity C-reactive protein concentrations among patients with and without diabetes in a multiethnic population of Singapore: CREDESCENCE Study. **2010**, 3, 187-95 5
- 436 Practical use of the Framingham risk score in primary prevention: Canadian perspective. **2011**, 57, 417-23 34
- 435 Heart disease is still a primary emphasis. **2009**, 9, 173-4
- 434 C-Reactive Protein: How Has JUPITER Impacted Clinical Practice?. **2009**, 9, 204-10 6
- 433 Modulatory Effect of Inflammation on Blood Pressure Reduction via Therapeutic Lifestyle Change. **2009**, 9, 175-80
- 432 Jeremiah Metzger Lecture: cholesterol, inflammation and atherosclerotic cardiovascular disease: is it all LDL?. **2011**, 122, 256-89 33
- 431 Implications for reproductive medicine: Sex differences in cardiovascular disease. **2011**, 9, 21-28 11
- 430 Primary prevention of CVD: treating dyslipidaemia. **2010**, 2010, 2
- 429 Components of the complete blood count as risk predictors for coronary heart disease: in-depth review and update. **2013**, 40, 17-29 102
- 428 The effects of rosiglitazone on inflammatory biomarkers and adipokines in diabetic, hypertensive patients. **2012**, 17, 191-6 2
- 427 Effect of rosuvastatin on systemic blood pressure in patients with hypercholesterolemia. **2012**, 17, 221-5 4
- 426 Rheumatoid arthritis and atypical cardiovascular disease: inflammation changing the clinical presentation. **2013**, 59, 505-9 1
- 425 Cholesterol and cardiovascular disease in the elderly. Facts and gaps. **2013**, 4, 154-69 33
- 424 Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials?. **2013**, 124, 174-90 56
- 423 Approach to identifying and managing atherogenic dyslipidemia: a metabolic consequence of obesity and diabetes. **2013**, 59, 1169-80 35
- 422 High sensitivity C-reactive protein levels in Acute Ischemic Stroke and subtypes: A study from a tertiary care center. **2013**, 12, 92-7 13
- 421 Benefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians - a population with the highest risk of premature coronary artery disease & diabetes. **2013**, 138, 461-91 13

- 420 Method of LDL cholesterol measurement influences classification of LDL cholesterol treatment goals: clinical research study. **2010**, 58, 945-9 9
- 419 Evolution of lipid management guidelines: evidence might set you free. **2014**, 60, 612-7, e333-9
- 418 An overview of cholesterol management. **2008**, 1, 39-48 10
- 417 Adiponectin & inflammatory biomarkers in coronary artery disease. **2014**, 139, 799-801
- 416 Future management of carotid stenosis: role of urgent carotid interventions in the acutely symptomatic carotid patient and best medical therapy for asymptomatic carotid disease. **2014**, 14, 608-15 13
- 415 The effects of different doses of atorvastatin on serum lipid profile, glycemic control, and liver enzymes in patients with ischemic cerebrovascular accident. **2014**, 10, 298-304 5
- 414 Statin therapy for heart failure: to prescribe or not?. **2015**, 7, 1702-3
- 413 Anticoagulants and Statins As Pharmacological Agents in Free Flap Surgery: Current Rationale. **2015**, 15, e51 6
- 412 The Interaction Between Statins and Exercise: Mechanisms and Strategies to Counter the Musculoskeletal Side Effects of This Combination Therapy. **2015**, 15, 429-37 16
- 411 Coronary atherosclerosis burden is not advanced in patients with β -thalassemia despite premature extracardiac atherosclerosis: a coronary artery calcium score and carotid intima-media thickness study. **2016**, 13, 158-62 2
- 410 Statins for everyone?. **2010**, 2, 80-1
- 409 Approach to preventive care in the elderly. **2016**, 62, 717-21 5
- 408 [Aborder les soins prventifs chez les aîs]. **2016**, 62, e508-13
- 407 Should Patients Continue to Receive Statins Once They Reach 80 Years of Age?. **2017**, 70, 243-246 0
- 406 Comparison of the low-density lipoprotein cholesterol target value and the preventive effect of statins in elderly patients and younger patients. **2017**, 14, 383-391
- 405 Therapeutic effect of rosuvastatin and propylthiouracil on ameliorating high-cholesterol diet-induced fatty liver disease, fibrosis and inflammation in rabbit. **2017**, 9, 3827-3841 3
- 404 Reaching target LDL cholesterol has become more affordable with launch of ezetimibe/simvastatin combination in South Africa. **2010**, 21, 291
- 403 ASCOT analysis with atorvastatin shows limits of CRP as indicator of cardiovascular risk. **2011**, 22, 51

402	Cardiovascular disease in HIV: traditional and nontraditional risk factors. 2014 , 22, 676-9	13
401	HIV-Related Cardiovascular Disease, Statins, and the REPRIEVE Trial. 2015 , 23, 146-9	65
400	Aging, inflammation, and HIV infection. 2012 , 20, 101-5	85
399	Cannabis and Myocardial Infarction: Risk Factors and Pathogenetic Insights. 2017 , 1,	2
398	Clinical Characteristics and Angiographic Findings of Acute Myocardial Infarction Associated With Marijuana Use: Consecutive Case Series. 2017 , 2,	2
397	Almost everyone over 50 should be put on a statin to reduce the risk of cardiovascular disease: A protagonist view. 2013 , 110, 332-8	
396	Almost everyone over 50 should be put on a statin to reduce the risk of cardiovascular disease: A contrarian view. 2013 , 110, 339-41	
395	Common sense treatment for common lipid disorders. 2011 , 108, 107-12	
394	Cardiology Meets Personalized Lifestyle Medicine. 2017 , 16, 12-16	
393	Evidence of Connections Between Periodontitis and Ischemic Cardiac Disease - an Updated Systematic Review. 2019 , 14, 384-390	1
392	Significant reduction in the LDL cholesterol increases the risk of intracerebral hemorrhage: a systematic review and meta-analysis of 33 randomized controlled trials. 2020 , 12, 463-477	6
391	Vulnerable atherosclerotic plaque features: findings from coronary imaging. 2021 , 18, 577-584	1
390	Early Detection of Cardiotoxicity From Systemic and Radiation Therapy in Patients With Breast Cancer: Protocol for a Multi-Institutional Prospective Study.. 2022 , 11, e31887	
389	Chinese Guideline on the Primary Prevention of Cardiovascular Disease. 2021 , Publish Ahead of Print,	2
388	Inflammation and ischemic heart disease: The next therapeutic target?. 2021 , 40, 785-796	1
387	COVID-19 and Diabetes: A Comprehensive Review of Angiotensin Converting Enzyme 2, Mutual Effects and Pharmacotherapy. 2021 , 12, 772865	3
386	Implementation of the Treat-to-Target Concept in Evaluation of Psoriatic Arthritis Patients. 2021 , 10,	
385	CETP-inhibitors: from HDL-C to LDL-C lowering agents?. 2021 ,	3

384	Synergistic actions between angiotensin-converting enzyme inhibitors and statins in atherosclerosis.. 2021 ,	1
383	A Randomized Open Label Clinical Trial of Lipid-Lowering Therapy in Psoriasis to Reduce Vascular Endothelial Inflammation. 2021 ,	4
382	Fluvastatin Reduces Glucose Tolerance in Healthy Young Individuals Independently of Cold Induced BAT Activity. 2021 , 12, 765807	0
381	Behavioral Nudges as Patient Decision Support for Medication Adherence: The ENCOURAGE Randomized Controlled Trial. 2021 , 244, 125-125	3
380	Anti-inflammatory effect of rosuvastatin in patients with HIV infection: An FDG-PET pilot study. 2021 , 1	0
379	Association of Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 With Angiotensin II Type 1 Receptor Impacts Mitochondrial Quality Control, Offering Promise for the Treatment of Vascular Senescence. 2021 , 8, 788655	1
378	Low grade systemic inflammation is a risk factor for infection death: an observational cohort study.	
377	Statins and Peripheral Arterial Disease: A Narrative Review. 2021 , 8, 777016	0
376	C-reactive Protein, Free Fatty Acid, and Uric Acid as Predictors of Adverse Events after Endovascular Revascularization of Arterial Femoropopliteal Occlusion Lesions. 2021 ,	
375	Microvascular Inflammation and Cardiovascular Prevention: The Role of Microcirculation as Earlier Determinant of Cardiovascular Risk. 2021 , 1	1
374	Soluble Tumor Necrosis Factor Receptor 1 is Associated With Cardiovascular Risk in Persons With Coronary Artery Calcium Score of Zero.. 2021 , 6, 135-148	0
373	Statins and Inflammation. 2021 , 23, 80	3
372	Curcumin improves atherosclerosis by inhibiting the epigenetic repression of lncRNA MIAT to miR-124.. 2022 , 17085381211040974	0
371	Hypothyroidism risk associated with rheumatoid arthritis: A population-based retrospective cohort study.. 2022 , 101, e28487	
370	A Cohort Analysis of Statin Treatment Patterns Among Small-Sized Primary Care Practices.. 2022 , 1	0
369	Bowman-Birk Major Type Trypsin Inhibitor Derived from Foxtail Millet Bran Attenuate Atherosclerosis via Remodeling Gut Microbiota in ApoE ^{-/-} Mice.. 2022 ,	2
368	Prevalence of statin intolerance: a meta-analysis.. 2022 ,	8
367	Kardiovaskuläre Inflammation: Stand von Klinik und Forschung.	

- 366 Review of the Protective Effects of Statins on Cognition. **2021**, 29, 328-335 0
- 365 Clinical Outcomes of Olmesartan/Rosuvastatin Combination Therapy in Acute Coronary Syndrome Patients With Essential Hypertension. **2020**, 0
- 364 [Key aspects of drug therapy in vascular surgery].. **2021**, 27, 17-25
- 363 The safety and efficacy of Ezetimibe Plus Statins on ASVD and Related Diseases. **2021**, 12, 1857-1871 0
- 362 Inflammatory Burden and Immunomodulative Therapeutics of Cardiovascular Diseases.. **2022**, 23, 0
- 361 Anti-inflammatory strategies for atherosclerotic artery disease.. **2022**, 1
- 360 Inflammation as A Precursor of Atherothrombosis, Diabetes and Early Vascular Aging.. **2022**, 23, 3
- 359 Altern messen im Alterungsprozesses. **2022**, 19-48
- 358 Optimal Low-Density Lipoprotein Cholesterol Levels in Adults Without Diabetes Mellitus: A Nationwide Population-Based Study Including More Than 4 Million Individuals From South Korea.. **2021**, 8, 812416 1
- 357 Effect of Statins on Serum level of hs-CRP and CRP in Patients with Cardiovascular Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. **2022**, 2022, 8732360 4
- 356 Baseline hemoglobin A1c and risk of statin-induced diabetes: results of Veterans Affairs Database analysis.. **2022**, 10, 0
- 355 Where the Action Is-Leukocyte Recruitment in Atherosclerosis.. **2021**, 8, 813984 4
- 354 Decrease in the Size of Fat-Enlarged Axillary Lymph Nodes and Serum Lipids after Bariatric Surgery.. **2022**, 11, 0
- 353 Targeted proteomics improves cardiovascular risk prediction in secondary prevention.. **2022**, 3
- 352 The pathogenic role of foam cells in atherogenesis: Do they represent novel therapeutic targets?. **2022**,
- 351 Additive Effects of Genetic Interleukin-6 Signaling Downregulation and Low-Density Lipoprotein Cholesterol Lowering on Cardiovascular Disease: A 2x2 Factorial Mendelian Randomization Analysis.. **2021**, e023277 0
- 350 Guidelines versus trial-evidence for statin use in primary prevention: The Copenhagen General Population Study.. **2021**, 341, 20-26 0
- 349 Psoriasis and Cardiovascular Disease-An Ounce of Prevention Is Worth a Pound of Cure.. **2022**, 2

348 Should a Statin be Given to All Hypertensive Patients?. **2022**, 24, 21

347 Dyslipidemia. **2022**, 529-537

346 A Prospective Randomized, Double-Blind, Multi-Center, Phase III Clinical Trial Evaluating the Efficacy and Safety of Olmesartan/Amlodipine plus Rosuvastatin Combination Treatment in Patients with Concomitant Hypertension and Dyslipidemia: A LEISURE Study.. **2022**, 11, 0

345 The role of inflammation as a preponderant risk factor in cardiovascular diseases.. **2022**, 0

344 Synergistic Effects of Inflammation and Atherogenic Dyslipidemia on Subclinical Carotid Atherosclerosis Assessed by Ultrasound in Patients with Familial Hypercholesterolemia and Their Family Members.. **2022**, 10,

343 Assessment of Comorbidity Burden and Treatment Response: Reanalysis of the SCD-HEFT Trial.. **2022**, 39, 165

342 Inflammation as a mechanism and therapeutic target in peripheral artery disease.. **2022**, 0

341 Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: a post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials.. **2022**, 0

340 Both low and high levels of low-density lipoprotein cholesterol are risk factors for diabetes diagnosis in Chinese adults. **2022**, 6, 100050

339 Plasma apolipoprotein concentrations and incident diabetes in subjects with prediabetes.. **2022**, 21, 21 2

338 L'uso di statine diminuisce il rischio di orbitopatia in pazienti con nuova diagnosi di malattia di Graves-Basedow. **2022**, 23, 111

337 Biomarker Development in Cardiology: Reviewing the Past to Inform the Future.. **2022**, 11, 0

336 Retinal Microcirculation Changes in Crohn's Disease Patients under Biologics, a Potential Biomarker of Severity: A Pilot Study.. **2022**, 12, 0

335 Prognostic Value of Baseline Inflammation in Diabetic and Nondiabetic Patients Undergoing PCI.. **2022**, 0

334 CAC for Risk Stratification Among Individuals With Hypertriglyceridemia Free of Clinical Atherosclerotic Cardiovascular Disease.. **2021**, 1

333 Inflammation in Coronary Microvascular Dysfunction.. **2021**, 22, 5

332 Transitional Changes in the Structure of C-Reactive Protein Create Highly Pro-Inflammatory Molecules: Therapeutic Implications for Cardiovascular Diseases.

331 Dyslipidemia. **2022**, 461-472

330	Estimated Cardiovascular Benefits of Bempedoic Acid in Patients with Established Cardiovascular Disease.	
329	Biomarkers of Inflammation and Oxidative stress in the Prediction and Management of Acute Coronary Syndrome. 3,	
328	Cardiovascular Implications of Immune Disorders in Women.. 2022 , 130, 593-610	0
327	Statins Associated with Better Long-Term Outcomes in Aged Hospitalized Patients with COPD: A Real-World Experience from Pay-for-Performance Program.. 2022 , 12,	
326	Relative contributions of statin intensity, achieved low-density lipoprotein cholesterol level, and statin therapy duration to cardiovascular risk reduction in patients with type 2 diabetes: population based cohort study.. 2022 , 21, 28	1
325	Association between maternal gestational diabetes mellitus and high-sensitivity C-reactive protein levels in 8-year-old children: the Yamanashi Adjunct Study of the Japan Environment and Children's Study (JECS).. 2022 ,	
324	Evaluating the Association Between Low-Density Lipoprotein Cholesterol Reduction and Relative and Absolute Effects of Statin Treatment: A Systematic Review and Meta-analysis.. 2022 ,	4
323	Contemporary Management of Dyslipidemia.. 2022 , 1	1
322	Personalised Approach to Diagnosing and Managing Ischemic Stroke with a Plasma-Soluble Urokinase-Type Plasminogen Activator Receptor.. 2022 , 12,	1
321	Cardiac Glycosides Lower C-Reactive Protein Plasma Levels in Patients with Decompensated Heart Failure: Results from the Single-Center C-Reactive Protein-Digoxin Observational Study (C-DOS).. 2022 , 11,	0
320	Coronary plaque vulnerability in statin-treated patients with elevated LDL-C and hs-CRP: optical coherence tomography study. 1	
319	Safety and efficacy of anti-inflammatory therapy in patients with coronary artery disease: a systematic review and meta-analysis.. 2022 , 22, 84	1
318	Side effects of statins-from pathophysiology and epidemiology to diagnostic and therapeutic implications.. 2022 ,	4
317	The Impact of Time Horizon on Classification Accuracy: Application of Machine Learning to Prediction of Incident Coronary Heart Disease (Preprint).	
316	Statin use in hospitalized patients with COVID-19: A comprehensive analysis of the New York City Public Hospital System.. 2022 ,	1
315	Lipid-Targeted Atherosclerotic Risk Reduction in Older Adults: A Review.. 2022 , 7,	
314	Molecular Biological and Clinical Understanding of the Statin Residual Cardiovascular Disease Risk and Peroxisome Proliferator-Activated Receptor Alpha Agonists and Ezetimibe for Its Treatment.. 2022 , 23,	0
313	The pleiotropic benefits of statins include the ability to reduce CD47 and amplify the effect of pro-efferocytic therapies in atherosclerosis. 2022 , 1, 253-262	2

312	Frequency of Statin Prescription Among Individuals with Coronary Artery Calcifications Detected Through Lung Cancer Screening.. 2022 ,	
311	Acute kidney injury post coronary angioplasty.. 2022 , 15,	
310	A machine learning model in predicting hemodynamically significant coronary artery disease: A prospective cohort study. 2022 ,	
309	Evidence of an anti-inflammatory effect of statins in people living with HIV.. 2022 , 1	
308	Is Colchicine a New Game-Changer in Patients With Acute Coronary Syndrome?. 2022 , 14, e22874	
307	LDL como objetivo terapêutico. 2022 ,	
306	The effects of socioeconomic and geographic factors on chronic phase long-term survival after stroke in South Korea.. 2022 , 12, 4327	
305	Cardiovascular diseases in patients with psoriasis in clinical practice: case report. Eurasian heart journal. 2022 , 94-99	
304	Best Imaging Modalities to Decipher Coronary Microvascular Angina: Imaging & microvascular angina.. 2022 ,	
303	Ten-year atherosclerosis cardiovascular disease (ASCVD) risk score and its components among an Iranian population: a cohort-based cross-sectional study.. 2022 , 22, 162	1
302	Generation of cardio-protective antibodies after pneumococcal polysaccharide vaccine: Early results from a randomised controlled trial.. 2022 , 346, 68-74	
301	Statin-Associated Muscle Symptoms - A review: Individualizing the approach to optimize care.. 2022 ,	0
300	Small Dense LDL: Scientific Background, Clinical Relevance, and Recent Evidence Still a Risk Even with 'Normal' LDL-C Levels.. 2022 , 10,	1
299	A comparison of regression discontinuity and propensity score matching to estimate the causal effects of statins using electronic health records.	
298	Longitudinal follow-up study of the association between statin use and chronic periodontitis using national health screening cohort of Korean population.. 2022 , 12, 5504	0
297	Inflammation, coronary plaque progression, and statin use: A secondary analysis of the Risk Stratification with Image Guidance of HMG CoA Reductase Inhibitor Therapy (RIGHT) study.. 2022 ,	0
296	Targeting the residual cardiovascular risk by specific anti-inflammatory interventions as a therapeutic strategy in atherosclerosis.. 2022 , 178, 106157	2
295	Statin pretreatment combined with intravenous thrombolysis for ischemic stroke patients: A meta-analysis.. 2022 , 98, 142-148	1

- 294 Efficacy and Safety of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors as Adjuvant Treatments for Patients with Hypercholesterolemia Treated with Statin: A Systematic Review and Network Meta-analysis.. **2022**, 13, 832614 1
- 293 Assessing the effect of socioeconomic factors on prevalence of dyslipidemia among iranian adult population; district level analysis from 2016 STEPS national study using small area estimation. 1
- 292 A Paradigm Shift in Dyslipidemia Management in Primary Care: A 12-Month Cohort Study.. **2022**,
- 291 Outcomes after acute coronary syndrome in patients with inflammatory bowel disease.. **2022**, 1 0
- 290 Molecular targets of statins and their potential side effects: Not all the glitter is gold.. **2022**, 922, 174906 3
- 289 Intensive low-density lipoprotein cholesterol lowering improves fibrin clot properties: Association with lipoproteins and C-reactive protein.. **2022**, 106977 0
- 288 Transitional changes in the structure of C-reactive protein create highly pro-inflammatory molecules: Therapeutic implications for cardiovascular diseases.. **2022**, 108165 2
- 287 Renal allograft-related inflammation complicated by acute coronary syndromes: A case report.. **2021**, 100, e28205
- 286 The efficiency of two-level electrovectorcardiographic diagnostics of left ventricular hypertrophy in the medical examination of urban and rural population. **2021**, 18, 175-179
- 285 Effects of statin therapy on coronary plaque volume by decreasing CRP/hsCRP levels: A meta-regression of randomized controlled trials.
- 284 Combined berberine and probiotic treatment as an effective regimen for improving postprandial hyperlipidemia in type 2 diabetes patients: a double blinded placebo controlled randomized study.. **2022**, 14, 2003176 4
- 283 The "real world" is relative-and biased.. **2021**,
- 282 Heterogeneity in statin responses explained by variation in the human gut microbiome. 0
- 281 Hypertension mediated kidney and cardiovascular damage and risk stratification: Redefining concepts. **2021**,
- 280 The Complex Role of C-Reactive Protein in Systemic Lupus Erythematosus.. **2021**, 10, 4
- 279 Hypolipidemic Pharmacotherapy from the Latest Recommendations. **2020**, 97-107
- 278 Targeting C-Reactive Protein by Selective Apheresis in Humans: Pros and Cons.. **2022**, 11, 0
- 277 Inflammatory Biomarkers in Coronary Artery Ectasia: A Systematic Review and Meta-Analysis. **2022**, 12, 1026 2

276	The Canadian Women's Heart Health Alliance Atlas on the Epidemiology, Diagnosis, and Management of Cardiovascular Disease in Women-Chapter 6: Sex- And Gender-Specific Diagnosis and Treatment. 2022,	0
275	Compounding Benefits of Cholesterol-Lowering Therapy for the Reduction of Major Cardiovascular Events: Systematic Review and Meta-Analysis.. 2022, 101161CIRCOUTCOMES121008552	1
274	Immune Pathways in Etiology, Acute Phase, and Chronic Sequelae of Ischemic Stroke.. 2022, 130, 1167-1186	6
273	Presentation_1.pdf. 2020,	
272	Image1.tiff. 2017,	
271	DataSheet_1.pdf. 2020,	
270	[Statin intolerance and statin-associated muscular pain].. 2022, 1	
269	Calm the raging hormone - A new therapeutic strategy involving progesterone-signaling for hemorrhagic CCMs.. 2021, 5,	
268	Role of inflammatory markers in the diagnosis of vascular contributions to cognitive impairment and dementia: a systematic review and meta-analysis.. 2022,	0
267	The Impact of Age on Statin-Related Glycemia: A Propensity Score-Matched Cohort Study in Korea. 2022, 10, 777	
266	High stroke rate in patients with medically managed asymptomatic carotid stenosis at an academic center in the Southeastern United States.. 2022,	0
265	Undertreatment or Overtreatment With Statins: Where Are We?. 2022, 9, 808712	1
264	The Influence of Treatment with PCSK9 Inhibitors and Variants in the CRP (rs1800947), TNFA (rs1800629), and IL6 (rs1800795) Genes on the Corresponding Inflammatory Markers in Patients with Very High Lipoprotein(a) Levels. 2022, 9, 127	0
263	Age-Related Associations of Low-Density Lipoprotein Cholesterol and Atherosclerotic Cardiovascular Disease: A Nationwide Population-Based Cohort Study.. 2022, 11, e024637	1
262	Systemic inflammation is associated with future risk of fatal infection: an observational cohort study.. 2022,	1
261	Heterogeneity in statin responses explained by variation in the human gut microbiome. 2022,	0
260	Anti-inflammatory effect of SGLT-2 inhibitors via uric acid and insulin.. 2022, 79, 273	2
259	ICH-LR2S2: a new risk score for predicting stroke-associated pneumonia from spontaneous intracerebral hemorrhage.. 2022, 20, 193	0

- 258 Exploration of Black Boxes of Supervised Machine Learning Models: A Demonstration on Development of Predictive Heart Risk Score. **2022**, 2022, 1-11 1
- 257 Cardiovascular risk management requires a combination of cardiovascular preventive pharmacotherapy and non-pharmacological interventions.. **2022**,
- 256 Lipid-modifying and antiatherosclerotic drugs. **2013**, 398-435 3
- 255 THE CONCERNS OF ROSUVASTATIN CLINICAL EFFICACY AND SAFETY. **2013**, 35-42
- 254 Statins Are Associated with Improved Survival of Patients with Gastric Cancer: A Systematic Review and Meta-Analysis. **2022**, 2022, 1-9 0
- 253 Innate immune cells in the pathophysiology of calcific aortic valve disease: lessons to be learned from atherosclerotic cardiovascular disease?. **2022**, 117, 28 1
- 252 Cardiovascular Risk Assessment in Primary Prevention. **2022**, 3-19
- 251 High-Sensitivity C-Reactive Protein. **2022**, 347-375
- 250 Precision Medicine for Diabetes and Dyslipidemia. **2022**, 65-87
- 249 Ethnic Factors in the Assessment of Cardiovascular Risk for Primary Prevention. **2022**, 199-226
- 248 Inflammatory Diseases and Risk of Atherosclerotic Cardiovascular Disease: A New Focus on Prevention. **2022**, 247-270 1
- 247 Impact of statins in patients with vasospastic angina: A multicenter registry study of the Japanese Coronary Spasm Association. **2022**, 0
- 246 Estrategias de tratamiento de las dislipemias en prevención primaria y secundaria. Registro de la Sociedad Española de Arteriosclerosis. **2022**,
- 245 Estimated cardiovascular benefits of bempedoic acid in patients with established cardiovascular disease. **2022**, 0
- 244 Synergistic effect of the commonest residual risk factors, remnant cholesterol, lipoprotein(a), and inflammation, on prognosis of statin-treated patients with chronic coronary syndrome. **2022**, 20, 0
- 243 Measures of Endothelial Function in Type 2 Diabetes: A Focus on Circulatory Biomarkers. **2022**, 1-22
- 242 Role of plasma extracellular vesicles in prediction of cardiovascular risk and alterations in response to statin therapy in hypertensive patients. Publish Ahead of Print, 0
- 241 Non-Lipid Effects of PCSK9 Monoclonal Antibodies on Vessel Wall. **2022**, 11, 3625 0

240	Would You Recommend a Statin to This Patient for Primary Prevention of Cardiovascular Disease?. 2022 , 175, 862-872	1
239	Adequate enrollment of women in cardiovascular drug trials and the need for sex-specific assessment and reporting. 2022 , 100155	
238	Chasing LDL cholesterol to the bottom [PCSK9 in perspective. 2022 , 1, 554-561	2
237	Preadmission Statin Treatment and Outcome in Patients Hospitalized With COVID-19. 2022 ,	2
236	Novel predictive risk factor for erectile dysfunction: Serum high-sensitivity C-reactive protein.	
235	The Relationship between Enhancing Left Atrial Adipose Tissue at CT and Recurrent Atrial Fibrillation.	0
234	Differences in the diabetogenic effect of statins in patients with prediabetes. The PRELIPID study. 2022 , 158, 531-539	
233	Association of Statin Usage and the Development of Diabetes Mellitus after Acute Pancreatitis. 2022 ,	1
232	Major Concepts in Treatment with Bempedoic Acid and Inclisiran that Clinicians Need To Know.	0
231	Combined Lipid Goal Attainment in Patients with Type 2 Diabetes and Dyslipidemia: A Head-to-Head Comparative Trial of Statins. Publish Ahead of Print,	0
230	2022 Taiwan lipid guidelines for primary prevention. 2022 ,	1
229	THE ROLE OF INFLAMMATION AND THE POSSIBILITIES OF INFLAMMATION REDUCTION TO PREVENT CARDIOVASCULAR EVENTS.	2
228	Statins and renal cell carcinoma: Antitumor activity and influence on cancer risk and survival. 2022 , 176, 103731	2
227	Vasculome. 2022 , 441-451	
226	Guidelines for the Prevention of Symptomatic Cardiovascular Disease, Based upon the Presence of Coronary Artery Calcified Plaque Provided by the Society for the Prevention of Symptomatic Heart Disease. 2022 , 12, 320-341	0
225	Association of coronary artery calcium with adverse cardiovascular outcomes and death in patients with chronic kidney disease: results from the KNOW-CKD.	0
224	Hepatocyte Rap1a Contributes To Obesity- and Statin-Associated Hyperglycemia.	
223	Cardiorespiratory Fitness and Carotid Intima Media Thickness in Physically Active Young Adults: CHIEF Atherosclerosis Study. 2022 , 11, 3653	0

- 222 Gene Expression Profiling of Markers of Inflammation, Angiogenesis, Coagulation and Fibrinolysis in Patients with Coronary Artery Disease with Very High Lipoprotein(a) Levels Treated with PCSK9 Inhibitors. **2022**, 9, 211 1
- 221 Review of Drug Therapy for Peripheral Facial Nerve Regeneration That Can Be Used in Actual Clinical Practice. **2022**, 10, 1678
- 220 Harmonisation of large-scale, heterogeneous individual participant adverse event data from randomised trials of statin therapy. 174077452211055
- 219 Cholesterol and its biological significance. Atherosclerosis. Statin therapy (Part 2). **2022**, 37, 13-20
- 218 Safety of Statins and Nonstatins for Treatment of Dyslipidemia. **2022**, 0
- 217 Tratamiento de la hipertrigliceridemia con icosapento de etilo en pacientes de alto/muy alto riesgo cardiovascular. Documento de consenso de la Sociedad Española de Cardiología y Sociedad Española de Diabetes. **2022**, 0
- 216 Lipid profile of patients with arterial hypertension who underwent COVID-19: possibilities of drug therapy/ LEADER. **2022**, 18, 282-288
- 215 Serial Changes in Coronary Plaque Formation Using CT Angiography in Patients Undergoing PCSK9-Inhibitor Therapy With 1-year Follow-up. Publish Ahead of Print,
- 214 Dyslipidemia in Diabetes. **2022**, 0
- 213 Common misconceptions of randomized controlled trials in oncology.
- 212 Management of dyslipidemia and atherosclerotic cardiovascular risk in prediabetes. **2022**, 190, 109980 0
- 211 Polygenic risk score and statin relative risk reduction for primary prevention of myocardial infarction in a real-world population. 0
- 210 A Real Pandora's Box in Pandemic Times: A Narrative Review on the Acute Cardiac Injury Due to COVID-19. **2022**, 12, 1085 1
- 209 The effect of various types and doses of statins on C-reactive protein levels in patients with dyslipidemia or coronary heart disease: A systematic review and network meta-analysis. 9,
- 208 The Impact of Time Horizon on Classification Accuracy: Application of Machine Learning to Prediction of Incident Coronary Heart Disease (Preprint). 1
- 207 Combination Therapy of Ezetimibe and Rosuvastatin for Dyslipidemia: Current Insights. Volume 16, 2177-2186 0
- 206 Topical Biological Agents as Adjuncts to Improve Wound Healing in Chronic Diabetic Wounds: A Systematic Review of Clinical Evidence and Future Directions. **2022**, 0
- 205 Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements. **2022**, 20, 609-625 0

204	Impact of outcome definitions on cardiovascular risk prediction in a contemporary primary prevention population.	
203	Statins for primary cardiovascular disease prevention among people with HIV: emergent directions. 2022 , 17, 293-300	0
202	There Is Urgent Need to Treat Atherosclerotic Cardiovascular Disease Risk Earlier, More Intensively, and with Greater Precision. A Review of Current Practice and Recommendations for Improved Effectiveness.. 2022 , 100371	2
201	Association between C-reactive protein levels and development of post-stroke depression: A systematic review and meta-analysis. 003693302211175	
200	Treatment of Periodontitis and C-Reactive Protein: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.	0
199	Statins in High Cardiovascular Risk Patients: Do Comorbidities and Characteristics Matter?. 2022 , 23, 9326	0
198	Statin Prescription Patterns and Associations with Subclinical Inflammation. 2022 , 58, 1096	
197	2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk. 2022 ,	4
196	Hepatocyte Rap1a contributes to obesity- and statin-associated hyperglycemia. 2022 , 40, 111259	0
195	Neutrophils and Neutrophil Extracellular Traps in Cardiovascular Disease: An Overview and Potential Therapeutic Approaches. 2022 , 10, 1850	1
194	WITHDRAWN: American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan 2022 Update. 2022 ,	8
193	Is Alcohol Consumption Associated with a Lower Risk of Cardiovascular Events in Patients Treated with Statins? An Observational Real-World Experience. 2022 , 11, 4797	
192	Rosuvastatin Slows Progression of Carotid Intima-Media Thickness: The METEOR-China Randomized Controlled Study.	0
191	Outcomes of a bypass-first strategy in chronic limb-threatening ischemia based on the Global Vascular Guidelines. 2022 ,	0
190	Extent of LDL-cholesterol Reduction and All-cause and Cardiovascular Mortality Benefit: a Systematic Review and Meta-analysis. 2022 , Publish Ahead of Print,	
189	Association of Physical Activity With Bioactive Lipids and Cardiovascular Events. 2022 , 131,	1
188	Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1 β , Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy. 2022 , 146, 372-379	9
187	Statin Use for the Primary Prevention of Cardiovascular Disease in Adults. 2022 , 328, 746	3

186	Targeted proteomics improves cardiovascular risk prediction in secondary prevention: the impact of statin treatment?.	0
185	Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions.	4
184	Statin therapy is not warranted for a person with high LDL-cholesterol on a low-carbohydrate diet. Publish Ahead of Print,	0
183	Statin Use for the Primary Prevention of Cardiovascular Disease in Adults. 2022 , 328, 754	1
182	Integrating Advanced Lipid Testing and Biomarkers in Assessment and Treatment.	
181	Statin therapy for the primary prevention of cardiovascular disease: Cons. 2022 , 356, 46-49	
180	The chain mediating role of C-reactive protein and triglyceride-glucose index between lung function and cognitive function in a systemic low-grade inflammation state. 2022 ,	0
179	Acceptability of predictive testing for ischemic heart disease in those with a family history and the impact of results on behavioural intention and behaviour change: a systematic review. 2022 , 22,	0
178	PAPEL TERAPÉUTICO DE LA COLCHICINA EN LA REDUCCIÓN DEL RIESGO CARDIOVASCULAR ASOCIADO A LA INFLAMACIÓN. 2022 , 69, 551-553	0
177	Data-driven clustering approach to identify novel phenotypes using multiple biomarkers in acute ischaemic stroke: A retrospective, multicentre cohort study. 2022 , 53, 101639	1
176	Effect of different doses of colchicine on high sensitivity C-reactive protein in patients with acute minor stroke or transient ischemic attack: A pilot randomized controlled trial. 2022 , 178, 106288	0
175	Correlation of markers of inflammation with hormonal, metabolic parameters, insulin resistance and adiposity indices in first-degree relatives of patient with polycystic ovary syndrome.. 2022 , 15, 250	0
174	Reading and Interpreting the Literature on Randomized Controlled Trials. 2022 , 2197-2208	0
173	Correlation of markers of inflammation with hormonal, metabolic parameters, insulin resistance and adiposity indices in first-degree relatives of patient with polycystic ovary syndrome.. 2022 , 15, 250	0
172	Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement.	17
171	Vascular Aging and COVID-19. 000331972211210	1
170	LDL as a therapeutic target. 2022 , 34, 271-284	0
169	Is It About the Destination or About the Journey?.	0

168	Statin uses in adults with non-dialysis advanced chronic kidney disease: Focus on clinical outcomes of infectious and cardiovascular diseases. 13,	0
167	Measures of Endothelial Function in Type 2 Diabetes: A Focus on Circulatory Biomarkers. 2023 , 867-888	0
166	Atorvastatin efficacy in the management of mild to moderate hospitalized COVID-19: a pilot randomized triple-blind placebo-controlled clinical trial. 2022 , 17,	3
165	Evidence of seasonal changes in airborne particulate matter concentration and occupation-specific variations in pulmonary function and haematological parameters among some workers in Enugu Southeast Nigeria: a randomized cross-sectional observational study. 2022 , 80,	0
164	Impact of dyslipidemia in the development of cardiovascular complications: Delineating the potential therapeutic role of coenzyme Q10. 2022 ,	0
163	Evaluating Statin Tolerability in Historically Intolerant Patients After Correcting for Subclinical Hypothyroidism and Vitamin D Insufficiency. 2022 , 29, 409-415	0
162	Systematic Review and Meta-Analysis of Statin Use and Mortality, Intensive Care Unit Admission and Requirement for Mechanical Ventilation in COVID-19 Patients. 2022 , 11, 5454	2
161	Common and Rare PCSK9 Variants Associated with Low-Density Lipoprotein Cholesterol Levels and the Risk of Diabetes Mellitus: A Mendelian Randomization Study. 2022 , 23, 10418	1
160	Comparison of High-Sensitivity C-Reactive Protein vs C-reactive Protein for Cardiovascular Risk Prediction in Chronic Cardiac Disease.	0
159	Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK. 2022 , 400, 733-743	3
158	Association between remnant lipoprotein cholesterol, high-sensitivity C-reactive protein, and risk of atherosclerotic cardiovascular disease events in the Multi-Ethnic Study of Atherosclerosis (MESA). 2022 ,	0
157	Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. 2022 , 400, 832-845	1
156	Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials. 2022 , 21,	0
155	Targeting innate immunity-driven inflammation in CKD and cardiovascular disease.	2
154	Peripheral artery disease and the risk of venous thromboembolism.	0
153	C-reactive protein, immunothrombosis and venous thromboembolism. 13,	3
152	Reduction of C-reactive protein, low-density lipoprotein cholesterol, and its relationship with cardiovascular events of different lipid-lowering therapies: A systematic review and meta-analysis of randomized controlled trials. 2022 , 101, e30563	0
151	Demographic, behavioral, dietary, and clinical predictors of high-sensitivity C-reactive protein: The National Health and Nutrition Examination Surveys (NHANES). 2022 , 21, 100196	0

- 150 Medical treatment of dyslipidemia in the elderly. **2022**, 1, 65-72 ○
- 149 Effects of rosuvastatin on serum glucose and insulin in hyperuricemic rats. **2022**, 23, ○
- 148 Increasing statin prescription rates to prevent cardiovascular disease among high-risk populations: a quality improvement intervention centred on a novel interactive tool. **2022**, 11, e001947 ○
- 147 Association of Low-Density Lipoprotein Cholesterol Levels During Statin Treatment With Cardiovascular and Renal Outcomes in Patients With Moderate Chronic Kidney Disease. **2022**, 11, ○
- 146 Joint High Level of Oxidized Low-Density Lipoprotein and High-Sensitivity C-Reactive Protein are Associated With Recurrent Stroke and Poor Functional Outcome in Minor Stroke or Transient Ischemic Attack. 1
- 145 Statin Myopathy. **2022**, 137-147 ○
- 144 Peripheral Arterial Atherogenesis. **2022**, 1-48 ○
- 143 Atherosclerosis Imaging. **2022**, 241-254 ○
- 142 Homogeneous ensemble models for predicting infection levels and mortality of COVID-19 patients: Evidence from China. **2022**, 8, 205520762211336 ○
- 141 Prior antibiotics and risk of subsequent Herpes zoster: A population-based case control study. **2022**, 17, e0276807 ○
- 140 Systemic immune-inflammation index as a prognostic marker for advanced chronic heart failure with renal dysfunction. ○
- 139 Therapeutic Effects of Lipid Lowering Medications on Myocardial Blood Flow, Inflammation, and Sympathetic Nerve Activity Using Nuclear Techniques. ○
- 138 Cross-Ancestry Investigation of Venous Thromboembolism Genomic Predictors. **2022**, 146, 1225-1242 ○
- 137 Influence of HIV on in-hospital outcomes in patients with atrial fibrillation. 1-8 1
- 136 Inflammation in coronary artery disease-clinical implications of novel HDL-cholesterol-related inflammatory parameters as predictors. Publish Ahead of Print, 1
- 135 Phenotypical and Functional Alteration of T_H Lymphocytes in COVID-19 Patients: Reversal by Statins. **2022**, 11, 3449 ○
- 134 Elevated HsCRP in Chronic Obstructive Pulmonary Disease: A Prospective Study of Long-Term Outcomes After Percutaneous Coronary Intervention. Volume 17, 2517-2528 ○
- 133 Inflammatory and Prothrombotic Biomarkers, DNA Polymorphisms, MicroRNAs and Personalized Medicine for Patients with Peripheral Arterial Disease. **2022**, 23, 12054 1

132	Management of patients with statin intolerance. 2022 , 101714	1
131	Mortality Analysis of Endovascular Aneurysm Sealing versus Endovascular Aneurysm Repair. 2022 ,	0
130	Assessment of cardiovascular risk factors in obese women with HIV. 095646242211326	0
129	Role of High-Sensitivity C-reactive Protein (Hs-CRP) in Non-communicable Diseases: A Review. 2022	0
128	Non-fasting changes of Hs-CRP level in Chinese patients with coronary heart disease after a daily meal. 2022 , 12,	0
127	Dyslipidemia treatment strategies in primary and secondary prevention. Dyslipemia Registry of the Spanish Arteriosclerosis Society. 2022 ,	0
126	Inflammation and Thrombosis in Coronary Atherosclerosis: Pathophysiologic Mechanisms and Clinical Correlations. 71-78	4
125	Bending the Cardiovascular Event Curve by Evaluating the Potential Impact of Achieving Low-Density Lipoprotein Cholesterol Goal Across a Large Health System Among Secondary Prevention Patients. 2023 , 186, 91-99	0
124	Letter by Sherratt Regarding Article, Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1 β , Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy. 2022 , 146,	0
123	Cardiovascular Risk Prediction Using Machine Learning in a Large Japanese Cohort. 2022 ,	0
122	A Systematic Review and Meta-Analysis of Advanced Biomarkers for Predicting Incident Cardiovascular Disease among Asymptomatic Middle-Aged Adults. 2022 , 23, 13540	1
121	Defining Preventive Cardiology: A Clinical Practice Statement from the American Society for Preventive Cardiology. 2022 , 100432	2
120	Treatment of hypertriglyceridaemia with icosapent ethyl in patients with high/very high cardiovascular risk. Consensus document of the Sociedad Española de Cardiología [Spanish Society of Cardiology] and the Sociedad Española de Diabetes [Spanish Diabetes Society]. 2022 ,	0
119	Optimal target of LDL cholesterol level for statin treatment: challenges to monotonic relationship with cardiovascular events. 2022 , 20,	0
118	Atherogenic Lipoproteins for the Statin Residual Cardiovascular Disease Risk. 2022 , 23, 13499	1
117	Comparative Effects of Low-Dose Rosuvastatin, Placebo and Dietary Supplements on Lipids and Inflammatory Biomarkers. 2022 ,	3
116	Statin associated muscle symptoms: An update and review. 2022 ,	0
115	Therapeutic role of colchicine in reducing cardiovascular risk associated with inflammation. 2022 ,	0

- 114 Effects of Vitamin D Supplementation in Patients with Statin-Associated Muscle Symptoms and Low Vitamin D Levels. ○
- 113 C-reactive protein and coronary atheroma regression following statin therapy: A meta-regression of randomized controlled trials. 9, ○
- 112 The protective effect of rivaroxaban with or without aspirin on inflammation, oxidative stress, and platelet reactivity in isoproterenol-induced cardiac injury in rats. ○
- 111 Synergistic effect of lipoprotein (a) and C-reactive protein on prognosis of familial hypercholesterolemia. **2022**, 12, 100428 ○
- 110 Dyslipidemia in Chronic Kidney Disease. **2022**, 549-572 ○
- 109 Development of Machine Learning Tools for Predicting Coronary Artery Disease in the Chinese Population. **2022**, 2022, 1-18 ○
- 108 Pharmacological treatment in patients with aortic dissection. **2022**, 9, e002082 ○
- 107 Atorvastatin ameliorates lipid overload-induced mitochondrial dysfunction and myocardial hypertrophy by decreasing fatty acid oxidation through inactivation of the p-STAT3/CPT1 pathway. **2023**, 157, 114024 ○
- 106 Refinando o Risco Cardiovascular: Olhando Abaixo da Superfície do Cltulo. **2022**, 119, 921-922 ○
- 105 Effectiveness of statin treatment in reducing red cell distribution width and mean platelet volume in patients with stable coronary artery disease: A retrospective study. **2022**, 8, 110 ○
- 104 Coffee or tea: Anti-inflammatory properties in the context of atherosclerotic cardiovascular disease prevention. **2023**, 187, 106596 ○
- 103 Are serum hsCRP and IL-6 prognostic markers in somatic symptom disorder and related disorders? An exploratory analysis in a prospective cohort study. **2023**, 157, 88-95 ○
- 102 Statins in Primary Prevention in People Over 80 Years. **2023**, 187, 62-73 ○
- 101 Cardiovascular Disease in Large Vessel Vasculitis. **2023**, 49, 81-96 ○
- 100 Statins and neuroprotective effects. **2021**, 22, 45-49 ○
- 99 European, Russian and American Clinical Guidelines on dyslipidemias management [where do we stand? European, Russian, and US guidelines on dyslipidemias. **2022**, 1, 48-53 ○
- 98 Revisiting secondary prevention in coronary heart disease. **2022**, 74, 431-440 ○
- 97 Hibernation or Transformation? Challenges in Cardiovascular Drug Development. **2022**, 102-140 ○

96	Patients with a range of rheumatic diseases are at increased risk of cardiovascular disorders towards a re-evaluation of the European League against Rheumatism (EULAR) recommendations for cardiovascular risk management?. <i>ard-2022-223315</i>	0
95	Association of statin therapy with progression of carotid arterial stiffness: the Multi-Ethnic Study of Atherosclerosis (MESA).	0
94	PCSK9 inhibitors for anti-inflammation in atherosclerosis: protocol for a systematic review and meta-analysis of randomised controlled trials. 2022 , 12, e062046	1
93	Analysis of Cardiovascular Complications During Delivery Admissions Among Patients With Systemic Lupus Erythematosus, 2004-2019. 2022 , 5, e2243388	0
92	C-reactive protein and statins in heart failure with reduced and preserved ejection fraction. 9,	0
91	The Impact of Cytokines in Coronary Atherosclerotic Plaque: Current Therapeutic Approaches. 2022 , 23, 15937	0
90	Rheopheresis Performed in Hemodialysis Patients Targets Endothelium and Has an Acute Anti-Inflammatory Effect. 2023 , 12, 105	0
89	A randomized, double-blind, multicenter, phase III study on the efficacy and safety of a combination treatment involving fimasartan, amlodipine, rosuvastatin in patients with essential hypertension and dyslipidemia who fail to respond adequately to fimasartan monotherapy. 2022 , 28,	0
88	Lipid-Lowering Trials Are Not Representative of Patients Managed in Clinical Practice: A Systematic Review and Meta-Analysis of Exclusion Criteria.	0
87	Persistent Asthma Is Associated With Carotid Plaque in MESA. 2022 , 11,	1
86	Impact of Statins on Survival and Limb Salvage in Patients Undergoing Peripheral Endovascular Intervention for Chronic Limb Threatening Ischemia. 2022 ,	1
85	Clinical and Coronary Plaque Predictors of Atherosclerotic Nonresponse to Statin Therapy. 2022 ,	1
84	Barriers and facilitators to deprescribing of cardiovascular medications: a systematic review. 2022 , 12, e061686	0
83	Drug-Drug Interaction between Antiplatelet Therapy and Lipid-Lowering Agents (Statins and PCSK9 Inhibitors).	0
82	Pharmaco-invasive therapy: Early implementation of statins and proprotein convertase subtilisin/kexin type 9 inhibitors after acute coronary syndrome. 9,	0
81	Contrast-induced acute kidney injury and its contemporary prevention. 9,	0
80	Exploring the Subclinical Atherosclerotic Load in Patients With Rheumatoid Arthritis: A Cross-Sectional Study. 2022 ,	0
79	In-hospital mortality risk stratification of Asian ACS patients with artificial intelligence algorithm. 2022 , 17, e0278944	0

78	Statin related muscle symptoms: is it time to move on. o2939	0
77	The role of statins in diabetic retinopathy. 2022 ,	1
76	Offering a lifestyle intervention to women of premenopausal age as primary prevention for cardiovascular disease? Assessing its cost-effectiveness. 2022 , 19,	0
75	Current Understanding of Diabetic Dyslipidemia: A Review.	0
74	Anti-Inflammatory Drug Candidates for Prevention and Treatment of Cardiovascular Diseases. 2023 , 16, 78	0
73	Mitochondria-derived damage associated molecular patterns and inflammation in the ischemic-reperfused heart.	0
72	Atherosclerotic Cardiovascular Disease Prevention in the Older Adult: Part 2. 2023 , 67-138	0
71	Associations of relative fat mass, a new index of adiposity, with type-2 diabetes in the general population. 2023 ,	0
70	Imaging subclinical coronary atherosclerosis to guide lipid management, are we there yet?. 2023 , 13, 100451	0
69	Restoring mortality data in the FOURIER cardiovascular outcomes trial of evolocumab in patients with cardiovascular disease: a reanalysis based on regulatory data. 2022 , 12, e060172	3
68	Testosterone is associated with abdominal body composition derived from computed tomography: a large cross sectional study. 2022 , 12,	0
67	Factors associated with incidence of acute kidney injury: a Japanese regional population-based cohort study, the Shizuoka study.	0
66	Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues. 2023 , 25, 1-17	5
65	Formulation of risk prediction model for cardiovascular diseases using conventional logistic regression analysis. 2023 ,	0
64	A Hidden Organism, Chlamydia in the Age of Atherosclerosis.	0
63	Indicators of carbohydrate metabolism in a patient with dyslipidemia and impaired fasting glycemia receiving pitavastatin: a case report. 2023 , 21, 3496	0
62	Associations among cardiorespiratory fitness, C-reactive protein, and all-cause mortality in men and women. 108155892211491	0
61	Monomeric C-Reactive Protein in Atherosclerotic Cardiovascular Disease: Advances and Perspectives. 2023 , 24, 2079	0

- 60 Association between Low-Density Lipoprotein Cholesterol Level and Cardiovascular Outcomes in Korean Adults: A Nationwide Cohort Study. **2023**, 47, 59-71 ○
- 59 Lipid-Lowering Efficacy of Combined Lipid-Lowering Therapy and Its Effect on Glucose Metabolism. **2023**, 13, 1567-1573 ○
- 58 Current Applications and New Perspectives in Optical Coherence Tomography (OCT) Coronary Atherosclerotic Plaque Assessment: From PCI Optimization to Pharmacological Treatment Guidance. **2023**, 10, 158 ○
- 57 Clinical Challenges in Diagnosing and Monitoring Periodontal Inflammation. **2010**, 38, 263-270 ○
- 56 Hypertension mediated kidney and cardiovascular damage and risk stratification: Redefining concepts. **2022**, 42, 519-530 ○
- 55 Management of Risks Factors for Older Women: Osteoporosis and Cardiovascular Disease (CVD). **2023**, 1-16 ○
- 54 Lectin-Like Oxidized Low-Density Lipoprotein Receptor 1 Inhibition in Type 2 Diabetes: Phase 1 Results. **2023**, 12, ○
- 53 The fundamental role of obesity management in cardiometabolic risk reduction: nonpharmacological, pharmacological, and surgical approaches. **2023**, 273-309 ○
- 52 Effects of bempedoic acid on CRP, IL-6, fibrinogen and lipoprotein(a) in patients with residual inflammatory risk: A secondary analysis of the CLEAR harmony trial. **2023**, 17, 297-302 ○
- 51 Multifaceted role of cardiovascular biomarkers. **2023**, 75, 91-97 ○
- 50 Increased A-to-I RNA editing in atherosclerosis and cardiomyopathies. **2023**, 19, e1010923 ○
- 49 Association of Initial and Longitudinal Changes in C-reactive Protein With the Risk of Cardiovascular Disease, Cancer, and Mortality. **2023**, 98, 549-558 ○
- 48 Biologics for Reducing Cardiovascular Risk in Psoriasis Patients. **2023**, 12, 1162 ○
- 47 PAX5/ITGAX Contributed to the Progression of Atherosclerosis by Regulation of B Differentiation via TNF- β Signaling Pathway. **2023**, 42, 97-104 ○
- 46 Unexploited potential of risk factor treatment in patients with atherosclerotic cardiovascular disease. ○
- 45 Statin withdrawal and health-related quality of life in a primary cardiovascular prevention cohort. ○
- 44 Statins and diabetes: What are the connections?. **2023**, 37, 101749 ○
- 43 Distinct WBC Trajectories are Associated with the Risks of Incident CVD and All-Cause Mortality. **2023**, ○

- 42 The Role of Preoperative Chronic Statin Therapy in Heart Transplant Receipts: A Retrospective Single-Center Cohort Study. **2023**, 20, 3471 ○
- 41 Altered choline level in atherosclerotic lesions: Upregulation of choline transporter-like protein 1 in human coronary unstable plaque. **2023**, 18, e0281730 ○
- 40 The 2022 focused update of the 2018 Korean Hypertension Society Guidelines for the management of hypertension. **2023**, 29, ○
- 39 Association between obesity and high-sensitivity C-reactive protein in Korean adults without cardiovascular disease. **2023**, 25, 32-42 ○
- 38 Assessment of C-Reactive Protein/Serum Albumin Ratio in Relation to Acute Presentation and Early Outcome of Patients with Acute Coronary Syndrome. **2023**, 11, 239-253 ○
- 37 Long-term neurodevelopmental follow-up of children exposed to pravastatin in utero. **2023**, ○
- 36 Inclisiran: new era of lipid-lowering therapy?. **2023**, 65, 69-75 ○
- 35 High-sensitivity C-reactive protein modifies the prognostic value of platelet count for clinical outcomes after ischemic stroke. ○
- 34 Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials. **2023**, 401, 1293-1301 1
- 33 Complexity of Inflammation in the Trajectory of Vascular Disease: Interleukin 6 and Beyond. **2023**, 16, 8-16 ○
- 32 Baseline inflammatory status affects the prognostic impact of statins in patients with peripheral arterial disease. ○
- 31 High-throughput screening for prescribing cascades among real world statin initiators. ○
- 30 Lipid-lowering Efficacy and Safety of High Doses of Atorvastatin and Rosuvastatin. **2023**, 63, 59-67 ○
- 29 Medical Therapy After CABG: the Known Knowns, the Known Unknowns, and the Unknown Unknowns. ○
- 28 Impact of In-hospital Statin Use on Mortality in COVID-19 Patients from a Majority African American Population. **2023**, ○
- 27 Inflammation in Chronic Periodontitis and Significant Systemic Diseases. **2010**, 38, 247-257 ○
- 26 Serum calcium and magnesium were inversely associated with high sensitivity C-reactive protein in Chinese adults with coronary artery disease. **2023**, 39, 497-503 ○
- 25 Effect of rosuvastatin 20 mg versus rosuvastatin 5 mg plus ezetimibe on statin side-effects in elderly patients with atherosclerotic cardiovascular disease: Rationale and design of a randomized, controlled SaveSAMS trial. **2023**, 261, 45-50 ○

- 24 Efficacy and Safety of Coadministered Ezetimibe/Rosuvastatin plus Telmisartan in South Korean Patients with Dyslipidemia and Hypertension: A Multicenter, Randomized, Double-Blind, Active-Controlled, Phase III Trial. **2023**, 12, 2377 ○
- 23 Recent Trials on the Cardioprotective Effects of New Generation Anti-diabetic and Lipid-Lowering Agents. **2023**, 117-167 ○
- 22 Hepatitis C virus eradication by direct-acting antivirals causes a simultaneous increase in the prevalence of fatty liver and hyper low-density lipoprotein cholesterolemia without an increase in body weight. ○
- 21 Improving diagnostic assessments in the ever-changing landscape of atherosclerosis. **2023**, 24, 221-229 ○
- 20 Sex differences in Parkinson disease-associated episodic memory and processing speed deficits. 1-8 ○
- 19 Genetically Proxied CRP (C-Reactive Protein) Levels and Lobar Intracerebral Hemorrhage Risk. **2023**, 54, ○
- 18 Regression discontinuity design to evaluate the effect of statins on myocardial infarction in electronic health records. **2023**, 38, 393-402 ○
- 17 Inflammation Beats Cholesterol: A Comment on the Unequivocal Driver of Cardiovascular Disease Risk. **2023**, 12, 2519 ○
- 16 Neutrophils in Health and Disease: From Receptor Sensing to Inflammasome Activation. **2023**, 24, 6340 ○
- 15 Association between lipid levels and all-cause and cause-specific mortality in critically ill patients. **2023**, 13, ○
- 14 Desipramine enhances the stability of atherosclerotic plaque in rabbits monitored with molecular imaging. **2023**, 18, e0283612 ○
- 13 Aortic Inflammation. **2023**, 2, 100283 ○
- 12 Bempedoic acid lowers high-sensitivity C-reactive protein and low-density lipoprotein cholesterol: Analysis of pooled data from four phase 3 clinical trials. **2023**, 373, 1-9 ○
- 11 An Expert Opinion on the Role of the Rosuvastatin/Amlodipine Single Pill Fixed Dose Combination in Cardiovascular Prevention. **2023**, 30, 83-91 ○
- 10 High-dose Polyphenol-rich Nutrition Improves Lipid and Inflammation Profiles and Triggers Apoptotic Signaling in Healthy Elderly People (the ErdBEHR Study). ○
- 9 Rhabdomyolysis caused by interaction between rosuvastatin and vadadustat: a case control study. **2023**, 9, ○
- 8 Tumor Necrosis Factor Superfamily 14 (LIGHT) Restricts Neovascularization by Decreasing Circulating Endothelial Progenitor Cells and Function. **2023**, 24, 6997 ○
- 7 Innate Immunity System in Patients With Cardiovascular and Kidney Disease. **2023**, 132, 915-932 ○

- 6 The Relevance of Thrombo-Inflammatory Biomarkers and Their Relationship with Circulating Glycosaminoglycans in End-Stage Renal Disease Patients. **2023**, 29, 107602962311695
- 5 Geographic and ethnic variations in response to lipid-lowering therapies: why do they matter?.
- 4 Clinical Trial Design for Lipoprotein(a)-Lowering Therapies. **2023**, 81, 1633-1645
- 3 Long-term, in vivo therapeutic effects of a single dose of miR-145 micelles for atherosclerosis. **2023**, 27, 327-336
- 2 Understanding the molecular mechanisms of statin pleiotropic effects.
- 1 Atorvastatin Attenuates Diet-Induced Non-Alcoholic Steatohepatitis in APOE*3-Leiden Mice by Reducing Hepatic Inflammation. **2023**, 24, 7818